id	sid	tid	token	lemma	pos
dpc-2641	1	1	dermatology	dermatology	NOUN
dpc-2641	1	2	:	:	PUNCT
dpc-2641	1	3	practical	practical	ADJ
dpc-2641	1	4	and	and	CCONJ
dpc-2641	1	5	conceptual	conceptual	ADJ
dpc-2641	1	6	original	original	ADJ
dpc-2641	1	7	article	article	NOUN
dpc-2641	1	8	|	|	ADV
dpc-2641	1	9	dermatol	dermatol	ADJ
dpc-2641	1	10	pract	pract	NOUN
dpc-2641	1	11	concept	concept	NOUN
dpc-2641	1	12	.	.	PUNCT
dpc-2641	2	1	2023;13(2):e2023081	2023;13(2):e2023081	NUM
dpc-2641	2	2	1	1	NUM
dpc-2641	2	3	antinuclear	antinuclear	ADJ
dpc-2641	2	4	antibody	antibody	NOUN
dpc-2641	2	5	positivity	positivity	NOUN
dpc-2641	2	6	in	in	ADP
dpc-2641	2	7	patients	patient	NOUN
dpc-2641	2	8	with	with	ADP
dpc-2641	2	9	hair	hair	NOUN
dpc-2641	2	10	loss	loss	NOUN
dpc-2641	2	11	after	after	ADP
dpc-2641	2	12	covid-19	covid-19	PROPN
dpc-2641	2	13	infection	infection	NOUN
dpc-2641	2	14	vildan	vildan	PROPN
dpc-2641	2	15	manav1,2	manav1,2	PROPN
dpc-2641	2	16	,	,	PUNCT
dpc-2641	2	17	duygu	duygu	PROPN
dpc-2641	2	18	erdil1	erdil1	PROPN
dpc-2641	2	19	,	,	PUNCT
dpc-2641	2	20	ayşe	ayşe	PROPN
dpc-2641	2	21	esra	esra	PROPN
dpc-2641	2	22	koku	koku	PROPN
dpc-2641	2	23	aksu1	aksu1	PROPN
dpc-2641	3	1	1	1	NUM
dpc-2641	3	2	department	department	NOUN
dpc-2641	3	3	of	of	ADP
dpc-2641	3	4	dermatology	dermatology	NOUN
dpc-2641	3	5	,	,	PUNCT
dpc-2641	3	6	university	university	NOUN
dpc-2641	3	7	of	of	ADP
dpc-2641	3	8	health	health	PROPN
dpc-2641	3	9	sciences	science	NOUN
dpc-2641	3	10	,	,	PUNCT
dpc-2641	3	11	i̇stanbul	i̇stanbul	CCONJ
dpc-2641	3	12	training	training	NOUN
dpc-2641	3	13	and	and	CCONJ
dpc-2641	3	14	research	research	NOUN
dpc-2641	3	15	hospital	hospital	NOUN
dpc-2641	3	16	,	,	PUNCT
dpc-2641	3	17	i̇stanbul	i̇stanbul	ADV
dpc-2641	3	18	,	,	PUNCT
dpc-2641	3	19	turkey	turkey	NOUN
dpc-2641	3	20	2	2	NUM
dpc-2641	3	21	cosmetology	cosmetology	NOUN
dpc-2641	3	22	,	,	PUNCT
dpc-2641	3	23	i̇stanbul	i̇stanbul	PUNCT
dpc-2641	3	24	university	university	NOUN
dpc-2641	3	25	graduate	graduate	NOUN
dpc-2641	3	26	school	school	NOUN
dpc-2641	3	27	of	of	ADP
dpc-2641	3	28	medicine	medicine	NOUN
dpc-2641	3	29	,	,	PUNCT
dpc-2641	3	30	i̇stanbul	i̇stanbul	ADV
dpc-2641	3	31	,	,	PUNCT
dpc-2641	3	32	turkey	turkey	PROPN
dpc-2641	3	33	key	key	ADJ
dpc-2641	3	34	words	word	NOUN
dpc-2641	3	35	:	:	PUNCT
dpc-2641	3	36	sars	sars	PROPN
dpc-2641	3	37	-	-	PUNCT
dpc-2641	3	38	cov-19	cov-19	PROPN
dpc-2641	3	39	,	,	PUNCT
dpc-2641	3	40	hair	hair	NOUN
dpc-2641	3	41	loss	loss	NOUN
dpc-2641	3	42	,	,	PUNCT
dpc-2641	3	43	antinuclear	antinuclear	ADJ
dpc-2641	3	44	antibody	antibody	NOUN
dpc-2641	3	45	positivity	positivity	NOUN
dpc-2641	3	46	,	,	PUNCT
dpc-2641	3	47	trichodynia	trichodynia	PROPN
dpc-2641	3	48	citation	citation	NOUN
dpc-2641	3	49	:	:	PUNCT
dpc-2641	3	50	manav	manav	PROPN
dpc-2641	3	51	v	v	NOUN
dpc-2641	3	52	,	,	PUNCT
dpc-2641	3	53	erdil	erdil	ADJ
dpc-2641	3	54	d	d	NOUN
dpc-2641	3	55	,	,	PUNCT
dpc-2641	3	56	koku	koku	PROPN
dpc-2641	3	57	aksu	aksu	PROPN
dpc-2641	3	58	a.	a.	PROPN
dpc-2641	3	59	antinuclear	antinuclear	PROPN
dpc-2641	3	60	antibody	antibody	NOUN
dpc-2641	3	61	positivity	positivity	NOUN
dpc-2641	3	62	in	in	ADP
dpc-2641	3	63	patients	patient	NOUN
dpc-2641	3	64	with	with	ADP
dpc-2641	3	65	hair	hair	NOUN
dpc-2641	3	66	loss	loss	NOUN
dpc-2641	3	67	after	after	ADP
dpc-2641	3	68	covid-19	covid-19	PROPN
dpc-2641	3	69	infection	infection	NOUN
dpc-2641	3	70	.	.	PUNCT
dpc-2641	4	1	dermatol	dermatol	NOUN
dpc-2641	4	2	pract	pract	PROPN
dpc-2641	4	3	concept	concept	NOUN
dpc-2641	4	4	.	.	PUNCT
dpc-2641	5	1	2023;13(2):e2023081	2023;13(2):e2023081	X
dpc-2641	5	2	.	.	PUNCT
dpc-2641	5	3	doi	doi	PROPN
dpc-2641	5	4	:	:	PUNCT
dpc-2641	5	5	https://doi.org/10.5826/dpc.1302a81	https://doi.org/10.5826/dpc.1302a81	NOUN
dpc-2641	5	6	accepted	accept	VERB
dpc-2641	5	7	:	:	PUNCT
dpc-2641	5	8	august	august	PROPN
dpc-2641	5	9	29	29	NUM
dpc-2641	5	10	,	,	PUNCT
dpc-2641	5	11	2022	2022	NUM
dpc-2641	5	12	;	;	PUNCT
dpc-2641	5	13	published	publish	VERB
dpc-2641	5	14	:	:	PUNCT
dpc-2641	6	1	april	april	PROPN
dpc-2641	6	2	2023	2023	NUM
dpc-2641	6	3	copyright	copyright	NOUN
dpc-2641	6	4	:	:	PUNCT
dpc-2641	6	5	©	©	PROPN
dpc-2641	6	6	2023	2023	NUM
dpc-2641	6	7	manav	manav	PROPN
dpc-2641	6	8	et	et	PROPN
dpc-2641	6	9	al	al	PROPN
dpc-2641	6	10	.	.	PUNCT
dpc-2641	7	1	this	this	PRON
dpc-2641	7	2	is	be	AUX
dpc-2641	7	3	an	an	DET
dpc-2641	7	4	open	open	ADJ
dpc-2641	7	5	-	-	PUNCT
dpc-2641	7	6	access	access	NOUN
dpc-2641	7	7	article	article	NOUN
dpc-2641	7	8	distributed	distribute	VERB
dpc-2641	7	9	under	under	ADP
dpc-2641	7	10	the	the	DET
dpc-2641	7	11	terms	term	NOUN
dpc-2641	7	12	of	of	ADP
dpc-2641	7	13	the	the	DET
dpc-2641	7	14	creative	creative	ADJ
dpc-2641	7	15	commons	common	NOUN
dpc-2641	7	16	attributionnoncommercial	attributionnoncommercial	ADJ
dpc-2641	7	17	license	license	NOUN
dpc-2641	7	18	(	(	PUNCT
dpc-2641	7	19	by	by	ADP
dpc-2641	7	20	-	-	PUNCT
dpc-2641	7	21	nc-4.0	nc-4.0	NOUN
dpc-2641	7	22	)	)	PUNCT
dpc-2641	7	23	,	,	PUNCT
dpc-2641	7	24	https://creativecommons.org/licenses/by-nc/4.0/	https://creativecommons.org/licenses/by-nc/4.0/	PROPN
dpc-2641	7	25	,	,	PUNCT
dpc-2641	7	26	which	which	PRON
dpc-2641	7	27	permits	permit	VERB
dpc-2641	7	28	unrestricted	unrestricted	ADJ
dpc-2641	7	29	noncommercial	noncommercial	ADJ
dpc-2641	7	30	use	use	NOUN
dpc-2641	7	31	,	,	PUNCT
dpc-2641	7	32	distribution	distribution	NOUN
dpc-2641	7	33	,	,	PUNCT
dpc-2641	7	34	and	and	CCONJ
dpc-2641	7	35	reproduction	reproduction	NOUN
dpc-2641	7	36	in	in	ADP
dpc-2641	7	37	any	any	DET
dpc-2641	7	38	medium	medium	NOUN
dpc-2641	7	39	,	,	PUNCT
dpc-2641	7	40	provided	provide	VERB
dpc-2641	7	41	the	the	DET
dpc-2641	7	42	original	original	ADJ
dpc-2641	7	43	authors	author	NOUN
dpc-2641	7	44	and	and	CCONJ
dpc-2641	7	45	source	source	NOUN
dpc-2641	7	46	are	be	AUX
dpc-2641	7	47	credited	credit	VERB
dpc-2641	7	48	.	.	PUNCT
dpc-2641	8	1	funding	funding	NOUN
dpc-2641	8	2	:	:	PUNCT
dpc-2641	8	3	none	none	NOUN
dpc-2641	8	4	.	.	PUNCT
dpc-2641	9	1	competing	compete	VERB
dpc-2641	9	2	interests	interest	NOUN
dpc-2641	9	3	:	:	PUNCT
dpc-2641	9	4	none	none	NOUN
dpc-2641	9	5	.	.	PUNCT
dpc-2641	10	1	authorship	authorship	NOUN
dpc-2641	10	2	:	:	PUNCT
dpc-2641	10	3	all	all	DET
dpc-2641	10	4	authors	author	NOUN
dpc-2641	10	5	have	have	AUX
dpc-2641	10	6	contributed	contribute	VERB
dpc-2641	10	7	significantly	significantly	ADV
dpc-2641	10	8	to	to	ADP
dpc-2641	10	9	this	this	DET
dpc-2641	10	10	publication	publication	NOUN
dpc-2641	10	11	.	.	PUNCT
dpc-2641	11	1	corresponding	correspond	VERB
dpc-2641	11	2	author	author	NOUN
dpc-2641	11	3	:	:	PUNCT
dpc-2641	11	4	vildan	vildan	PROPN
dpc-2641	11	5	manav	manav	PROPN
dpc-2641	11	6	,	,	PUNCT
dpc-2641	11	7	md	md	PROPN
dpc-2641	11	8	,	,	PUNCT
dpc-2641	11	9	istanbul	istanbul	PROPN
dpc-2641	11	10	training	training	NOUN
dpc-2641	11	11	and	and	CCONJ
dpc-2641	11	12	research	research	NOUN
dpc-2641	11	13	hospital	hospital	NOUN
dpc-2641	11	14	,	,	PUNCT
dpc-2641	11	15	department	department	NOUN
dpc-2641	11	16	of	of	ADP
dpc-2641	11	17	dermatology	dermatology	NOUN
dpc-2641	11	18	,	,	PUNCT
dpc-2641	11	19	kasap	kasap	PROPN
dpc-2641	11	20	i̇lyas	i̇lyas	PROPN
dpc-2641	11	21	mah	mah	PROPN
dpc-2641	11	22	.	.	PUNCT
dpc-2641	11	23	org	org	PROPN
dpc-2641	11	24	.	.	PUNCT
dpc-2641	12	1	abdurrahman	abdurrahman	PROPN
dpc-2641	12	2	nafiz	nafiz	PROPN
dpc-2641	12	3	gürman	gürman	PROPN
dpc-2641	12	4	cd	cd	PROPN
dpc-2641	12	5	.	.	PUNCT
dpc-2641	13	1	pk	pk	PROPN
dpc-2641	13	2	:	:	PUNCT
dpc-2641	13	3	34098	34098	NUM
dpc-2641	13	4	,	,	PUNCT
dpc-2641	13	5	istanbul	istanbul	PROPN
dpc-2641	13	6	,	,	PUNCT
dpc-2641	13	7	turkey	turkey	PROPN
dpc-2641	13	8	.	.	PUNCT
dpc-2641	14	1	phone	phone	NOUN
dpc-2641	14	2	:	:	PUNCT
dpc-2641	14	3	+905334323524	+905334323524	PROPN
dpc-2641	14	4	.	.	PUNCT
dpc-2641	15	1	fax	fax	NOUN
dpc-2641	15	2	:	:	PUNCT
dpc-2641	15	3	+9002126320060	+9002126320060	NOUN
dpc-2641	15	4	,	,	PUNCT
dpc-2641	15	5	e	e	NOUN
dpc-2641	15	6	-	-	NOUN
dpc-2641	15	7	mail	mail	NOUN
dpc-2641	15	8	:	:	PUNCT
dpc-2641	15	9	drvildanmanav@gmail.com	drvildanmanav@gmail.com	X
dpc-2641	16	1	introduction	introduction	NOUN
dpc-2641	16	2	:	:	PUNCT
dpc-2641	16	3	hair	hair	NOUN
dpc-2641	16	4	loss	loss	NOUN
dpc-2641	16	5	is	be	AUX
dpc-2641	16	6	one	one	NUM
dpc-2641	16	7	of	of	ADP
dpc-2641	16	8	the	the	DET
dpc-2641	16	9	most	most	ADV
dpc-2641	16	10	common	common	ADJ
dpc-2641	16	11	disorders	disorder	NOUN
dpc-2641	16	12	after	after	ADP
dpc-2641	16	13	coronavirus	coronavirus	NOUN
dpc-2641	16	14	disease	disease	NOUN
dpc-2641	16	15	2019	2019	NUM
dpc-2641	16	16	(	(	PUNCT
dpc-2641	16	17	covid-19	covid-19	PROPN
dpc-2641	16	18	)	)	PUNCT
dpc-2641	16	19	infection	infection	NOUN
dpc-2641	16	20	.	.	PUNCT
dpc-2641	17	1	this	this	DET
dpc-2641	17	2	study	study	NOUN
dpc-2641	17	3	aimed	aim	VERB
dpc-2641	17	4	to	to	PART
dpc-2641	17	5	investigate	investigate	VERB
dpc-2641	17	6	the	the	DET
dpc-2641	17	7	relationship	relationship	NOUN
dpc-2641	17	8	between	between	ADP
dpc-2641	17	9	covid-19	covid-19	PROPN
dpc-2641	17	10	-	-	PUNCT
dpc-2641	17	11	related	relate	VERB
dpc-2641	17	12	hair	hair	NOUN
dpc-2641	17	13	loss	loss	NOUN
dpc-2641	17	14	and	and	CCONJ
dpc-2641	17	15	antinuclear	antinuclear	ADJ
dpc-2641	17	16	antibody	antibody	NOUN
dpc-2641	17	17	(	(	PUNCT
dpc-2641	17	18	ana	ana	PROPN
dpc-2641	17	19	)	)	PUNCT
dpc-2641	17	20	positivity	positivity	NOUN
dpc-2641	17	21	and	and	CCONJ
dpc-2641	17	22	patterns	pattern	NOUN
dpc-2641	17	23	.	.	PUNCT
dpc-2641	18	1	methods	method	NOUN
dpc-2641	18	2	:	:	PUNCT
dpc-2641	18	3	ana	ana	PROPN
dpc-2641	18	4	positivity	positivity	NOUN
dpc-2641	18	5	and	and	CCONJ
dpc-2641	18	6	patterns	pattern	NOUN
dpc-2641	18	7	were	be	AUX
dpc-2641	18	8	analyzed	analyze	VERB
dpc-2641	18	9	in	in	ADP
dpc-2641	18	10	30	30	NUM
dpc-2641	18	11	female	female	ADJ
dpc-2641	18	12	covid-19	covid-19	PROPN
dpc-2641	18	13	patients	patient	NOUN
dpc-2641	18	14	with	with	ADP
dpc-2641	18	15	hair	hair	NOUN
dpc-2641	18	16	loss	loss	NOUN
dpc-2641	18	17	complaints	complaint	NOUN
dpc-2641	18	18	and	and	CCONJ
dpc-2641	18	19	compared	compare	VERB
dpc-2641	18	20	in	in	ADP
dpc-2641	18	21	terms	term	NOUN
dpc-2641	18	22	of	of	ADP
dpc-2641	18	23	the	the	DET
dpc-2641	18	24	presence	presence	NOUN
dpc-2641	18	25	of	of	ADP
dpc-2641	18	26	autoimmunity	autoimmunity	NOUN
dpc-2641	18	27	between	between	ADP
dpc-2641	18	28	patients	patient	NOUN
dpc-2641	18	29	with	with	ADP
dpc-2641	18	30	and	and	CCONJ
dpc-2641	18	31	without	without	ADP
dpc-2641	18	32	covid-19	covid-19	PROPN
dpc-2641	18	33	exhibiting	exhibit	VERB
dpc-2641	18	34	hair	hair	NOUN
dpc-2641	18	35	loss	loss	NOUN
dpc-2641	18	36	.	.	PUNCT
dpc-2641	19	1	results	result	NOUN
dpc-2641	19	2	:	:	PUNCT
dpc-2641	19	3	ana	ana	PROPN
dpc-2641	19	4	positivity	positivity	NOUN
dpc-2641	19	5	and	and	CCONJ
dpc-2641	19	6	cytoplasmic	cytoplasmic	ADJ
dpc-2641	19	7	patterns	pattern	NOUN
dpc-2641	19	8	were	be	AUX
dpc-2641	19	9	detected	detect	VERB
dpc-2641	19	10	in	in	ADP
dpc-2641	19	11	40	40	NUM
dpc-2641	19	12	%	%	NOUN
dpc-2641	19	13	of	of	ADP
dpc-2641	19	14	the	the	DET
dpc-2641	19	15	patients	patient	NOUN
dpc-2641	19	16	with	with	ADP
dpc-2641	19	17	covid-19	covid-19	PROPN
dpc-2641	19	18	infection	infection	NOUN
dpc-2641	19	19	and	and	CCONJ
dpc-2641	19	20	hair	hair	NOUN
dpc-2641	19	21	loss	loss	NOUN
dpc-2641	19	22	.	.	PUNCT
dpc-2641	20	1	trichodynia	trichodynia	NOUN
dpc-2641	20	2	and	and	CCONJ
dpc-2641	20	3	diffuse	diffuse	VERB
dpc-2641	20	4	hair	hair	NOUN
dpc-2641	20	5	loss	loss	NOUN
dpc-2641	20	6	were	be	AUX
dpc-2641	20	7	observed	observe	VERB
dpc-2641	20	8	in	in	ADP
dpc-2641	20	9	63.3	63.3	NUM
dpc-2641	20	10	%	%	NOUN
dpc-2641	20	11	and	and	CCONJ
dpc-2641	20	12	53.3	53.3	NUM
dpc-2641	20	13	%	%	NOUN
dpc-2641	20	14	,	,	PUNCT
dpc-2641	20	15	respectively	respectively	ADV
dpc-2641	20	16	.	.	PUNCT
dpc-2641	21	1	conclusions	conclusion	NOUN
dpc-2641	21	2	:	:	PUNCT
dpc-2641	21	3	in	in	ADP
dpc-2641	21	4	patients	patient	NOUN
dpc-2641	21	5	with	with	ADP
dpc-2641	21	6	covid-19	covid-19	PROPN
dpc-2641	21	7	-	-	PUNCT
dpc-2641	21	8	related	relate	VERB
dpc-2641	21	9	hair	hair	NOUN
dpc-2641	21	10	loss	loss	NOUN
dpc-2641	21	11	,	,	PUNCT
dpc-2641	21	12	diffuse	diffuse	VERB
dpc-2641	21	13	hair	hair	NOUN
dpc-2641	21	14	loss	loss	NOUN
dpc-2641	21	15	and	and	CCONJ
dpc-2641	21	16	ana	ana	PROPN
dpc-2641	21	17	positivity	positivity	NOUN
dpc-2641	21	18	may	may	AUX
dpc-2641	21	19	be	be	AUX
dpc-2641	21	20	related	relate	VERB
dpc-2641	21	21	to	to	ADP
dpc-2641	21	22	the	the	DET
dpc-2641	21	23	high	high	ADJ
dpc-2641	21	24	antibody	antibody	NOUN
dpc-2641	21	25	levels	level	NOUN
dpc-2641	21	26	triggered	trigger	VERB
dpc-2641	21	27	by	by	ADP
dpc-2641	21	28	covid-19	covid-19	PROPN
dpc-2641	21	29	infection	infection	NOUN
dpc-2641	21	30	.	.	PUNCT
dpc-2641	22	1	abstract	abstract	ADJ
dpc-2641	22	2	introduction	introduction	NOUN
dpc-2641	22	3	more	more	ADJ
dpc-2641	22	4	than	than	ADP
dpc-2641	22	5	175	175	NUM
dpc-2641	22	6	million	million	NUM
dpc-2641	22	7	people	people	NOUN
dpc-2641	22	8	were	be	AUX
dpc-2641	22	9	infected	infect	VERB
dpc-2641	22	10	with	with	ADP
dpc-2641	22	11	coronavirus	coronavirus	NOUN
dpc-2641	22	12	disease	disease	NOUN
dpc-2641	22	13	2019	2019	NUM
dpc-2641	22	14	(	(	PUNCT
dpc-2641	22	15	covid-19	covid-19	PROPN
dpc-2641	22	16	)	)	PUNCT
dpc-2641	22	17	within	within	ADP
dpc-2641	22	18	one	one	NUM
dpc-2641	22	19	year	year	NOUN
dpc-2641	22	20	of	of	ADP
dpc-2641	22	21	the	the	DET
dpc-2641	22	22	first	first	ADJ
dpc-2641	22	23	covid-19	covid-19	PROPN
dpc-2641	22	24	infection	infection	NOUN
dpc-2641	22	25	reported	report	VERB
dpc-2641	22	26	in	in	ADP
dpc-2641	22	27	china	china	PROPN
dpc-2641	22	28	in	in	ADP
dpc-2641	22	29	early	early	ADJ
dpc-2641	22	30	december	december	PROPN
dpc-2641	22	31	2019	2019	NUM
dpc-2641	23	1	[	[	X
dpc-2641	23	2	1	1	NUM
dpc-2641	23	3	]	]	PUNCT
dpc-2641	23	4	.	.	PUNCT
dpc-2641	24	1	it	it	PRON
dpc-2641	24	2	has	have	AUX
dpc-2641	24	3	been	be	AUX
dpc-2641	24	4	reported	report	VERB
dpc-2641	24	5	that	that	SCONJ
dpc-2641	24	6	80	80	NUM
dpc-2641	24	7	%	%	NOUN
dpc-2641	24	8	of	of	ADP
dpc-2641	24	9	patients	patient	NOUN
dpc-2641	24	10	with	with	ADP
dpc-2641	24	11	covid-19	covid-19	PROPN
dpc-2641	24	12	infection	infection	NOUN
dpc-2641	24	13	develop	develop	VERB
dpc-2641	24	14	one	one	NUM
dpc-2641	24	15	or	or	CCONJ
dpc-2641	24	16	more	more	ADJ
dpc-2641	24	17	long	long	ADJ
dpc-2641	24	18	-	-	PUNCT
dpc-2641	24	19	term	term	NOUN
dpc-2641	24	20	symptoms	symptom	NOUN
dpc-2641	24	21	.	.	PUNCT
dpc-2641	25	1	the	the	DET
dpc-2641	25	2	most	most	ADV
dpc-2641	25	3	common	common	ADJ
dpc-2641	25	4	symptoms	symptom	NOUN
dpc-2641	25	5	are	be	AUX
dpc-2641	25	6	fatigue	fatigue	NOUN
dpc-2641	25	7	(	(	PUNCT
dpc-2641	25	8	58	58	NUM
dpc-2641	25	9	%	%	NOUN
dpc-2641	25	10	)	)	PUNCT
dpc-2641	25	11	,	,	PUNCT
dpc-2641	25	12	headache	headache	NOUN
dpc-2641	25	13	(	(	PUNCT
dpc-2641	25	14	44	44	NUM
dpc-2641	25	15	%	%	NOUN
dpc-2641	25	16	)	)	PUNCT
dpc-2641	25	17	,	,	PUNCT
dpc-2641	25	18	attention	attention	NOUN
dpc-2641	25	19	deficit	deficit	NOUN
dpc-2641	25	20	(	(	PUNCT
dpc-2641	25	21	24	24	NUM
dpc-2641	25	22	%	%	NOUN
dpc-2641	25	23	)	)	PUNCT
dpc-2641	25	24	,	,	PUNCT
dpc-2641	25	25	and	and	CCONJ
dpc-2641	25	26	hair	hair	NOUN
dpc-2641	25	27	loss	loss	NOUN
dpc-2641	25	28	(	(	PUNCT
dpc-2641	25	29	25	25	NUM
dpc-2641	25	30	%	%	NOUN
dpc-2641	25	31	)	)	PUNCT
dpc-2641	26	1	[	[	X
dpc-2641	26	2	2	2	NUM
dpc-2641	26	3	]	]	PUNCT
dpc-2641	26	4	.	.	PUNCT
dpc-2641	27	1	skin	skin	NOUN
dpc-2641	27	2	findings	finding	NOUN
dpc-2641	27	3	have	have	AUX
dpc-2641	27	4	received	receive	VERB
dpc-2641	27	5	increasing	increase	VERB
dpc-2641	27	6	attention	attention	NOUN
dpc-2641	27	7	for	for	ADP
dpc-2641	27	8	the	the	DET
dpc-2641	27	9	early	early	ADJ
dpc-2641	27	10	2	2	NUM
dpc-2641	27	11	original	original	ADJ
dpc-2641	27	12	article	article	NOUN
dpc-2641	27	13	|	|	ADV
dpc-2641	27	14	dermatol	dermatol	ADJ
dpc-2641	27	15	pract	pract	NOUN
dpc-2641	27	16	concept	concept	NOUN
dpc-2641	27	17	.	.	PUNCT
dpc-2641	28	1	2023;13(2):e2023081	2023;13(2):e2023081	NUM
dpc-2641	28	2	diagnosis	diagnosis	NOUN
dpc-2641	28	3	of	of	ADP
dpc-2641	28	4	covid-19	covid-19	PROPN
dpc-2641	28	5	.	.	PUNCT
dpc-2641	28	6	covid-19	covid-19	PROPN
dpc-2641	28	7	-	-	PUNCT
dpc-2641	28	8	related	relate	VERB
dpc-2641	28	9	skin	skin	NOUN
dpc-2641	28	10	findings	finding	NOUN
dpc-2641	28	11	include	include	VERB
dpc-2641	28	12	vascular	vascular	ADJ
dpc-2641	28	13	eruptions	eruption	NOUN
dpc-2641	28	14	,	,	PUNCT
dpc-2641	28	15	maculopapular	maculopapular	ADJ
dpc-2641	28	16	eruptions	eruption	NOUN
dpc-2641	28	17	(	(	PUNCT
dpc-2641	28	18	atypical	atypical	ADJ
dpc-2641	28	19	forms	form	NOUN
dpc-2641	28	20	of	of	ADP
dpc-2641	28	21	pityriasis	pityriasis	NOUN
dpc-2641	28	22	rosea	rosea	NOUN
dpc-2641	28	23	)	)	PUNCT
dpc-2641	29	1	[	[	X
dpc-2641	29	2	3	3	NUM
dpc-2641	29	3	]	]	PUNCT
dpc-2641	29	4	,	,	PUNCT
dpc-2641	29	5	urticarial	urticarial	ADJ
dpc-2641	29	6	rash	rash	NOUN
dpc-2641	29	7	,	,	PUNCT
dpc-2641	29	8	vesicular	vesicular	ADJ
dpc-2641	29	9	,	,	PUNCT
dpc-2641	29	10	petechiae	petechiae	NOUN
dpc-2641	29	11	/	/	SYM
dpc-2641	29	12	purpuric	purpuric	ADJ
dpc-2641	29	13	eruptions	eruption	NOUN
dpc-2641	29	14	,	,	PUNCT
dpc-2641	29	15	erythema	erythema	ADJ
dpc-2641	29	16	multiforme	multiforme	NOUN
dpc-2641	29	17	–	–	PUNCT
dpc-2641	29	18	like	like	ADP
dpc-2641	29	19	rash	rash	NOUN
dpc-2641	29	20	,	,	PUNCT
dpc-2641	29	21	palmar	palmar	X
dpc-2641	29	22	erythema	erythema	ADV
dpc-2641	29	23	,	,	PUNCT
dpc-2641	29	24	perifollicular	perifollicular	ADJ
dpc-2641	29	25	eruption	eruption	NOUN
dpc-2641	29	26	,	,	PUNCT
dpc-2641	29	27	pruritus	pruritus	NOUN
dpc-2641	29	28	,	,	PUNCT
dpc-2641	29	29	mucosal	mucosal	ADJ
dpc-2641	29	30	rash	rash	NOUN
dpc-2641	29	31	,	,	PUNCT
dpc-2641	29	32	and	and	CCONJ
dpc-2641	29	33	androgenetic	androgenetic	ADJ
dpc-2641	29	34	alopecia	alopecia	NOUN
dpc-2641	29	35	[	[	X
dpc-2641	29	36	4	4	NUM
dpc-2641	29	37	]	]	PUNCT
dpc-2641	29	38	.	.	PUNCT
dpc-2641	30	1	autoimmune	autoimmune	ADJ
dpc-2641	30	2	diseases	disease	NOUN
dpc-2641	30	3	that	that	PRON
dpc-2641	30	4	develop	develop	VERB
dpc-2641	30	5	or	or	CCONJ
dpc-2641	30	6	worsen	worsen	VERB
dpc-2641	30	7	after	after	SCONJ
dpc-2641	30	8	covid-19	covid-19	PROPN
dpc-2641	30	9	infection	infection	NOUN
dpc-2641	30	10	have	have	AUX
dpc-2641	30	11	also	also	ADV
dpc-2641	30	12	been	be	AUX
dpc-2641	30	13	increasingly	increasingly	ADV
dpc-2641	30	14	reported	report	VERB
dpc-2641	30	15	.	.	PUNCT
dpc-2641	31	1	these	these	PRON
dpc-2641	31	2	include	include	VERB
dpc-2641	31	3	connective	connective	ADJ
dpc-2641	31	4	tissue	tissue	NOUN
dpc-2641	31	5	diseases	disease	NOUN
dpc-2641	31	6	(	(	PUNCT
dpc-2641	31	7	rheumatoid	rheumatoid	NOUN
dpc-2641	31	8	arthritis	arthritis	NOUN
dpc-2641	31	9	,	,	PUNCT
dpc-2641	31	10	systemic	systemic	ADJ
dpc-2641	31	11	lupus	lupus	PROPN
dpc-2641	31	12	erythematosus	erythematosus	PROPN
dpc-2641	31	13	vasculitis	vasculitis	PROPN
dpc-2641	31	14	,	,	PUNCT
dpc-2641	31	15	myositis	myositis	NOUN
dpc-2641	31	16	,	,	PUNCT
dpc-2641	31	17	systemic	systemic	ADJ
dpc-2641	31	18	sclerosis	sclerosis	NOUN
dpc-2641	31	19	,	,	PUNCT
dpc-2641	31	20	and	and	CCONJ
dpc-2641	31	21	psoriatic	psoriatic	ADJ
dpc-2641	31	22	arthritis	arthritis	NOUN
dpc-2641	31	23	)	)	PUNCT
dpc-2641	32	1	[	[	X
dpc-2641	32	2	5	5	NUM
dpc-2641	32	3	]	]	PUNCT
dpc-2641	32	4	,	,	PUNCT
dpc-2641	32	5	multiple	multiple	ADJ
dpc-2641	32	6	sclerosis	sclerosis	NOUN
dpc-2641	32	7	,	,	PUNCT
dpc-2641	32	8	and	and	CCONJ
dpc-2641	32	9	autoimmune	autoimmune	ADJ
dpc-2641	32	10	hepatitis	hepatitis	NOUN
dpc-2641	33	1	[	[	X
dpc-2641	33	2	6	6	NUM
dpc-2641	33	3	]	]	PUNCT
dpc-2641	33	4	in	in	ADP
dpc-2641	33	5	adults	adult	NOUN
dpc-2641	33	6	,	,	PUNCT
dpc-2641	33	7	as	as	ADV
dpc-2641	33	8	well	well	ADV
dpc-2641	33	9	as	as	ADP
dpc-2641	33	10	rheumatic	rheumatic	ADJ
dpc-2641	33	11	diseases	disease	NOUN
dpc-2641	33	12	[	[	X
dpc-2641	33	13	7,8	7,8	NUM
dpc-2641	33	14	]	]	PUNCT
dpc-2641	33	15	and	and	CCONJ
dpc-2641	33	16	type	type	NOUN
dpc-2641	33	17	1	1	NUM
dpc-2641	33	18	diabetes	diabetes	NOUN
dpc-2641	33	19	in	in	ADP
dpc-2641	33	20	children	child	NOUN
dpc-2641	34	1	[	[	X
dpc-2641	34	2	9	9	NUM
dpc-2641	34	3	]	]	PUNCT
dpc-2641	34	4	.	.	PUNCT
dpc-2641	35	1	antinuclear	antinuclear	ADJ
dpc-2641	35	2	antibody	antibody	NOUN
dpc-2641	35	3	(	(	PUNCT
dpc-2641	35	4	ana	ana	PROPN
dpc-2641	35	5	)	)	PUNCT
dpc-2641	35	6	tests	test	NOUN
dpc-2641	35	7	were	be	AUX
dpc-2641	35	8	mainly	mainly	ADV
dpc-2641	35	9	developed	develop	VERB
dpc-2641	35	10	for	for	ADP
dpc-2641	35	11	systemic	systemic	ADJ
dpc-2641	35	12	lupus	lupus	PROPN
dpc-2641	35	13	erythematosus	erythematosus	NOUN
dpc-2641	35	14	screening	screen	VERB
dpc-2641	35	15	.	.	PUNCT
dpc-2641	36	1	however	however	ADV
dpc-2641	36	2	,	,	PUNCT
dpc-2641	36	3	ana	ana	PROPN
dpc-2641	36	4	positivity	positivity	NOUN
dpc-2641	36	5	has	have	AUX
dpc-2641	36	6	also	also	ADV
dpc-2641	36	7	been	be	AUX
dpc-2641	36	8	detected	detect	VERB
dpc-2641	36	9	in	in	ADP
dpc-2641	36	10	many	many	ADJ
dpc-2641	36	11	rheumatic	rheumatic	ADJ
dpc-2641	36	12	diseases	disease	NOUN
dpc-2641	36	13	and	and	CCONJ
dpc-2641	36	14	is	be	AUX
dpc-2641	36	15	an	an	DET
dpc-2641	36	16	indicator	indicator	NOUN
dpc-2641	36	17	of	of	ADP
dpc-2641	36	18	autoimmunity	autoimmunity	NOUN
dpc-2641	36	19	[	[	X
dpc-2641	36	20	10	10	NUM
dpc-2641	36	21	]	]	PUNCT
dpc-2641	36	22	.	.	PUNCT
dpc-2641	37	1	ana	ana	PROPN
dpc-2641	37	2	positivity	positivity	PROPN
dpc-2641	37	3	is	be	AUX
dpc-2641	37	4	not	not	PART
dpc-2641	37	5	expected	expect	VERB
dpc-2641	37	6	in	in	ADP
dpc-2641	37	7	non	non	ADJ
dpc-2641	37	8	-	-	ADJ
dpc-2641	37	9	scarring	scarring	ADJ
dpc-2641	37	10	hair	hair	NOUN
dpc-2641	37	11	loss	loss	NOUN
dpc-2641	37	12	.	.	PUNCT
dpc-2641	38	1	in	in	ADP
dpc-2641	38	2	only	only	ADV
dpc-2641	38	3	one	one	NUM
dpc-2641	38	4	study	study	NOUN
dpc-2641	38	5	,	,	PUNCT
dpc-2641	38	6	the	the	DET
dpc-2641	38	7	rate	rate	NOUN
dpc-2641	38	8	of	of	ADP
dpc-2641	38	9	ana	ana	PROPN
dpc-2641	38	10	positivity	positivity	NOUN
dpc-2641	38	11	was	be	AUX
dpc-2641	38	12	reported	report	VERB
dpc-2641	38	13	in	in	ADP
dpc-2641	38	14	patients	patient	NOUN
dpc-2641	38	15	with	with	ADP
dpc-2641	38	16	pattern	pattern	NOUN
dpc-2641	38	17	hair	hair	NOUN
dpc-2641	38	18	loss	loss	NOUN
dpc-2641	38	19	(	(	PUNCT
dpc-2641	38	20	30.4	30.4	NUM
dpc-2641	38	21	%	%	NOUN
dpc-2641	38	22	)	)	PUNCT
dpc-2641	39	1	[	[	X
dpc-2641	39	2	11	11	NUM
dpc-2641	39	3	]	]	PUNCT
dpc-2641	39	4	.	.	PUNCT
dpc-2641	40	1	objectives	objective	NOUN
dpc-2641	40	2	since	since	SCONJ
dpc-2641	40	3	covid-19	covid-19	PROPN
dpc-2641	40	4	can	can	AUX
dpc-2641	40	5	trigger	trigger	VERB
dpc-2641	40	6	autoimmunity	autoimmunity	NOUN
dpc-2641	40	7	,	,	PUNCT
dpc-2641	40	8	and	and	CCONJ
dpc-2641	40	9	as	as	SCONJ
dpc-2641	40	10	hair	hair	NOUN
dpc-2641	40	11	loss	loss	NOUN
dpc-2641	40	12	is	be	AUX
dpc-2641	40	13	one	one	NUM
dpc-2641	40	14	of	of	ADP
dpc-2641	40	15	the	the	DET
dpc-2641	40	16	most	most	ADV
dpc-2641	40	17	common	common	ADJ
dpc-2641	40	18	symptoms	symptom	NOUN
dpc-2641	40	19	after	after	ADP
dpc-2641	40	20	covid-19	covid-19	PROPN
dpc-2641	40	21	infection	infection	NOUN
dpc-2641	40	22	,	,	PUNCT
dpc-2641	40	23	this	this	DET
dpc-2641	40	24	study	study	NOUN
dpc-2641	40	25	aimed	aim	VERB
dpc-2641	40	26	to	to	PART
dpc-2641	40	27	evaluate	evaluate	VERB
dpc-2641	40	28	the	the	DET
dpc-2641	40	29	relationship	relationship	NOUN
dpc-2641	40	30	between	between	ADP
dpc-2641	40	31	the	the	DET
dpc-2641	40	32	two	two	NUM
dpc-2641	40	33	and	and	CCONJ
dpc-2641	40	34	investigate	investigate	VERB
dpc-2641	40	35	the	the	DET
dpc-2641	40	36	differences	difference	NOUN
dpc-2641	40	37	between	between	ADP
dpc-2641	40	38	autoimmunity	autoimmunity	NOUN
dpc-2641	40	39	and	and	CCONJ
dpc-2641	40	40	non	non	ADJ
dpc-2641	40	41	-	-	ADJ
dpc-2641	40	42	autoimmunity	autoimmunity	NOUN
dpc-2641	40	43	-	-	PUNCT
dpc-2641	40	44	related	relate	VERB
dpc-2641	40	45	hair	hair	NOUN
dpc-2641	40	46	loss	loss	NOUN
dpc-2641	40	47	.	.	PUNCT
dpc-2641	41	1	methods	method	NOUN
dpc-2641	41	2	this	this	DET
dpc-2641	41	3	cross	cross	ADJ
dpc-2641	41	4	-	-	ADJ
dpc-2641	41	5	sectional	sectional	ADJ
dpc-2641	41	6	case	case	NOUN
dpc-2641	41	7	-	-	PUNCT
dpc-2641	41	8	control	control	NOUN
dpc-2641	41	9	study	study	NOUN
dpc-2641	41	10	was	be	AUX
dpc-2641	41	11	performed	perform	VERB
dpc-2641	41	12	between	between	ADP
dpc-2641	41	13	june	june	PROPN
dpc-2641	41	14	and	and	CCONJ
dpc-2641	41	15	september	september	PROPN
dpc-2641	41	16	2021	2021	NUM
dpc-2641	41	17	.	.	PUNCT
dpc-2641	42	1	the	the	DET
dpc-2641	42	2	case	case	NOUN
dpc-2641	42	3	group	group	NOUN
dpc-2641	42	4	consisted	consist	VERB
dpc-2641	42	5	of	of	ADP
dpc-2641	42	6	30	30	NUM
dpc-2641	42	7	patients	patient	NOUN
dpc-2641	42	8	who	who	PRON
dpc-2641	42	9	had	have	AUX
dpc-2641	42	10	contracted	contract	VERB
dpc-2641	42	11	covid-19	covid-19	PROPN
dpc-2641	42	12	up	up	ADP
dpc-2641	42	13	to	to	ADP
dpc-2641	42	14	12	12	NUM
dpc-2641	42	15	 	 	SPACE
dpc-2641	42	16	weeks	week	NOUN
dpc-2641	42	17	previously	previously	ADV
dpc-2641	42	18	and	and	CCONJ
dpc-2641	42	19	had	have	VERB
dpc-2641	42	20	hair	hair	NOUN
dpc-2641	42	21	loss	loss	NOUN
dpc-2641	42	22	complaints	complaint	NOUN
dpc-2641	42	23	.	.	PUNCT
dpc-2641	43	1	the	the	DET
dpc-2641	43	2	control	control	PROPN
dpc-2641	43	3	group	group	NOUN
dpc-2641	43	4	consisted	consist	VERB
dpc-2641	43	5	of	of	ADP
dpc-2641	43	6	60	60	NUM
dpc-2641	43	7	patients	patient	NOUN
dpc-2641	43	8	who	who	PRON
dpc-2641	43	9	complained	complain	VERB
dpc-2641	43	10	about	about	ADP
dpc-2641	43	11	hair	hair	NOUN
dpc-2641	43	12	loss	loss	NOUN
dpc-2641	43	13	but	but	CCONJ
dpc-2641	43	14	did	do	AUX
dpc-2641	43	15	not	not	PART
dpc-2641	43	16	have	have	VERB
dpc-2641	43	17	covid-19	covid-19	PROPN
dpc-2641	43	18	.	.	PROPN
dpc-2641	44	1	for	for	ADP
dpc-2641	44	2	the	the	DET
dpc-2641	44	3	control	control	NOUN
dpc-2641	44	4	group	group	NOUN
dpc-2641	44	5	,	,	PUNCT
dpc-2641	44	6	each	each	DET
dpc-2641	44	7	patient	patient	NOUN
dpc-2641	44	8	consisted	consist	VERB
dpc-2641	44	9	of	of	ADP
dpc-2641	44	10	2	2	NUM
dpc-2641	44	11	consecutive	consecutive	ADJ
dpc-2641	44	12	patients	patient	NOUN
dpc-2641	44	13	who	who	PRON
dpc-2641	44	14	came	come	VERB
dpc-2641	44	15	to	to	ADP
dpc-2641	44	16	the	the	DET
dpc-2641	44	17	dermatology	dermatology	NOUN
dpc-2641	44	18	outpatient	outpatient	NOUN
dpc-2641	44	19	clinic	clinic	NOUN
dpc-2641	44	20	immediately	immediately	ADV
dpc-2641	44	21	after	after	SCONJ
dpc-2641	44	22	the	the	DET
dpc-2641	44	23	patient	patient	NOUN
dpc-2641	44	24	selected	select	VERB
dpc-2641	44	25	for	for	ADP
dpc-2641	44	26	covid-19related	covid-19relate	VERB
dpc-2641	44	27	hair	hair	NOUN
dpc-2641	44	28	loss	loss	NOUN
dpc-2641	44	29	.	.	PUNCT
dpc-2641	45	1	patients	patient	NOUN
dpc-2641	45	2	under	under	ADP
dpc-2641	45	3	the	the	DET
dpc-2641	45	4	age	age	NOUN
dpc-2641	45	5	of	of	ADP
dpc-2641	45	6	18	18	NUM
dpc-2641	45	7	years	year	NOUN
dpc-2641	45	8	,	,	PUNCT
dpc-2641	45	9	patients	patient	NOUN
dpc-2641	45	10	with	with	ADP
dpc-2641	45	11	autoimmune	autoimmune	ADJ
dpc-2641	45	12	or	or	CCONJ
dpc-2641	45	13	inflammatory	inflammatory	ADJ
dpc-2641	45	14	diseases	disease	NOUN
dpc-2641	45	15	or	or	CCONJ
dpc-2641	45	16	acute	acute	ADJ
dpc-2641	45	17	or	or	CCONJ
dpc-2641	45	18	chronic	chronic	ADJ
dpc-2641	45	19	infections	infection	NOUN
dpc-2641	45	20	,	,	PUNCT
dpc-2641	45	21	patients	patient	NOUN
dpc-2641	45	22	receiving	receive	VERB
dpc-2641	45	23	any	any	DET
dpc-2641	45	24	medications	medication	NOUN
dpc-2641	45	25	(	(	PUNCT
dpc-2641	45	26	corticosteroids	corticosteroid	NOUN
dpc-2641	45	27	,	,	PUNCT
dpc-2641	45	28	biological	biological	ADJ
dpc-2641	45	29	agents	agent	NOUN
dpc-2641	45	30	,	,	PUNCT
dpc-2641	45	31	antibiotics	antibiotic	NOUN
dpc-2641	45	32	,	,	PUNCT
dpc-2641	45	33	or	or	CCONJ
dpc-2641	45	34	vitamin	vitamin	NOUN
dpc-2641	45	35	or	or	CCONJ
dpc-2641	45	36	mineral	mineral	NOUN
dpc-2641	45	37	supplements	supplement	NOUN
dpc-2641	45	38	)	)	PUNCT
dpc-2641	45	39	,	,	PUNCT
dpc-2641	45	40	and	and	CCONJ
dpc-2641	45	41	pregnant	pregnant	ADJ
dpc-2641	45	42	or	or	CCONJ
dpc-2641	45	43	lactating	lactate	VERB
dpc-2641	45	44	women	woman	NOUN
dpc-2641	45	45	were	be	AUX
dpc-2641	45	46	excluded	exclude	VERB
dpc-2641	45	47	from	from	ADP
dpc-2641	45	48	the	the	DET
dpc-2641	45	49	study	study	NOUN
dpc-2641	45	50	.	.	PUNCT
dpc-2641	46	1	covid-19	covid-19	PROPN
dpc-2641	46	2	infection	infection	NOUN
dpc-2641	46	3	was	be	AUX
dpc-2641	46	4	confirmed	confirm	VERB
dpc-2641	46	5	using	use	VERB
dpc-2641	46	6	nasopharyngeal	nasopharyngeal	ADJ
dpc-2641	46	7	swabs	swab	NOUN
dpc-2641	46	8	and	and	CCONJ
dpc-2641	46	9	polymerase	polymerase	NOUN
dpc-2641	46	10	chain	chain	NOUN
dpc-2641	46	11	reaction	reaction	NOUN
dpc-2641	46	12	tests	test	NOUN
dpc-2641	46	13	.	.	PUNCT
dpc-2641	47	1	demographic	demographic	ADJ
dpc-2641	47	2	characteristics	characteristic	NOUN
dpc-2641	47	3	(	(	PUNCT
dpc-2641	47	4	age	age	NOUN
dpc-2641	47	5	and	and	CCONJ
dpc-2641	47	6	gender	gender	NOUN
dpc-2641	47	7	)	)	PUNCT
dpc-2641	47	8	and	and	CCONJ
dpc-2641	47	9	clinical	clinical	ADJ
dpc-2641	47	10	findings	finding	NOUN
dpc-2641	47	11	(	(	PUNCT
dpc-2641	47	12	date	date	NOUN
dpc-2641	47	13	of	of	ADP
dpc-2641	47	14	covid-19	covid-19	PROPN
dpc-2641	47	15	infection	infection	NOUN
dpc-2641	47	16	,	,	PUNCT
dpc-2641	47	17	duration	duration	NOUN
dpc-2641	47	18	of	of	ADP
dpc-2641	47	19	hair	hair	NOUN
dpc-2641	47	20	loss	loss	NOUN
dpc-2641	47	21	after	after	ADP
dpc-2641	47	22	covid-19	covid-19	PROPN
dpc-2641	47	23	infection	infection	NOUN
dpc-2641	47	24	(	(	PUNCT
dpc-2641	47	25	time	time	NOUN
dpc-2641	47	26	from	from	ADP
dpc-2641	47	27	hair	hair	NOUN
dpc-2641	47	28	loss	loss	NOUN
dpc-2641	47	29	onset	onset	NOUN
dpc-2641	47	30	to	to	ADP
dpc-2641	47	31	presentation	presentation	NOUN
dpc-2641	47	32	to	to	ADP
dpc-2641	47	33	the	the	DET
dpc-2641	47	34	clinic	clinic	NOUN
dpc-2641	47	35	)	)	PUNCT
dpc-2641	47	36	,	,	PUNCT
dpc-2641	47	37	severity	severity	NOUN
dpc-2641	47	38	of	of	ADP
dpc-2641	47	39	hair	hair	NOUN
dpc-2641	47	40	loss	loss	NOUN
dpc-2641	47	41	,	,	PUNCT
dpc-2641	47	42	and	and	CCONJ
dpc-2641	47	43	presence	presence	NOUN
dpc-2641	47	44	of	of	ADP
dpc-2641	47	45	trichodynia	trichodynia	PROPN
dpc-2641	47	46	,	,	PUNCT
dpc-2641	47	47	oily	oily	ADJ
dpc-2641	47	48	scalp	scalp	NOUN
dpc-2641	47	49	,	,	PUNCT
dpc-2641	47	50	dandruff	dandruff	NOUN
dpc-2641	47	51	,	,	PUNCT
dpc-2641	47	52	and	and	CCONJ
dpc-2641	47	53	diffuse	diffuse	VERB
dpc-2641	47	54	hair	hair	NOUN
dpc-2641	47	55	loss	loss	NOUN
dpc-2641	47	56	)	)	PUNCT
dpc-2641	47	57	were	be	AUX
dpc-2641	47	58	collected	collect	VERB
dpc-2641	47	59	.	.	PUNCT
dpc-2641	48	1	hair	hair	NOUN
dpc-2641	48	2	loss	loss	NOUN
dpc-2641	48	3	was	be	AUX
dpc-2641	48	4	recorded	record	VERB
dpc-2641	48	5	using	use	VERB
dpc-2641	48	6	the	the	DET
dpc-2641	48	7	hair	hair	NOUN
dpc-2641	48	8	-	-	PUNCT
dpc-2641	48	9	shedding	shed	VERB
dpc-2641	48	10	visual	visual	ADJ
dpc-2641	48	11	scale	scale	NOUN
dpc-2641	49	1	[	[	X
dpc-2641	49	2	12	12	NUM
dpc-2641	49	3	]	]	PUNCT
dpc-2641	49	4	as	as	SCONJ
dpc-2641	49	5	follows	follow	VERB
dpc-2641	49	6	:	:	PUNCT
dpc-2641	49	7	<	<	X
dpc-2641	49	8	50	50	NUM
dpc-2641	49	9	,	,	PUNCT
dpc-2641	49	10	50–100	50–100	NUM
dpc-2641	49	11	,	,	PUNCT
dpc-2641	49	12	100–150	100–150	NUM
dpc-2641	49	13	,	,	PUNCT
dpc-2641	49	14	and	and	CCONJ
dpc-2641	49	15	>	>	X
dpc-2641	49	16	150	150	NUM
dpc-2641	49	17	hairs	hair	NOUN
dpc-2641	49	18	/	/	SYM
dpc-2641	49	19	day	day	NOUN
dpc-2641	49	20	.	.	PUNCT
dpc-2641	50	1	additionally	additionally	ADV
dpc-2641	50	2	,	,	PUNCT
dpc-2641	50	3	a	a	DET
dpc-2641	50	4	pull	pull	NOUN
dpc-2641	50	5	test	test	NOUN
dpc-2641	50	6	was	be	AUX
dpc-2641	50	7	performed	perform	VERB
dpc-2641	50	8	at	at	ADP
dpc-2641	50	9	four	four	NUM
dpc-2641	50	10	locations	location	NOUN
dpc-2641	50	11	on	on	ADP
dpc-2641	50	12	the	the	DET
dpc-2641	50	13	scalp	scalp	NOUN
dpc-2641	50	14	.	.	PUNCT
dpc-2641	51	1	the	the	DET
dpc-2641	51	2	pull	pull	NOUN
dpc-2641	51	3	test	test	NOUN
dpc-2641	51	4	was	be	AUX
dpc-2641	51	5	considered	consider	VERB
dpc-2641	51	6	positive	positive	ADJ
dpc-2641	51	7	when	when	SCONJ
dpc-2641	51	8	more	more	ADJ
dpc-2641	51	9	than	than	ADP
dpc-2641	51	10	10	10	NUM
dpc-2641	51	11	%	%	NOUN
dpc-2641	51	12	of	of	ADP
dpc-2641	51	13	the	the	DET
dpc-2641	51	14	hair	hair	NOUN
dpc-2641	51	15	at	at	ADP
dpc-2641	51	16	each	each	DET
dpc-2641	51	17	location	location	NOUN
dpc-2641	51	18	was	be	AUX
dpc-2641	51	19	removed	remove	VERB
dpc-2641	51	20	after	after	ADP
dpc-2641	51	21	applying	apply	VERB
dpc-2641	51	22	steady	steady	ADJ
dpc-2641	51	23	traction	traction	NOUN
dpc-2641	51	24	.	.	PUNCT
dpc-2641	52	1	chemiluminescence	chemiluminescence	NOUN
dpc-2641	52	2	enzyme	enzyme	NOUN
dpc-2641	52	3	immunoassays	immunoassay	NOUN
dpc-2641	52	4	were	be	AUX
dpc-2641	52	5	performed	perform	VERB
dpc-2641	52	6	to	to	PART
dpc-2641	52	7	measure	measure	VERB
dpc-2641	52	8	vitamin	vitamin	NOUN
dpc-2641	52	9	b12	b12	NOUN
dpc-2641	52	10	and	and	CCONJ
dpc-2641	52	11	ferritin	ferritin	ADJ
dpc-2641	52	12	levels	level	NOUN
dpc-2641	52	13	using	use	VERB
dpc-2641	52	14	an	an	DET
dpc-2641	52	15	immunity	immunity	NOUN
dpc-2641	52	16	2000	2000	NUM
dpc-2641	52	17	device	device	NOUN
dpc-2641	52	18	(	(	PUNCT
dpc-2641	52	19	diagnostic	diagnostic	ADJ
dpc-2641	52	20	products	product	NOUN
dpc-2641	52	21	corporation	corporation	NOUN
dpc-2641	52	22	)	)	PUNCT
dpc-2641	52	23	.	.	PUNCT
dpc-2641	53	1	tsh	tsh	NOUN
dpc-2641	53	2	(	(	PUNCT
dpc-2641	53	3	thyroid	thyroid	NOUN
dpc-2641	53	4	stimulating	stimulate	VERB
dpc-2641	53	5	hormone	hormone	NOUN
dpc-2641	53	6	)	)	PUNCT
dpc-2641	53	7	and	and	CCONJ
dpc-2641	53	8	anti	anti	ADJ
dpc-2641	53	9	-	-	ADJ
dpc-2641	53	10	tpo	tpo	ADJ
dpc-2641	53	11	(	(	PUNCT
dpc-2641	53	12	anti	anti	ADJ
dpc-2641	53	13	-	-	ADJ
dpc-2641	53	14	thyroid	thyroid	ADJ
dpc-2641	53	15	peroxidase	peroxidase	NOUN
dpc-2641	53	16	)	)	PUNCT
dpc-2641	53	17	levels	level	NOUN
dpc-2641	53	18	were	be	AUX
dpc-2641	53	19	measured	measure	VERB
dpc-2641	53	20	using	use	VERB
dpc-2641	53	21	an	an	DET
dpc-2641	53	22	architect	architect	NOUN
dpc-2641	53	23	ci16200	ci16200	NOUN
dpc-2641	53	24	integrated	integrate	VERB
dpc-2641	53	25	system	system	NOUN
dpc-2641	53	26	(	(	PUNCT
dpc-2641	53	27	abbot	abbot	NOUN
dpc-2641	53	28	diagnostics	diagnostic	NOUN
dpc-2641	53	29	)	)	PUNCT
dpc-2641	53	30	.	.	PUNCT
dpc-2641	54	1	antinuclear	antinuclear	ADJ
dpc-2641	54	2	antibody	antibody	NOUN
dpc-2641	54	3	titers	titer	NOUN
dpc-2641	54	4	and	and	CCONJ
dpc-2641	54	5	patterns	pattern	NOUN
dpc-2641	54	6	were	be	AUX
dpc-2641	54	7	studied	study	VERB
dpc-2641	54	8	using	use	VERB
dpc-2641	54	9	enzyme	enzyme	NOUN
dpc-2641	54	10	-	-	PUNCT
dpc-2641	54	11	linked	link	VERB
dpc-2641	54	12	immunosorbent	immunosorbent	ADJ
dpc-2641	54	13	assays	assay	NOUN
dpc-2641	54	14	and	and	CCONJ
dpc-2641	54	15	immunofluorescence	immunofluorescence	NOUN
dpc-2641	54	16	,	,	PUNCT
dpc-2641	54	17	with	with	ADP
dpc-2641	54	18	human	human	ADJ
dpc-2641	54	19	epithelioma	epithelioma	NOUN
dpc-2641	54	20	type	type	NOUN
dpc-2641	54	21	2	2	NUM
dpc-2641	54	22	(	(	PUNCT
dpc-2641	54	23	hep-2	hep-2	NOUN
dpc-2641	54	24	)	)	PUNCT
dpc-2641	54	25	cells	cell	NOUN
dpc-2641	54	26	used	use	VERB
dpc-2641	54	27	as	as	ADP
dpc-2641	54	28	the	the	DET
dpc-2641	54	29	substrate	substrate	NOUN
dpc-2641	54	30	.	.	PUNCT
dpc-2641	55	1	the	the	DET
dpc-2641	55	2	ana	ana	PROPN
dpc-2641	55	3	tests	test	NOUN
dpc-2641	55	4	were	be	AUX
dpc-2641	55	5	first	first	ADV
dpc-2641	55	6	run	run	VERB
dpc-2641	55	7	at	at	ADP
dpc-2641	55	8	titers	titer	NOUN
dpc-2641	55	9	of	of	ADP
dpc-2641	55	10	1:100	1:100	NUM
dpc-2641	55	11	with	with	ADP
dpc-2641	55	12	both	both	DET
dpc-2641	55	13	kits	kit	NOUN
dpc-2641	55	14	,	,	PUNCT
dpc-2641	55	15	and	and	CCONJ
dpc-2641	55	16	positive	positive	ADJ
dpc-2641	55	17	samples	sample	NOUN
dpc-2641	55	18	were	be	AUX
dpc-2641	55	19	reanalyzed	reanalyze	VERB
dpc-2641	55	20	with	with	ADP
dpc-2641	55	21	further	further	ADJ
dpc-2641	55	22	serial	serial	ADJ
dpc-2641	55	23	dilutions	dilution	NOUN
dpc-2641	55	24	(	(	PUNCT
dpc-2641	55	25	1:160	1:160	NUM
dpc-2641	55	26	,	,	PUNCT
dpc-2641	55	27	1:320	1:320	NOUN
dpc-2641	55	28	,	,	PUNCT
dpc-2641	55	29	1:640	1:640	NUM
dpc-2641	55	30	,	,	PUNCT
dpc-2641	55	31	1:1280	1:1280	NUM
dpc-2641	55	32	,	,	PUNCT
dpc-2641	55	33	1:2560	1:2560	NUM
dpc-2641	55	34	,	,	PUNCT
dpc-2641	55	35	and	and	CCONJ
dpc-2641	55	36	1:5120	1:5120	NUM
dpc-2641	55	37	)	)	PUNCT
dpc-2641	55	38	.	.	PUNCT
dpc-2641	56	1	c3	c3	PROPN
dpc-2641	56	2	and	and	CCONJ
dpc-2641	56	3	c4	c4	NOUN
dpc-2641	56	4	levels	level	NOUN
dpc-2641	56	5	were	be	AUX
dpc-2641	56	6	measured	measure	VERB
dpc-2641	56	7	using	use	VERB
dpc-2641	56	8	a	a	DET
dpc-2641	56	9	behring	behring	NOUN
dpc-2641	56	10	nephelometer	nephelometer	NOUN
dpc-2641	56	11	and	and	CCONJ
dpc-2641	56	12	beckman	beckman	PROPN
dpc-2641	56	13	reagent	reagent	PROPN
dpc-2641	56	14	kits	kit	NOUN
dpc-2641	56	15	.	.	PUNCT
dpc-2641	57	1	this	this	DET
dpc-2641	57	2	study	study	NOUN
dpc-2641	57	3	was	be	AUX
dpc-2641	57	4	approved	approve	VERB
dpc-2641	57	5	by	by	ADP
dpc-2641	57	6	the	the	DET
dpc-2641	57	7	tertiary	tertiary	ADJ
dpc-2641	57	8	hospital	hospital	NOUN
dpc-2641	57	9	ethics	ethic	NOUN
dpc-2641	57	10	committee	committee	PROPN
dpc-2641	57	11	(	(	PUNCT
dpc-2641	57	12	no	no	INTJ
dpc-2641	57	13	.	.	NOUN
dpc-2641	57	14	2939	2939	NUM
dpc-2641	57	15	;	;	PUNCT
dpc-2641	57	16	october	october	PROPN
dpc-2641	57	17	8	8	NUM
dpc-2641	57	18	,	,	PUNCT
dpc-2641	57	19	2021	2021	NUM
dpc-2641	57	20	)	)	PUNCT
dpc-2641	57	21	.	.	PUNCT
dpc-2641	58	1	written	write	VERB
dpc-2641	58	2	informed	informed	ADJ
dpc-2641	58	3	consent	consent	NOUN
dpc-2641	58	4	was	be	AUX
dpc-2641	58	5	obtained	obtain	VERB
dpc-2641	58	6	from	from	ADP
dpc-2641	58	7	all	all	DET
dpc-2641	58	8	participants	participant	NOUN
dpc-2641	58	9	.	.	PUNCT
dpc-2641	59	1	statistical	statistical	ADJ
dpc-2641	59	2	analysis	analysis	NOUN
dpc-2641	59	3	statistical	statistical	ADJ
dpc-2641	59	4	analyses	analysis	NOUN
dpc-2641	59	5	were	be	AUX
dpc-2641	59	6	performed	perform	VERB
dpc-2641	59	7	using	use	VERB
dpc-2641	59	8	spss	spss	PROPN
dpc-2641	59	9	version	version	NOUN
dpc-2641	59	10	25.0	25.0	NUM
dpc-2641	59	11	(	(	PUNCT
dpc-2641	59	12	ibm	ibm	PROPN
dpc-2641	59	13	)	)	PUNCT
dpc-2641	59	14	.	.	PUNCT
dpc-2641	60	1	histograms	histogram	NOUN
dpc-2641	60	2	and	and	CCONJ
dpc-2641	60	3	the	the	DET
dpc-2641	60	4	kolmogorov	kolmogorov	PROPN
dpc-2641	60	5	–	–	PUNCT
dpc-2641	60	6	smirnov	smirnov	ADJ
dpc-2641	60	7	test	test	NOUN
dpc-2641	60	8	were	be	AUX
dpc-2641	60	9	used	use	VERB
dpc-2641	60	10	to	to	PART
dpc-2641	60	11	assess	assess	VERB
dpc-2641	60	12	data	datum	NOUN
dpc-2641	60	13	normality	normality	NOUN
dpc-2641	60	14	.	.	PUNCT
dpc-2641	61	1	in	in	ADP
dpc-2641	61	2	descriptive	descriptive	ADJ
dpc-2641	61	3	analyses	analysis	NOUN
dpc-2641	61	4	,	,	PUNCT
dpc-2641	61	5	means	mean	VERB
dpc-2641	61	6	±	±	NUM
dpc-2641	61	7	standard	standard	ADJ
dpc-2641	61	8	deviations	deviation	NOUN
dpc-2641	61	9	and	and	CCONJ
dpc-2641	61	10	medians	median	NOUN
dpc-2641	61	11	were	be	AUX
dpc-2641	61	12	used	use	VERB
dpc-2641	61	13	.	.	PUNCT
dpc-2641	62	1	categorical	categorical	ADJ
dpc-2641	62	2	variables	variable	NOUN
dpc-2641	62	3	were	be	AUX
dpc-2641	62	4	compared	compare	VERB
dpc-2641	62	5	using	use	VERB
dpc-2641	62	6	pearson	pearson	PROPN
dpc-2641	62	7	chi	chi	PROPN
dpc-2641	62	8	-	-	PUNCT
dpc-2641	62	9	squared	square	VERB
dpc-2641	62	10	test	test	NOUN
dpc-2641	62	11	.	.	PUNCT
dpc-2641	63	1	the	the	DET
dpc-2641	63	2	mann	mann	PROPN
dpc-2641	63	3	–	–	PUNCT
dpc-2641	63	4	whitney	whitney	PROPN
dpc-2641	63	5	u	u	PROPN
dpc-2641	63	6	test	test	NOUN
dpc-2641	63	7	was	be	AUX
dpc-2641	63	8	used	use	VERB
dpc-2641	63	9	to	to	PART
dpc-2641	63	10	evaluate	evaluate	VERB
dpc-2641	63	11	non	non	ADJ
dpc-2641	63	12	-	-	ADJ
dpc-2641	63	13	normally	normally	ADV
dpc-2641	63	14	distributed	distribute	VERB
dpc-2641	63	15	(	(	PUNCT
dpc-2641	63	16	nonparametric	nonparametric	NOUN
dpc-2641	63	17	)	)	PUNCT
dpc-2641	63	18	variables	variable	NOUN
dpc-2641	63	19	between	between	ADP
dpc-2641	63	20	the	the	DET
dpc-2641	63	21	case	case	NOUN
dpc-2641	63	22	and	and	CCONJ
dpc-2641	63	23	control	control	NOUN
dpc-2641	63	24	groups	group	NOUN
dpc-2641	63	25	,	,	PUNCT
dpc-2641	63	26	and	and	CCONJ
dpc-2641	63	27	the	the	DET
dpc-2641	63	28	kruskal	kruskal	PROPN
dpc-2641	63	29	–	–	PUNCT
dpc-2641	63	30	wallis	wallis	PROPN
dpc-2641	63	31	test	test	NOUN
dpc-2641	63	32	was	be	AUX
dpc-2641	63	33	used	use	VERB
dpc-2641	63	34	for	for	ADP
dpc-2641	63	35	comparisons	comparison	NOUN
dpc-2641	63	36	between	between	ADP
dpc-2641	63	37	more	more	ADJ
dpc-2641	63	38	than	than	ADP
dpc-2641	63	39	two	two	NUM
dpc-2641	63	40	variables	variable	NOUN
dpc-2641	63	41	.	.	PUNCT
dpc-2641	64	1	spearman	spearman	NOUN
dpc-2641	64	2	correlation	correlation	NOUN
dpc-2641	64	3	coefficient	coefficient	NOUN
dpc-2641	64	4	was	be	AUX
dpc-2641	64	5	used	use	VERB
dpc-2641	64	6	to	to	PART
dpc-2641	64	7	investigate	investigate	VERB
dpc-2641	64	8	correlations	correlation	NOUN
dpc-2641	64	9	between	between	ADP
dpc-2641	64	10	variables	variable	NOUN
dpc-2641	64	11	.	.	PUNCT
dpc-2641	65	1	the	the	DET
dpc-2641	65	2	ability	ability	NOUN
dpc-2641	65	3	of	of	ADP
dpc-2641	65	4	c3	c3	PROPN
dpc-2641	65	5	and	and	CCONJ
dpc-2641	65	6	c4	c4	NOUN
dpc-2641	65	7	values	value	NOUN
dpc-2641	65	8	to	to	PART
dpc-2641	65	9	predict	predict	VERB
dpc-2641	65	10	ana	ana	PROPN
dpc-2641	65	11	positivity	positivity	NOUN
dpc-2641	65	12	was	be	AUX
dpc-2641	65	13	investigated	investigate	VERB
dpc-2641	65	14	using	use	VERB
dpc-2641	65	15	receiver	receiver	NOUN
dpc-2641	65	16	operating	operate	VERB
dpc-2641	65	17	characteristic	characteristic	NOUN
dpc-2641	65	18	(	(	PUNCT
dpc-2641	65	19	roc	roc	NOUN
dpc-2641	65	20	)	)	PUNCT
dpc-2641	65	21	curves	curve	NOUN
dpc-2641	65	22	.	.	PUNCT
dpc-2641	66	1	values	value	NOUN
dpc-2641	66	2	of	of	ADP
dpc-2641	66	3	p	p	NOUN
dpc-2641	66	4	<	<	X
dpc-2641	66	5	0.05	0.05	NUM
dpc-2641	66	6	were	be	AUX
dpc-2641	66	7	considered	consider	VERB
dpc-2641	66	8	statistically	statistically	ADV
dpc-2641	66	9	significant	significant	ADJ
dpc-2641	66	10	.	.	PUNCT
dpc-2641	67	1	results	result	VERB
dpc-2641	67	2	the	the	DET
dpc-2641	67	3	mean	mean	ADJ
dpc-2641	67	4	ages	age	NOUN
dpc-2641	67	5	of	of	ADP
dpc-2641	67	6	the	the	DET
dpc-2641	67	7	patients	patient	NOUN
dpc-2641	67	8	in	in	ADP
dpc-2641	67	9	the	the	DET
dpc-2641	67	10	case	case	NOUN
dpc-2641	67	11	and	and	CCONJ
dpc-2641	67	12	control	control	NOUN
dpc-2641	67	13	groups	group	NOUN
dpc-2641	67	14	were	be	AUX
dpc-2641	67	15	30.0	30.0	NUM
dpc-2641	67	16	±	±	NUM
dpc-2641	67	17	11.2	11.2	NUM
dpc-2641	67	18	and	and	CCONJ
dpc-2641	67	19	29.2	29.2	NUM
dpc-2641	67	20	±	±	NUM
dpc-2641	67	21	8.3	8.3	NUM
dpc-2641	67	22	years	year	NOUN
dpc-2641	67	23	,	,	PUNCT
dpc-2641	67	24	respectively	respectively	ADV
dpc-2641	67	25	.	.	PUNCT
dpc-2641	68	1	the	the	DET
dpc-2641	68	2	difference	difference	NOUN
dpc-2641	68	3	was	be	AUX
dpc-2641	68	4	not	not	PART
dpc-2641	68	5	statistically	statistically	ADV
dpc-2641	68	6	significant	significant	ADJ
dpc-2641	68	7	(	(	PUNCT
dpc-2641	68	8	p	p	X
dpc-2641	68	9	=	=	NOUN
dpc-2641	68	10	0.952	0.952	NUM
dpc-2641	68	11	)	)	PUNCT
dpc-2641	68	12	.	.	PUNCT
dpc-2641	69	1	all	all	DET
dpc-2641	69	2	patients	patient	NOUN
dpc-2641	69	3	were	be	AUX
dpc-2641	69	4	female	female	ADJ
dpc-2641	69	5	.	.	PUNCT
dpc-2641	70	1	there	there	PRON
dpc-2641	70	2	were	be	VERB
dpc-2641	70	3	no	no	DET
dpc-2641	70	4	statistically	statistically	ADV
dpc-2641	70	5	significant	significant	ADJ
dpc-2641	70	6	differences	difference	NOUN
dpc-2641	70	7	in	in	ADP
dpc-2641	70	8	standard	standard	ADJ
dpc-2641	70	9	laboratory	laboratory	NOUN
dpc-2641	70	10	test	test	NOUN
dpc-2641	70	11	values	value	NOUN
dpc-2641	70	12	between	between	ADP
dpc-2641	70	13	the	the	DET
dpc-2641	70	14	two	two	NUM
dpc-2641	70	15	groups	group	NOUN
dpc-2641	70	16	(	(	PUNCT
dpc-2641	70	17	table	table	NOUN
dpc-2641	70	18	 	 	SPACE
dpc-2641	70	19	1	1	NUM
dpc-2641	70	20	)	)	PUNCT
dpc-2641	70	21	.	.	PUNCT
dpc-2641	71	1	conversely	conversely	ADV
dpc-2641	71	2	,	,	PUNCT
dpc-2641	71	3	the	the	DET
dpc-2641	71	4	duration	duration	NOUN
dpc-2641	71	5	of	of	ADP
dpc-2641	71	6	hair	hair	NOUN
dpc-2641	71	7	loss	loss	NOUN
dpc-2641	71	8	was	be	AUX
dpc-2641	71	9	significantly	significantly	ADV
dpc-2641	71	10	longer	long	ADJ
dpc-2641	71	11	in	in	ADP
dpc-2641	71	12	the	the	DET
dpc-2641	71	13	control	control	NOUN
dpc-2641	71	14	group	group	NOUN
dpc-2641	71	15	than	than	ADP
dpc-2641	71	16	in	in	ADP
dpc-2641	71	17	the	the	DET
dpc-2641	71	18	case	case	NOUN
dpc-2641	71	19	group	group	NOUN
dpc-2641	71	20	(	(	PUNCT
dpc-2641	71	21	p	p	X
dpc-2641	71	22	 	 	SPACE
dpc-2641	71	23	<	<	NOUN
dpc-2641	71	24	 	 	SPACE
dpc-2641	71	25	0.001	0.001	NUM
dpc-2641	71	26	)	)	PUNCT
dpc-2641	71	27	.	.	PUNCT
dpc-2641	72	1	in	in	ADP
dpc-2641	72	2	the	the	DET
dpc-2641	72	3	case	case	NOUN
dpc-2641	72	4	group	group	NOUN
dpc-2641	72	5	,	,	PUNCT
dpc-2641	72	6	hair	hair	NOUN
dpc-2641	72	7	loss	loss	NOUN
dpc-2641	72	8	started	start	VERB
dpc-2641	72	9	5.2	5.2	NUM
dpc-2641	72	10	±	±	NUM
dpc-2641	72	11	3.4	3.4	NUM
dpc-2641	72	12	weeks	week	NOUN
dpc-2641	72	13	after	after	ADP
dpc-2641	72	14	covid-19	covid-19	PROPN
dpc-2641	72	15	infection	infection	NOUN
dpc-2641	72	16	.	.	PUNCT
dpc-2641	73	1	original	original	ADJ
dpc-2641	73	2	article	article	NOUN
dpc-2641	73	3	|	|	ADV
dpc-2641	73	4	dermatol	dermatol	ADJ
dpc-2641	73	5	pract	pract	NOUN
dpc-2641	73	6	concept	concept	NOUN
dpc-2641	73	7	.	.	PUNCT
dpc-2641	74	1	2023;13(2):e2023081	2023;13(2):e2023081	NUM
dpc-2641	74	2	3	3	NUM
dpc-2641	74	3	the	the	DET
dpc-2641	74	4	rate	rate	NOUN
dpc-2641	74	5	of	of	ADP
dpc-2641	74	6	patients	patient	NOUN
dpc-2641	74	7	in	in	ADP
dpc-2641	74	8	the	the	DET
dpc-2641	74	9	case	case	NOUN
dpc-2641	74	10	group	group	NOUN
dpc-2641	74	11	losing	lose	VERB
dpc-2641	74	12	more	more	ADJ
dpc-2641	74	13	than	than	ADP
dpc-2641	74	14	100	100	NUM
dpc-2641	74	15	hairs	hair	NOUN
dpc-2641	74	16	per	per	ADP
dpc-2641	74	17	day	day	NOUN
dpc-2641	74	18	was	be	AUX
dpc-2641	74	19	86	86	NUM
dpc-2641	74	20	%	%	NOUN
dpc-2641	74	21	,	,	PUNCT
dpc-2641	74	22	whereas	whereas	SCONJ
dpc-2641	74	23	the	the	DET
dpc-2641	74	24	corresponding	correspond	VERB
dpc-2641	74	25	rate	rate	NOUN
dpc-2641	74	26	in	in	ADP
dpc-2641	74	27	the	the	DET
dpc-2641	74	28	control	control	NOUN
dpc-2641	74	29	group	group	NOUN
dpc-2641	74	30	was	be	AUX
dpc-2641	74	31	only	only	ADV
dpc-2641	74	32	26	26	NUM
dpc-2641	74	33	%	%	NOUN
dpc-2641	74	34	(	(	PUNCT
dpc-2641	74	35	p	p	X
dpc-2641	74	36	<	<	X
dpc-2641	74	37	0.001	0.001	NUM
dpc-2641	74	38	)	)	PUNCT
dpc-2641	74	39	.	.	PUNCT
dpc-2641	75	1	trichodynia	trichodynia	PROPN
dpc-2641	75	2	,	,	PUNCT
dpc-2641	75	3	oily	oily	ADJ
dpc-2641	75	4	scalp	scalp	NOUN
dpc-2641	75	5	,	,	PUNCT
dpc-2641	75	6	and	and	CCONJ
dpc-2641	75	7	diffuse	diffuse	VERB
dpc-2641	75	8	hair	hair	NOUN
dpc-2641	75	9	loss	loss	NOUN
dpc-2641	75	10	were	be	AUX
dpc-2641	75	11	significantly	significantly	ADV
dpc-2641	75	12	more	more	ADV
dpc-2641	75	13	common	common	ADJ
dpc-2641	75	14	in	in	ADP
dpc-2641	75	15	the	the	DET
dpc-2641	75	16	case	case	NOUN
dpc-2641	75	17	group	group	NOUN
dpc-2641	75	18	than	than	ADP
dpc-2641	75	19	in	in	ADP
dpc-2641	75	20	the	the	DET
dpc-2641	75	21	control	control	NOUN
dpc-2641	75	22	group	group	NOUN
dpc-2641	75	23	(	(	PUNCT
dpc-2641	75	24	table	table	NOUN
dpc-2641	75	25	2	2	NUM
dpc-2641	75	26	)	)	PUNCT
dpc-2641	75	27	.	.	PUNCT
dpc-2641	76	1	moreover	moreover	ADV
dpc-2641	76	2	,	,	PUNCT
dpc-2641	76	3	the	the	DET
dpc-2641	76	4	case	case	NOUN
dpc-2641	76	5	group	group	NOUN
dpc-2641	76	6	had	have	VERB
dpc-2641	76	7	a	a	DET
dpc-2641	76	8	significantly	significantly	ADV
dpc-2641	76	9	higher	high	ADJ
dpc-2641	76	10	number	number	NOUN
dpc-2641	76	11	of	of	ADP
dpc-2641	76	12	ana	ana	PROPN
dpc-2641	76	13	-	-	PUNCT
dpc-2641	76	14	positive	positive	ADJ
dpc-2641	76	15	patients	patient	NOUN
dpc-2641	76	16	(	(	PUNCT
dpc-2641	76	17	40.0	40.0	NUM
dpc-2641	76	18	%	%	NOUN
dpc-2641	76	19	)	)	PUNCT
dpc-2641	76	20	than	than	ADP
dpc-2641	76	21	the	the	DET
dpc-2641	76	22	control	control	NOUN
dpc-2641	76	23	group	group	NOUN
dpc-2641	76	24	(	(	PUNCT
dpc-2641	76	25	11.6	11.6	NUM
dpc-2641	76	26	%	%	NOUN
dpc-2641	76	27	)	)	PUNCT
dpc-2641	76	28	(	(	PUNCT
dpc-2641	76	29	p	p	X
dpc-2641	76	30	=	=	NOUN
dpc-2641	76	31	0.002	0.002	NUM
dpc-2641	76	32	)	)	PUNCT
dpc-2641	76	33	.	.	PUNCT
dpc-2641	77	1	the	the	DET
dpc-2641	77	2	rate	rate	NOUN
dpc-2641	77	3	of	of	ADP
dpc-2641	77	4	cytoplasmic	cytoplasmic	ADJ
dpc-2641	77	5	ana	ana	PROPN
dpc-2641	77	6	patterns	pattern	NOUN
dpc-2641	77	7	in	in	ADP
dpc-2641	77	8	the	the	DET
dpc-2641	77	9	case	case	NOUN
dpc-2641	77	10	group	group	NOUN
dpc-2641	77	11	was	be	AUX
dpc-2641	77	12	83	83	NUM
dpc-2641	77	13	%	%	NOUN
dpc-2641	77	14	,	,	PUNCT
dpc-2641	77	15	which	which	PRON
dpc-2641	77	16	was	be	AUX
dpc-2641	77	17	significantly	significantly	ADV
dpc-2641	77	18	higher	high	ADJ
dpc-2641	77	19	than	than	ADP
dpc-2641	77	20	that	that	PRON
dpc-2641	77	21	in	in	ADP
dpc-2641	77	22	the	the	DET
dpc-2641	77	23	control	control	NOUN
dpc-2641	77	24	group	group	NOUN
dpc-2641	77	25	(	(	PUNCT
dpc-2641	77	26	p	p	NOUN
dpc-2641	77	27	=	=	NOUN
dpc-2641	77	28	0.001	0.001	NUM
dpc-2641	77	29	)	)	PUNCT
dpc-2641	77	30	.	.	PUNCT
dpc-2641	78	1	in	in	ADP
dpc-2641	78	2	the	the	DET
dpc-2641	78	3	control	control	NOUN
dpc-2641	78	4	group	group	NOUN
dpc-2641	78	5	,	,	PUNCT
dpc-2641	78	6	granular	granular	ADJ
dpc-2641	78	7	ana	ana	NOUN
dpc-2641	78	8	patterns	pattern	NOUN
dpc-2641	78	9	represented	represent	VERB
dpc-2641	78	10	71.4	71.4	NUM
dpc-2641	78	11	%	%	NOUN
dpc-2641	78	12	of	of	ADP
dpc-2641	78	13	the	the	DET
dpc-2641	78	14	patients	patient	NOUN
dpc-2641	78	15	.	.	PUNCT
dpc-2641	79	1	there	there	PRON
dpc-2641	79	2	was	be	VERB
dpc-2641	79	3	no	no	DET
dpc-2641	79	4	significant	significant	ADJ
dpc-2641	79	5	relationship	relationship	NOUN
dpc-2641	79	6	between	between	ADP
dpc-2641	79	7	ana	ana	PROPN
dpc-2641	79	8	patterns	pattern	NOUN
dpc-2641	79	9	and	and	CCONJ
dpc-2641	79	10	the	the	DET
dpc-2641	79	11	severity	severity	NOUN
dpc-2641	79	12	of	of	ADP
dpc-2641	79	13	hair	hair	NOUN
dpc-2641	79	14	loss	loss	NOUN
dpc-2641	79	15	in	in	ADP
dpc-2641	79	16	the	the	DET
dpc-2641	79	17	case	case	NOUN
dpc-2641	79	18	group	group	NOUN
dpc-2641	79	19	(	(	PUNCT
dpc-2641	79	20	table	table	NOUN
dpc-2641	79	21	3	3	NUM
dpc-2641	79	22	)	)	PUNCT
dpc-2641	79	23	.	.	PUNCT
dpc-2641	80	1	the	the	DET
dpc-2641	80	2	relationships	relationship	NOUN
dpc-2641	80	3	between	between	ADP
dpc-2641	80	4	ana	ana	PROPN
dpc-2641	80	5	positivity	positivity	NOUN
dpc-2641	80	6	and	and	CCONJ
dpc-2641	80	7	clinical	clinical	ADJ
dpc-2641	80	8	findings	finding	NOUN
dpc-2641	80	9	are	be	AUX
dpc-2641	80	10	shown	show	VERB
dpc-2641	80	11	in	in	ADP
dpc-2641	80	12	table	table	NOUN
dpc-2641	80	13	4	4	NUM
dpc-2641	80	14	.	.	PUNCT
dpc-2641	81	1	in	in	ADP
dpc-2641	81	2	the	the	DET
dpc-2641	81	3	covid	covid	NOUN
dpc-2641	81	4	-	-	PUNCT
dpc-2641	81	5	related	relate	VERB
dpc-2641	81	6	hair	hair	NOUN
dpc-2641	81	7	loss	loss	NOUN
dpc-2641	81	8	group	group	NOUN
dpc-2641	81	9	,	,	PUNCT
dpc-2641	81	10	the	the	DET
dpc-2641	81	11	relationship	relationship	NOUN
dpc-2641	81	12	between	between	ADP
dpc-2641	81	13	ana	ana	PROPN
dpc-2641	81	14	positivity	positivity	NOUN
dpc-2641	81	15	and	and	CCONJ
dpc-2641	81	16	trichodynia	trichodynia	NOUN
dpc-2641	81	17	,	,	PUNCT
dpc-2641	81	18	duration	duration	NOUN
dpc-2641	81	19	of	of	ADP
dpc-2641	81	20	hair	hair	NOUN
dpc-2641	81	21	loss	loss	NOUN
dpc-2641	81	22	(	(	PUNCT
dpc-2641	81	23	week	week	NOUN
dpc-2641	81	24	)	)	PUNCT
dpc-2641	81	25	,	,	PUNCT
dpc-2641	81	26	oilyscalp	oilyscalp	ADJ
dpc-2641	81	27	,	,	PUNCT
dpc-2641	81	28	dandruff	dandruff	NOUN
dpc-2641	81	29	,	,	PUNCT
dpc-2641	81	30	diffuse	diffuse	ADJ
dpc-2641	81	31	loss	loss	NOUN
dpc-2641	81	32	of	of	ADP
dpc-2641	81	33	hair	hair	NOUN
dpc-2641	81	34	volume	volume	NOUN
dpc-2641	81	35	,	,	PUNCT
dpc-2641	81	36	pull	pull	NOUN
dpc-2641	81	37	test	test	NOUN
dpc-2641	81	38	was	be	AUX
dpc-2641	81	39	investigated	investigate	VERB
dpc-2641	81	40	.	.	PUNCT
dpc-2641	82	1	accordingly	accordingly	ADV
dpc-2641	82	2	,	,	PUNCT
dpc-2641	82	3	in	in	ADP
dpc-2641	82	4	the	the	DET
dpc-2641	82	5	covid	covid	NOUN
dpc-2641	82	6	-	-	PUNCT
dpc-2641	82	7	related	relate	VERB
dpc-2641	82	8	hair	hair	NOUN
dpc-2641	82	9	loss	loss	NOUN
dpc-2641	82	10	group	group	NOUN
dpc-2641	82	11	,	,	PUNCT
dpc-2641	82	12	all	all	DET
dpc-2641	82	13	ana	ana	PROPN
dpc-2641	82	14	positive	positive	ADJ
dpc-2641	82	15	patients	patient	NOUN
dpc-2641	82	16	had	have	VERB
dpc-2641	82	17	diffuse	diffuse	ADJ
dpc-2641	82	18	hair	hair	NOUN
dpc-2641	82	19	loss	loss	NOUN
dpc-2641	82	20	(	(	PUNCT
dpc-2641	82	21	12/12	12/12	NUM
dpc-2641	82	22	)	)	PUNCT
dpc-2641	82	23	whereas	whereas	SCONJ
dpc-2641	82	24	only	only	ADV
dpc-2641	82	25	%	%	NOUN
dpc-2641	82	26	22	22	NUM
dpc-2641	82	27	of	of	ADP
dpc-2641	82	28	ana	ana	PROPN
dpc-2641	82	29	negative	negative	ADJ
dpc-2641	82	30	patients	patient	NOUN
dpc-2641	82	31	(	(	PUNCT
dpc-2641	82	32	4/18	4/18	NUM
dpc-2641	82	33	)	)	PUNCT
dpc-2641	82	34	had	have	VERB
dpc-2641	82	35	diffuse	diffuse	ADJ
dpc-2641	82	36	hair	hair	NOUN
dpc-2641	82	37	loss	loss	NOUN
dpc-2641	82	38	and	and	CCONJ
dpc-2641	82	39	pull	pull	VERB
dpc-2641	82	40	test	test	NOUN
dpc-2641	82	41	positivity	positivity	NOUN
dpc-2641	82	42	were	be	AUX
dpc-2641	82	43	statistically	statistically	ADV
dpc-2641	82	44	significantly	significantly	ADV
dpc-2641	82	45	higher	high	ADJ
dpc-2641	82	46	in	in	ADP
dpc-2641	82	47	patients	patient	NOUN
dpc-2641	82	48	with	with	ADP
dpc-2641	82	49	ana	ana	PROPN
dpc-2641	82	50	positivity.in	positivity.in	PROPN
dpc-2641	82	51	the	the	DET
dpc-2641	82	52	case	case	NOUN
dpc-2641	82	53	group	group	NOUN
dpc-2641	82	54	,	,	PUNCT
dpc-2641	82	55	there	there	PRON
dpc-2641	82	56	were	be	VERB
dpc-2641	82	57	no	no	DET
dpc-2641	82	58	significant	significant	ADJ
dpc-2641	82	59	relationships	relationship	NOUN
dpc-2641	82	60	between	between	ADP
dpc-2641	82	61	ana	ana	PROPN
dpc-2641	82	62	positivity	positivity	NOUN
dpc-2641	82	63	and	and	CCONJ
dpc-2641	82	64	pattern	pattern	NOUN
dpc-2641	82	65	or	or	CCONJ
dpc-2641	82	66	trichodynia	trichodynia	NOUN
dpc-2641	82	67	(	(	PUNCT
dpc-2641	82	68	p	p	NOUN
dpc-2641	82	69	=	=	NOUN
dpc-2641	82	70	0.279	0.279	NUM
dpc-2641	82	71	and	and	CCONJ
dpc-2641	82	72	p	p	NOUN
dpc-2641	82	73	=	=	PROPN
dpc-2641	82	74	0.670	0.670	NUM
dpc-2641	82	75	,	,	PUNCT
dpc-2641	82	76	respectively	respectively	ADV
dpc-2641	82	77	)	)	PUNCT
dpc-2641	82	78	.	.	PUNCT
dpc-2641	83	1	likewise	likewise	ADV
dpc-2641	83	2	,	,	PUNCT
dpc-2641	83	3	there	there	PRON
dpc-2641	83	4	was	be	VERB
dpc-2641	83	5	no	no	DET
dpc-2641	83	6	significant	significant	ADJ
dpc-2641	83	7	correlation	correlation	NOUN
dpc-2641	83	8	between	between	ADP
dpc-2641	83	9	hair	hair	NOUN
dpc-2641	83	10	loss	loss	NOUN
dpc-2641	83	11	duration	duration	NOUN
dpc-2641	83	12	and	and	CCONJ
dpc-2641	83	13	ana	ana	PROPN
dpc-2641	83	14	positivity	positivity	NOUN
dpc-2641	83	15	(	(	PUNCT
dpc-2641	83	16	r	r	NOUN
dpc-2641	83	17	=	=	SYM
dpc-2641	83	18	−0.012	−0.012	PROPN
dpc-2641	83	19	,	,	PUNCT
dpc-2641	83	20	p	p	X
dpc-2641	83	21	=	=	NOUN
dpc-2641	83	22	0.949	0.949	NUM
dpc-2641	83	23	)	)	PUNCT
dpc-2641	83	24	.	.	PUNCT
dpc-2641	84	1	no	no	DET
dpc-2641	84	2	significant	significant	ADJ
dpc-2641	84	3	relationships	relationship	NOUN
dpc-2641	84	4	were	be	AUX
dpc-2641	84	5	observed	observe	VERB
dpc-2641	84	6	between	between	ADP
dpc-2641	84	7	ana	ana	PROPN
dpc-2641	84	8	positivity	positivity	NOUN
dpc-2641	84	9	and	and	CCONJ
dpc-2641	84	10	c3	c3	PROPN
dpc-2641	84	11	or	or	CCONJ
dpc-2641	84	12	c4	c4	NOUN
dpc-2641	84	13	levels	level	NOUN
dpc-2641	84	14	in	in	ADP
dpc-2641	84	15	the	the	DET
dpc-2641	84	16	case	case	NOUN
dpc-2641	84	17	group	group	NOUN
dpc-2641	84	18	(	(	PUNCT
dpc-2641	84	19	p	p	NOUN
dpc-2641	84	20	=	=	NOUN
dpc-2641	84	21	0.735	0.735	NUM
dpc-2641	84	22	and	and	CCONJ
dpc-2641	84	23	p	p	NOUN
dpc-2641	84	24	=	=	PROPN
dpc-2641	84	25	0.566	0.566	NUM
dpc-2641	84	26	,	,	PUNCT
dpc-2641	84	27	respectively	respectively	ADV
dpc-2641	84	28	)	)	PUNCT
dpc-2641	84	29	.	.	PUNCT
dpc-2641	85	1	furthermore	furthermore	ADV
dpc-2641	85	2	,	,	PUNCT
dpc-2641	85	3	the	the	DET
dpc-2641	85	4	roc	roc	PROPN
dpc-2641	85	5	analysis	analysis	NOUN
dpc-2641	85	6	indicated	indicate	VERB
dpc-2641	85	7	no	no	DET
dpc-2641	85	8	significant	significant	ADJ
dpc-2641	85	9	cut	cut	NOUN
dpc-2641	85	10	-	-	PUNCT
dpc-2641	85	11	off	off	ADP
dpc-2641	85	12	values	value	NOUN
dpc-2641	85	13	.	.	PUNCT
dpc-2641	86	1	conclusions	conclusion	NOUN
dpc-2641	86	2	ana	ana	PROPN
dpc-2641	86	3	positivity	positivity	PROPN
dpc-2641	86	4	is	be	AUX
dpc-2641	86	5	detected	detect	VERB
dpc-2641	86	6	in	in	ADP
dpc-2641	86	7	many	many	ADJ
dpc-2641	86	8	viral	viral	ADJ
dpc-2641	86	9	and	and	CCONJ
dpc-2641	86	10	autoimmune	autoimmune	ADJ
dpc-2641	86	11	diseases	disease	NOUN
dpc-2641	86	12	.	.	PUNCT
dpc-2641	87	1	however	however	ADV
dpc-2641	87	2	,	,	PUNCT
dpc-2641	87	3	studies	study	NOUN
dpc-2641	87	4	on	on	ADP
dpc-2641	87	5	antibody	antibody	NOUN
dpc-2641	87	6	responses	response	NOUN
dpc-2641	87	7	after	after	ADP
dpc-2641	87	8	covid-19	covid-19	PROPN
dpc-2641	87	9	infection	infection	NOUN
dpc-2641	87	10	have	have	AUX
dpc-2641	87	11	not	not	PART
dpc-2641	87	12	produced	produce	VERB
dpc-2641	87	13	definitive	definitive	ADJ
dpc-2641	87	14	results	result	NOUN
dpc-2641	87	15	[	[	X
dpc-2641	87	16	13,14	13,14	NUM
dpc-2641	87	17	]	]	PUNCT
dpc-2641	87	18	.	.	PUNCT
dpc-2641	88	1	it	it	PRON
dpc-2641	88	2	remains	remain	VERB
dpc-2641	88	3	unclear	unclear	ADJ
dpc-2641	88	4	whether	whether	SCONJ
dpc-2641	88	5	hair	hair	NOUN
dpc-2641	88	6	loss	loss	NOUN
dpc-2641	88	7	after	after	SCONJ
dpc-2641	88	8	covid-19	covid-19	PROPN
dpc-2641	88	9	infection	infection	NOUN
dpc-2641	88	10	is	be	AUX
dpc-2641	88	11	caused	cause	VERB
dpc-2641	88	12	by	by	ADP
dpc-2641	88	13	the	the	DET
dpc-2641	88	14	infection	infection	NOUN
dpc-2641	88	15	itself	itself	PRON
dpc-2641	88	16	,	,	PUNCT
dpc-2641	88	17	the	the	DET
dpc-2641	88	18	autoimmune	autoimmune	ADJ
dpc-2641	88	19	response	response	NOUN
dpc-2641	88	20	to	to	ADP
dpc-2641	88	21	the	the	DET
dpc-2641	88	22	infection	infection	NOUN
dpc-2641	88	23	,	,	PUNCT
dpc-2641	88	24	or	or	CCONJ
dpc-2641	88	25	stress	stress	NOUN
dpc-2641	88	26	triggered	trigger	VERB
dpc-2641	88	27	by	by	ADP
dpc-2641	88	28	the	the	DET
dpc-2641	88	29	covid-19	covid-19	PROPN
dpc-2641	88	30	pandemic	pandemic	NOUN
dpc-2641	88	31	.	.	PUNCT
dpc-2641	89	1	to	to	ADP
dpc-2641	89	2	our	our	PRON
dpc-2641	89	3	knowledge	knowledge	NOUN
dpc-2641	89	4	,	,	PUNCT
dpc-2641	89	5	the	the	DET
dpc-2641	89	6	relationship	relationship	NOUN
dpc-2641	89	7	between	between	ADP
dpc-2641	89	8	covid-19	covid-19	PROPN
dpc-2641	89	9	-	-	PUNCT
dpc-2641	89	10	related	relate	VERB
dpc-2641	89	11	ana	ana	NOUN
dpc-2641	89	12	positivity	positivity	NOUN
dpc-2641	89	13	and	and	CCONJ
dpc-2641	89	14	hair	hair	NOUN
dpc-2641	89	15	loss	loss	NOUN
dpc-2641	89	16	developing	develop	VERB
dpc-2641	89	17	after	after	SCONJ
dpc-2641	89	18	the	the	DET
dpc-2641	89	19	infection	infection	NOUN
dpc-2641	89	20	has	have	AUX
dpc-2641	89	21	not	not	PART
dpc-2641	89	22	been	be	AUX
dpc-2641	89	23	previously	previously	ADV
dpc-2641	89	24	investigated	investigate	VERB
dpc-2641	89	25	.	.	PUNCT
dpc-2641	90	1	in	in	ADP
dpc-2641	90	2	this	this	DET
dpc-2641	90	3	study	study	NOUN
dpc-2641	90	4	,	,	PUNCT
dpc-2641	90	5	we	we	PRON
dpc-2641	90	6	detected	detect	VERB
dpc-2641	90	7	ana	ana	PROPN
dpc-2641	90	8	positivity	positivity	NOUN
dpc-2641	90	9	in	in	ADP
dpc-2641	90	10	40	40	NUM
dpc-2641	90	11	%	%	NOUN
dpc-2641	90	12	of	of	ADP
dpc-2641	90	13	patients	patient	NOUN
dpc-2641	90	14	exhibiting	exhibit	VERB
dpc-2641	90	15	hair	hair	NOUN
dpc-2641	90	16	loss	loss	NOUN
dpc-2641	90	17	after	after	ADP
dpc-2641	90	18	covid-19	covid-19	PROPN
dpc-2641	90	19	infection	infection	NOUN
dpc-2641	90	20	.	.	PUNCT
dpc-2641	91	1	this	this	PRON
dpc-2641	91	2	is	be	AUX
dpc-2641	91	3	consistent	consistent	ADJ
dpc-2641	91	4	with	with	ADP
dpc-2641	91	5	previous	previous	ADJ
dpc-2641	91	6	studies	study	NOUN
dpc-2641	91	7	reporting	report	VERB
dpc-2641	91	8	rates	rate	NOUN
dpc-2641	91	9	ranging	range	VERB
dpc-2641	91	10	from	from	ADP
dpc-2641	91	11	21	21	NUM
dpc-2641	91	12	%	%	NOUN
dpc-2641	91	13	to	to	ADP
dpc-2641	91	14	64	64	NUM
dpc-2641	91	15	%	%	NOUN
dpc-2641	91	16	[	[	X
dpc-2641	91	17	15	15	NUM
dpc-2641	91	18	-	-	SYM
dpc-2641	91	19	20	20	NUM
dpc-2641	91	20	]	]	PUNCT
dpc-2641	91	21	.	.	PUNCT
dpc-2641	92	1	nevertheless	nevertheless	ADV
dpc-2641	92	2	,	,	PUNCT
dpc-2641	92	3	it	it	PRON
dpc-2641	92	4	is	be	AUX
dpc-2641	92	5	important	important	ADJ
dpc-2641	92	6	to	to	PART
dpc-2641	92	7	note	note	VERB
dpc-2641	92	8	that	that	SCONJ
dpc-2641	92	9	all	all	DET
dpc-2641	92	10	covid-19	covid-19	PROPN
dpc-2641	92	11	patients	patient	NOUN
dpc-2641	92	12	in	in	ADP
dpc-2641	92	13	those	those	DET
dpc-2641	92	14	studies	study	NOUN
dpc-2641	92	15	had	have	VERB
dpc-2641	92	16	severe	severe	ADJ
dpc-2641	92	17	or	or	CCONJ
dpc-2641	92	18	moderate	moderate	ADJ
dpc-2641	92	19	covid-19	covid-19	PROPN
dpc-2641	92	20	,	,	PUNCT
dpc-2641	92	21	whereas	whereas	SCONJ
dpc-2641	92	22	the	the	DET
dpc-2641	92	23	patients	patient	NOUN
dpc-2641	92	24	included	include	VERB
dpc-2641	92	25	in	in	ADP
dpc-2641	92	26	our	our	PRON
dpc-2641	92	27	study	study	NOUN
dpc-2641	92	28	had	have	VERB
dpc-2641	92	29	mild	mild	ADJ
dpc-2641	92	30	covid-19	covid-19	PROPN
dpc-2641	92	31	and	and	CCONJ
dpc-2641	92	32	did	do	AUX
dpc-2641	92	33	not	not	PART
dpc-2641	92	34	require	require	VERB
dpc-2641	92	35	hospitalization	hospitalization	NOUN
dpc-2641	92	36	.	.	PUNCT
dpc-2641	93	1	the	the	DET
dpc-2641	93	2	rate	rate	NOUN
dpc-2641	93	3	of	of	ADP
dpc-2641	93	4	ana	ana	PROPN
dpc-2641	93	5	positivity	positivity	NOUN
dpc-2641	93	6	observed	observe	VERB
dpc-2641	93	7	in	in	ADP
dpc-2641	93	8	this	this	DET
dpc-2641	93	9	study	study	NOUN
dpc-2641	93	10	is	be	AUX
dpc-2641	93	11	also	also	ADV
dpc-2641	93	12	in	in	ADP
dpc-2641	93	13	line	line	NOUN
dpc-2641	93	14	with	with	ADP
dpc-2641	93	15	studies	study	NOUN
dpc-2641	93	16	on	on	ADP
dpc-2641	93	17	hair	hair	NOUN
dpc-2641	93	18	diseases	disease	NOUN
dpc-2641	93	19	triggering	trigger	VERB
dpc-2641	93	20	stronger	strong	ADJ
dpc-2641	93	21	autoimmunity	autoimmunity	NOUN
dpc-2641	93	22	.	.	PUNCT
dpc-2641	94	1	such	such	ADJ
dpc-2641	94	2	studies	study	NOUN
dpc-2641	94	3	have	have	AUX
dpc-2641	94	4	reported	report	VERB
dpc-2641	94	5	rates	rate	NOUN
dpc-2641	94	6	of	of	ADP
dpc-2641	94	7	21.2	21.2	NUM
dpc-2641	94	8	%	%	NOUN
dpc-2641	94	9	in	in	ADP
dpc-2641	94	10	telogen	telogen	NOUN
dpc-2641	94	11	effluvium	effluvium	NOUN
dpc-2641	95	1	[	[	X
dpc-2641	95	2	21	21	NUM
dpc-2641	95	3	]	]	X
dpc-2641	95	4	,	,	PUNCT
dpc-2641	95	5	30.4	30.4	NUM
dpc-2641	95	6	%	%	NOUN
dpc-2641	95	7	in	in	ADP
dpc-2641	95	8	pattern	pattern	NOUN
dpc-2641	95	9	hair	hair	NOUN
dpc-2641	95	10	loss	loss	NOUN
dpc-2641	95	11	[	[	X
dpc-2641	95	12	11	11	NUM
dpc-2641	95	13	]	]	PUNCT
dpc-2641	95	14	,	,	PUNCT
dpc-2641	95	15	and	and	CCONJ
dpc-2641	95	16	46	46	NUM
dpc-2641	95	17	%	%	NOUN
dpc-2641	95	18	in	in	ADP
dpc-2641	95	19	lichen	lichen	NOUN
dpc-2641	95	20	planopilaris	planopilaris	NOUN
dpc-2641	96	1	[	[	X
dpc-2641	96	2	22	22	NUM
dpc-2641	96	3	]	]	PUNCT
dpc-2641	96	4	.	.	PUNCT
dpc-2641	97	1	surprisingly	surprisingly	ADV
dpc-2641	97	2	,	,	PUNCT
dpc-2641	97	3	in	in	ADP
dpc-2641	97	4	this	this	DET
dpc-2641	97	5	study	study	NOUN
dpc-2641	97	6	,	,	PUNCT
dpc-2641	97	7	cytoplasmic	cytoplasmic	ADJ
dpc-2641	97	8	ana	ana	PROPN
dpc-2641	97	9	patterns	pattern	NOUN
dpc-2641	97	10	were	be	AUX
dpc-2641	97	11	observed	observe	VERB
dpc-2641	97	12	in	in	ADP
dpc-2641	97	13	83.3	83.3	NUM
dpc-2641	97	14	%	%	NOUN
dpc-2641	97	15	of	of	ADP
dpc-2641	97	16	the	the	DET
dpc-2641	97	17	patients	patient	NOUN
dpc-2641	97	18	with	with	ADP
dpc-2641	97	19	hair	hair	NOUN
dpc-2641	97	20	loss	loss	NOUN
dpc-2641	97	21	after	after	ADP
dpc-2641	97	22	covid-19	covid-19	PROPN
dpc-2641	97	23	infection	infection	NOUN
dpc-2641	97	24	.	.	PUNCT
dpc-2641	98	1	trachtenberg	trachtenberg	PROPN
dpc-2641	98	2	et	et	PROPN
dpc-2641	98	3	al	al	PROPN
dpc-2641	98	4	.	.	PROPN
dpc-2641	98	5	,	,	PUNCT
dpc-2641	98	6	who	who	PRON
dpc-2641	98	7	reported	report	VERB
dpc-2641	98	8	64	64	NUM
dpc-2641	98	9	%	%	NOUN
dpc-2641	98	10	ana	ana	PROPN
dpc-2641	98	11	positivity	positivity	PROPN
dpc-2641	98	12	,	,	PUNCT
dpc-2641	98	13	found	find	VERB
dpc-2641	98	14	a	a	DET
dpc-2641	98	15	highly	highly	ADV
dpc-2641	98	16	dense	dense	ADJ
dpc-2641	98	17	and	and	CCONJ
dpc-2641	98	18	fine	fine	ADV
dpc-2641	98	19	-	-	PUNCT
dpc-2641	98	20	speckled	speckle	VERB
dpc-2641	98	21	cytoplasmic	cytoplasmic	ADJ
dpc-2641	98	22	pattern	pattern	NOUN
dpc-2641	98	23	associated	associate	VERB
dpc-2641	98	24	with	with	ADP
dpc-2641	98	25	covid-19	covid-19	PROPN
dpc-2641	98	26	worsening	worsen	VERB
dpc-2641	98	27	clinical	clinical	ADJ
dpc-2641	98	28	severity	severity	NOUN
dpc-2641	98	29	scores	score	NOUN
dpc-2641	98	30	[	[	X
dpc-2641	98	31	20	20	NUM
dpc-2641	98	32	]	]	PUNCT
dpc-2641	98	33	.	.	PUNCT
dpc-2641	99	1	however	however	ADV
dpc-2641	99	2	,	,	PUNCT
dpc-2641	99	3	as	as	SCONJ
dpc-2641	99	4	previously	previously	ADV
dpc-2641	99	5	noted	note	VERB
dpc-2641	99	6	,	,	PUNCT
dpc-2641	99	7	all	all	DET
dpc-2641	99	8	patients	patient	NOUN
dpc-2641	99	9	with	with	ADP
dpc-2641	99	10	hair	hair	NOUN
dpc-2641	99	11	loss	loss	NOUN
dpc-2641	99	12	in	in	ADP
dpc-2641	99	13	our	our	PRON
dpc-2641	99	14	study	study	NOUN
dpc-2641	99	15	had	have	VERB
dpc-2641	99	16	mild	mild	ADJ
dpc-2641	99	17	covid-19	covid-19	PROPN
dpc-2641	99	18	.	.	PUNCT
dpc-2641	100	1	chang	chang	PROPN
dpc-2641	100	2	et	et	PROPN
dpc-2641	100	3	al	al	PROPN
dpc-2641	100	4	detected	detect	VERB
dpc-2641	100	5	cytoplasmic	cytoplasmic	ADJ
dpc-2641	100	6	patterns	pattern	NOUN
dpc-2641	100	7	at	at	ADP
dpc-2641	100	8	titers	titer	NOUN
dpc-2641	100	9	higher	high	ADJ
dpc-2641	100	10	than	than	ADP
dpc-2641	100	11	1:160	1:160	NUM
dpc-2641	101	1	[	[	X
dpc-2641	101	2	23	23	NUM
dpc-2641	101	3	]	]	PUNCT
dpc-2641	101	4	,	,	PUNCT
dpc-2641	101	5	whereas	whereas	SCONJ
dpc-2641	101	6	in	in	ADP
dpc-2641	101	7	this	this	DET
dpc-2641	101	8	study	study	NOUN
dpc-2641	101	9	,	,	PUNCT
dpc-2641	101	10	we	we	PRON
dpc-2641	101	11	observed	observe	VERB
dpc-2641	101	12	table	table	NOUN
dpc-2641	101	13	1	1	NUM
dpc-2641	101	14	.	.	PUNCT
dpc-2641	101	15	comparison	comparison	NOUN
dpc-2641	101	16	of	of	ADP
dpc-2641	101	17	standard	standard	ADJ
dpc-2641	101	18	laboratory	laboratory	NOUN
dpc-2641	101	19	test	test	NOUN
dpc-2641	101	20	values	value	NOUN
dpc-2641	101	21	of	of	ADP
dpc-2641	101	22	patients	patient	NOUN
dpc-2641	101	23	with	with	ADP
dpc-2641	101	24	covid	covid	ADJ
dpc-2641	101	25	-	-	PUNCT
dpc-2641	101	26	related	relate	VERB
dpc-2641	101	27	hair	hair	NOUN
dpc-2641	101	28	loss	loss	NOUN
dpc-2641	101	29	and	and	CCONJ
dpc-2641	101	30	 	 	SPACE
dpc-2641	101	31	without	without	ADP
dpc-2641	101	32	covid	covid	ADJ
dpc-2641	101	33	-	-	PUNCT
dpc-2641	101	34	related	relate	VERB
dpc-2641	101	35	hair	hair	NOUN
dpc-2641	101	36	loss	loss	NOUN
dpc-2641	101	37	.	.	PUNCT
dpc-2641	102	1	covid	covid	NOUN
dpc-2641	102	2	-	-	PUNCT
dpc-2641	102	3	related	relate	VERB
dpc-2641	102	4	hair	hair	NOUN
dpc-2641	102	5	loss	loss	NOUN
dpc-2641	102	6	group	group	NOUN
dpc-2641	102	7	control	control	NOUN
dpc-2641	102	8	total	total	NOUN
dpc-2641	102	9	pamean	pamean	ADJ
dpc-2641	102	10	sd	sd	NOUN
dpc-2641	102	11	medin	medin	NOUN
dpc-2641	102	12	mean	mean	VERB
dpc-2641	102	13	sd	sd	ADP
dpc-2641	102	14	median	median	NOUN
dpc-2641	102	15	mean	mean	NOUN
dpc-2641	102	16	sd	sd	ADP
dpc-2641	102	17	median	median	ADJ
dpc-2641	102	18	age	age	NOUN
dpc-2641	102	19	(	(	PUNCT
dpc-2641	102	20	years	year	NOUN
dpc-2641	102	21	)	)	PUNCT
dpc-2641	102	22	30.03	30.03	NUM
dpc-2641	102	23	±11.22	±11.22	NUM
dpc-2641	102	24	27.00	27.00	NUM
dpc-2641	102	25	29.15	29.15	NUM
dpc-2641	102	26	±8.32	±8.32	PROPN
dpc-2641	102	27	27.00	27.00	NUM
dpc-2641	102	28	29.44	29.44	NUM
dpc-2641	102	29	±9.33	±9.33	PROPN
dpc-2641	102	30	27.00	27.00	NUM
dpc-2641	102	31	0.952	0.952	NUM
dpc-2641	102	32	duration	duration	NOUN
dpc-2641	102	33	of	of	ADP
dpc-2641	102	34	hair	hair	NOUN
dpc-2641	102	35	loss	loss	NOUN
dpc-2641	102	36	(	(	PUNCT
dpc-2641	102	37	weeks	week	NOUN
dpc-2641	102	38	)	)	PUNCT
dpc-2641	102	39	13.87	13.87	NUM
dpc-2641	102	40	±7.54	±7.54	NOUN
dpc-2641	102	41	12.00	12.00	NUM
dpc-2641	102	42	20.50	20.50	NUM
dpc-2641	102	43	±6.47	±6.47	X
dpc-2641	102	44	20.00	20.00	NUM
dpc-2641	102	45	18.29	18.29	NUM
dpc-2641	102	46	±7.49	±7.49	PROPN
dpc-2641	102	47	20.00	20.00	NUM
dpc-2641	102	48	<	<	NOUN
dpc-2641	102	49	0.001	0.001	NUM
dpc-2641	102	50	vitamin	vitamin	NOUN
dpc-2641	102	51	b12(ng	b12(ng	NUM
dpc-2641	102	52	/	/	SYM
dpc-2641	102	53	l	l	NOUN
dpc-2641	102	54	)	)	PUNCT
dpc-2641	102	55	295.83	295.83	NUM
dpc-2641	102	56	±125.18	±125.18	NOUN
dpc-2641	102	57	280.50	280.50	NUM
dpc-2641	102	58	300.13	300.13	NUM
dpc-2641	102	59	±117.86	±117.86	NOUN
dpc-2641	102	60	279.00	279.00	NUM
dpc-2641	102	61	298.70	298.70	NUM
dpc-2641	102	62	±119.66	±119.66	ADP
dpc-2641	102	63	279.50	279.50	NUM
dpc-2641	102	64	0.911	0.911	NUM
dpc-2641	102	65	ferritin	ferritin	ADJ
dpc-2641	102	66	(	(	PUNCT
dpc-2641	102	67	μgr	μgr	PROPN
dpc-2641	102	68	/	/	SYM
dpc-2641	102	69	l	l	NOUN
dpc-2641	102	70	)	)	PUNCT
dpc-2641	103	1	36.35	36.35	NUM
dpc-2641	103	2	±28.63	±28.63	NUM
dpc-2641	103	3	32.60	32.60	NUM
dpc-2641	103	4	33.33	33.33	NUM
dpc-2641	103	5	±32.62	±32.62	PROPN
dpc-2641	103	6	25.47	25.47	NUM
dpc-2641	103	7	34.34	34.34	NUM
dpc-2641	103	8	±31.22	±31.22	ADP
dpc-2641	103	9	26.38	26.38	NUM
dpc-2641	103	10	0.419	0.419	NUM
dpc-2641	103	11	c3(g	c3(g	NUM
dpc-2641	103	12	/	/	SYM
dpc-2641	103	13	l	l	NOUN
dpc-2641	103	14	)	)	PUNCT
dpc-2641	103	15	1.27	1.27	NUM
dpc-2641	103	16	±0.27	±0.27	PROPN
dpc-2641	103	17	1.26	1.26	NUM
dpc-2641	103	18	1.23	1.23	NUM
dpc-2641	103	19	±0.30	±0.30	PROPN
dpc-2641	103	20	1.26	1.26	NUM
dpc-2641	103	21	1.24	1.24	NUM
dpc-2641	103	22	±0.29	±0.29	PROPN
dpc-2641	103	23	1.26	1.26	NUM
dpc-2641	103	24	0.945	0.945	NUM
dpc-2641	103	25	c4(g	c4(g	NOUN
dpc-2641	103	26	/	/	SYM
dpc-2641	103	27	l	l	NOUN
dpc-2641	103	28	)	)	PUNCT
dpc-2641	103	29	0.64	0.64	NUM
dpc-2641	103	30	±2,20	±2,20	ADP
dpc-2641	103	31	0.25	0.25	NUM
dpc-2641	103	32	0.29	0.29	NUM
dpc-2641	103	33	±0.19	±0.19	NOUN
dpc-2641	103	34	0.26	0.26	NUM
dpc-2641	103	35	0.41	0.41	NUM
dpc-2641	103	36	±1.28	±1.28	NOUN
dpc-2641	103	37	0.25	0.25	NUM
dpc-2641	103	38	0.566	0.566	NUM
dpc-2641	103	39	tsh	tsh	NOUN
dpc-2641	103	40	(	(	PUNCT
dpc-2641	103	41	mu	mu	NOUN
dpc-2641	103	42	/	/	SYM
dpc-2641	103	43	l	l	NOUN
dpc-2641	103	44	)	)	PUNCT
dpc-2641	103	45	2.65	2.65	NUM
dpc-2641	103	46	±2.36	±2.36	NOUN
dpc-2641	103	47	1.98	1.98	NUM
dpc-2641	103	48	2.12	2.12	NUM
dpc-2641	103	49	±0.97	±0.97	NOUN
dpc-2641	103	50	2.04	2.04	NUM
dpc-2641	103	51	2.30	2.30	NUM
dpc-2641	103	52	±1.58	±1.58	PROPN
dpc-2641	103	53	2.04	2.04	NUM
dpc-2641	103	54	0.939	0.939	NUM
dpc-2641	103	55	sd	sd	NOUN
dpc-2641	103	56	=	=	PUNCT
dpc-2641	103	57	standard	standard	ADJ
dpc-2641	103	58	deviation	deviation	NOUN
dpc-2641	103	59	.	.	PUNCT
dpc-2641	104	1	amann	amann	PROPN
dpc-2641	104	2	whitney	whitney	PROPN
dpc-2641	104	3	u	u	PROPN
dpc-2641	104	4	test	test	NOUN
dpc-2641	104	5	4	4	NUM
dpc-2641	104	6	original	original	ADJ
dpc-2641	104	7	article	article	NOUN
dpc-2641	104	8	|	|	ADV
dpc-2641	104	9	dermatol	dermatol	ADJ
dpc-2641	104	10	pract	pract	NOUN
dpc-2641	104	11	concept	concept	NOUN
dpc-2641	104	12	.	.	PUNCT
dpc-2641	105	1	2023;13(2):e2023081	2023;13(2):e2023081	NUM
dpc-2641	105	2	table	table	NOUN
dpc-2641	105	3	2	2	NUM
dpc-2641	105	4	.	.	PUNCT
dpc-2641	105	5	comparison	comparison	NOUN
dpc-2641	105	6	of	of	ADP
dpc-2641	105	7	clinical	clinical	ADJ
dpc-2641	105	8	examination	examination	NOUN
dpc-2641	105	9	and	and	CCONJ
dpc-2641	105	10	laboratory	laboratory	NOUN
dpc-2641	105	11	findings	finding	NOUN
dpc-2641	105	12	of	of	ADP
dpc-2641	105	13	patients	patient	NOUN
dpc-2641	105	14	with	with	ADP
dpc-2641	105	15	covid	covid	ADJ
dpc-2641	105	16	-	-	PUNCT
dpc-2641	105	17	related	relate	VERB
dpc-2641	105	18	hair	hair	NOUN
dpc-2641	105	19	loss	loss	NOUN
dpc-2641	105	20	and	and	CCONJ
dpc-2641	105	21	without	without	ADP
dpc-2641	105	22	covid	covid	NOUN
dpc-2641	105	23	-	-	PUNCT
dpc-2641	105	24	related	relate	VERB
dpc-2641	105	25	hair	hair	NOUN
dpc-2641	105	26	loss	loss	NOUN
dpc-2641	105	27	.	.	PUNCT
dpc-2641	106	1	covid	covid	NOUN
dpc-2641	106	2	-	-	PUNCT
dpc-2641	106	3	related	relate	VERB
dpc-2641	106	4	hair	hair	NOUN
dpc-2641	106	5	loss	loss	NOUN
dpc-2641	106	6	group	group	NOUN
dpc-2641	106	7	control	control	NOUN
dpc-2641	106	8	total	total	PROPN
dpc-2641	106	9	pan	pan	NOUN
dpc-2641	106	10	(	(	PUNCT
dpc-2641	106	11	%	%	NOUN
dpc-2641	106	12	)	)	PUNCT
dpc-2641	106	13	n	n	CCONJ
dpc-2641	106	14	(	(	PUNCT
dpc-2641	106	15	%	%	NOUN
dpc-2641	106	16	)	)	PUNCT
dpc-2641	106	17	n	n	CCONJ
dpc-2641	106	18	(	(	PUNCT
dpc-2641	106	19	%	%	INTJ
dpc-2641	106	20	)	)	PUNCT
dpc-2641	106	21	pre	pre	ADJ
dpc-2641	106	22	-	-	ADJ
dpc-2641	106	23	exisiting	exisite	VERB
dpc-2641	106	24	te	te	ADP
dpc-2641	106	25	no	no	DET
dpc-2641	106	26	20	20	NUM
dpc-2641	106	27	(	(	PUNCT
dpc-2641	106	28	66.67	66.67	NUM
dpc-2641	106	29	)	)	PUNCT
dpc-2641	106	30	41	41	NUM
dpc-2641	106	31	(	(	PUNCT
dpc-2641	106	32	68.33	68.33	NUM
dpc-2641	106	33	)	)	PUNCT
dpc-2641	106	34	61	61	NUM
dpc-2641	106	35	(	(	PUNCT
dpc-2641	106	36	67.78	67.78	NUM
dpc-2641	106	37	)	)	PUNCT
dpc-2641	106	38	0.873	0.873	NUM
dpc-2641	106	39	yes	yes	NOUN
dpc-2641	106	40	10	10	NUM
dpc-2641	106	41	(	(	PUNCT
dpc-2641	106	42	33.33	33.33	NUM
dpc-2641	106	43	)	)	PUNCT
dpc-2641	106	44	19	19	NUM
dpc-2641	106	45	(	(	PUNCT
dpc-2641	106	46	31.67	31.67	NUM
dpc-2641	106	47	)	)	PUNCT
dpc-2641	106	48	29	29	NUM
dpc-2641	106	49	(	(	PUNCT
dpc-2641	106	50	32.22	32.22	NUM
dpc-2641	106	51	)	)	PUNCT
dpc-2641	106	52	amount	amount	NOUN
dpc-2641	106	53	of	of	ADP
dpc-2641	106	54	hair	hair	NOUN
dpc-2641	106	55	loss	loss	NOUN
dpc-2641	106	56	50hairs	50hairs	NUM
dpc-2641	106	57	/	/	SYM
dpc-2641	106	58	day	day	NOUN
dpc-2641	106	59	0	0	NUM
dpc-2641	106	60	(	(	PUNCT
dpc-2641	106	61	0.00	0.00	NUM
dpc-2641	106	62	)	)	SYM
dpc-2641	106	63	5	5	NUM
dpc-2641	106	64	(	(	PUNCT
dpc-2641	106	65	8.33	8.33	NUM
dpc-2641	106	66	)	)	PUNCT
dpc-2641	106	67	5	5	NUM
dpc-2641	106	68	(	(	PUNCT
dpc-2641	106	69	5.56	5.56	NUM
dpc-2641	106	70	)	)	PUNCT
dpc-2641	106	71	<	<	X
dpc-2641	106	72	0.001	0.001	NUM
dpc-2641	106	73	50	50	NUM
dpc-2641	106	74	-	-	PUNCT
dpc-2641	106	75	100hairs	100hairs	NUM
dpc-2641	106	76	/	/	SYM
dpc-2641	106	77	day	day	NOUN
dpc-2641	106	78	4	4	NUM
dpc-2641	106	79	(	(	PUNCT
dpc-2641	106	80	13.33	13.33	NUM
dpc-2641	106	81	)	)	PUNCT
dpc-2641	106	82	39	39	NUM
dpc-2641	106	83	(	(	PUNCT
dpc-2641	106	84	65.00	65.00	NUM
dpc-2641	106	85	)	)	PUNCT
dpc-2641	106	86	43	43	NUM
dpc-2641	106	87	(	(	PUNCT
dpc-2641	106	88	47.78	47.78	NUM
dpc-2641	106	89	)	)	PUNCT
dpc-2641	106	90	100	100	NUM
dpc-2641	106	91	-	-	PUNCT
dpc-2641	106	92	150hairs	150hairs	NUM
dpc-2641	106	93	/	/	SYM
dpc-2641	106	94	day	day	NOUN
dpc-2641	106	95	24	24	NUM
dpc-2641	106	96	(	(	PUNCT
dpc-2641	106	97	80.00	80.00	NUM
dpc-2641	106	98	)	)	PUNCT
dpc-2641	106	99	16	16	NUM
dpc-2641	106	100	(	(	PUNCT
dpc-2641	106	101	26.67	26.67	NUM
dpc-2641	106	102	)	)	PUNCT
dpc-2641	106	103	40	40	NUM
dpc-2641	106	104	(	(	PUNCT
dpc-2641	106	105	44.44	44.44	NUM
dpc-2641	106	106	)	)	PUNCT
dpc-2641	106	107	>	>	X
dpc-2641	106	108	150hairs	150hairs	PROPN
dpc-2641	106	109	/	/	SYM
dpc-2641	106	110	day	day	NOUN
dpc-2641	106	111	2	2	NUM
dpc-2641	106	112	(	(	PUNCT
dpc-2641	106	113	6.67	6.67	NUM
dpc-2641	106	114	)	)	PUNCT
dpc-2641	106	115	0	0	NUM
dpc-2641	107	1	(	(	PUNCT
dpc-2641	107	2	0.00	0.00	NUM
dpc-2641	107	3	)	)	SYM
dpc-2641	107	4	2	2	NUM
dpc-2641	107	5	(	(	PUNCT
dpc-2641	107	6	2.22	2.22	NUM
dpc-2641	107	7	)	)	PUNCT
dpc-2641	107	8	trichodynia	trichodynia	NOUN
dpc-2641	108	1	no	no	DET
dpc-2641	108	2	11	11	NUM
dpc-2641	108	3	(	(	PUNCT
dpc-2641	108	4	36.67	36.67	NUM
dpc-2641	108	5	)	)	PUNCT
dpc-2641	108	6	42	42	NUM
dpc-2641	108	7	(	(	PUNCT
dpc-2641	108	8	70.00	70.00	NUM
dpc-2641	108	9	)	)	PUNCT
dpc-2641	108	10	53	53	NUM
dpc-2641	108	11	(	(	PUNCT
dpc-2641	108	12	58.89	58.89	NUM
dpc-2641	108	13	)	)	PUNCT
dpc-2641	108	14	0.002	0.002	NUM
dpc-2641	109	1	yes	yes	NOUN
dpc-2641	109	2	19	19	NUM
dpc-2641	109	3	(	(	PUNCT
dpc-2641	109	4	63.33	63.33	NUM
dpc-2641	109	5	)	)	PUNCT
dpc-2641	109	6	18	18	NUM
dpc-2641	109	7	(	(	PUNCT
dpc-2641	109	8	30.00	30.00	NUM
dpc-2641	109	9	)	)	PUNCT
dpc-2641	109	10	37	37	NUM
dpc-2641	109	11	(	(	PUNCT
dpc-2641	109	12	41.11	41.11	NUM
dpc-2641	109	13	)	)	PUNCT
dpc-2641	109	14	oilyscalp	oilyscalp	ADP
dpc-2641	109	15	no	no	DET
dpc-2641	109	16	15	15	NUM
dpc-2641	109	17	(	(	PUNCT
dpc-2641	109	18	50.00	50.00	NUM
dpc-2641	109	19	)	)	PUNCT
dpc-2641	109	20	44	44	NUM
dpc-2641	109	21	(	(	PUNCT
dpc-2641	109	22	73.33	73.33	NUM
dpc-2641	109	23	)	)	PUNCT
dpc-2641	109	24	59	59	NUM
dpc-2641	109	25	(	(	PUNCT
dpc-2641	109	26	65.56	65.56	NUM
dpc-2641	109	27	)	)	PUNCT
dpc-2641	109	28	0.028	0.028	NUM
dpc-2641	109	29	yes	yes	NUM
dpc-2641	109	30	15	15	NUM
dpc-2641	109	31	(	(	PUNCT
dpc-2641	109	32	50.00	50.00	NUM
dpc-2641	109	33	)	)	PUNCT
dpc-2641	109	34	16	16	NUM
dpc-2641	109	35	(	(	PUNCT
dpc-2641	109	36	26.67	26.67	NUM
dpc-2641	109	37	)	)	PUNCT
dpc-2641	109	38	31	31	NUM
dpc-2641	109	39	(	(	PUNCT
dpc-2641	109	40	34.44	34.44	NUM
dpc-2641	109	41	)	)	PUNCT
dpc-2641	109	42	dandruff	dandruff	NOUN
dpc-2641	109	43	no	no	DET
dpc-2641	109	44	11	11	NUM
dpc-2641	109	45	(	(	PUNCT
dpc-2641	109	46	36.67	36.67	NUM
dpc-2641	109	47	)	)	PUNCT
dpc-2641	109	48	35	35	NUM
dpc-2641	109	49	(	(	PUNCT
dpc-2641	109	50	58.33	58.33	NUM
dpc-2641	109	51	)	)	PUNCT
dpc-2641	109	52	46	46	NUM
dpc-2641	109	53	(	(	PUNCT
dpc-2641	109	54	51.11	51.11	NUM
dpc-2641	109	55	)	)	PUNCT
dpc-2641	109	56	0.053	0.053	NUM
dpc-2641	109	57	yes	yes	NOUN
dpc-2641	109	58	19	19	NUM
dpc-2641	109	59	(	(	PUNCT
dpc-2641	109	60	63.33	63.33	NUM
dpc-2641	109	61	)	)	PUNCT
dpc-2641	109	62	25	25	NUM
dpc-2641	109	63	(	(	PUNCT
dpc-2641	109	64	41.67	41.67	NUM
dpc-2641	109	65	)	)	PUNCT
dpc-2641	109	66	44	44	NUM
dpc-2641	109	67	(	(	PUNCT
dpc-2641	109	68	48.89	48.89	NUM
dpc-2641	109	69	)	)	PUNCT
dpc-2641	109	70	diffuse	diffuse	NOUN
dpc-2641	109	71	loss	loss	NOUN
dpc-2641	109	72	of	of	ADP
dpc-2641	109	73	hair	hair	NOUN
dpc-2641	109	74	volume	volume	NOUN
dpc-2641	109	75	no	no	DET
dpc-2641	109	76	14	14	NUM
dpc-2641	109	77	(	(	PUNCT
dpc-2641	109	78	46.67	46.67	NUM
dpc-2641	109	79	)	)	PUNCT
dpc-2641	109	80	45	45	NUM
dpc-2641	109	81	(	(	PUNCT
dpc-2641	109	82	75.00	75.00	NUM
dpc-2641	109	83	)	)	PUNCT
dpc-2641	109	84	59	59	NUM
dpc-2641	109	85	(	(	PUNCT
dpc-2641	109	86	65.56	65.56	NUM
dpc-2641	109	87	)	)	PUNCT
dpc-2641	110	1	0.008	0.008	NUM
dpc-2641	110	2	yes	yes	NOUN
dpc-2641	110	3	16	16	NUM
dpc-2641	110	4	(	(	PUNCT
dpc-2641	110	5	53.33	53.33	NUM
dpc-2641	110	6	)	)	PUNCT
dpc-2641	110	7	15	15	NUM
dpc-2641	110	8	(	(	PUNCT
dpc-2641	110	9	25.00	25.00	NUM
dpc-2641	110	10	)	)	PUNCT
dpc-2641	110	11	31	31	NUM
dpc-2641	110	12	(	(	PUNCT
dpc-2641	110	13	34.44	34.44	NUM
dpc-2641	110	14	)	)	PUNCT
dpc-2641	110	15	pull	pull	VERB
dpc-2641	110	16	test	test	NOUN
dpc-2641	110	17	negative	negative	ADJ
dpc-2641	110	18	9	9	NUM
dpc-2641	110	19	(	(	PUNCT
dpc-2641	110	20	30.00	30.00	NUM
dpc-2641	110	21	)	)	PUNCT
dpc-2641	110	22	15	15	NUM
dpc-2641	110	23	(	(	PUNCT
dpc-2641	110	24	25.00	25.00	NUM
dpc-2641	110	25	)	)	SYM
dpc-2641	110	26	24	24	NUM
dpc-2641	110	27	(	(	PUNCT
dpc-2641	110	28	26.67	26.67	NUM
dpc-2641	110	29	)	)	PUNCT
dpc-2641	110	30	0.613	0.613	NUM
dpc-2641	110	31	positive	positive	ADJ
dpc-2641	110	32	21	21	NUM
dpc-2641	110	33	(	(	PUNCT
dpc-2641	110	34	70.00	70.00	NUM
dpc-2641	110	35	)	)	PUNCT
dpc-2641	110	36	45	45	NUM
dpc-2641	110	37	(	(	PUNCT
dpc-2641	110	38	75.00	75.00	NUM
dpc-2641	110	39	)	)	PUNCT
dpc-2641	110	40	66	66	NUM
dpc-2641	110	41	(	(	PUNCT
dpc-2641	110	42	73.33	73.33	NUM
dpc-2641	110	43	)	)	PUNCT
dpc-2641	110	44	ana	ana	PROPN
dpc-2641	110	45	positivity	positivity	NOUN
dpc-2641	110	46	negative	negative	ADJ
dpc-2641	110	47	18	18	NUM
dpc-2641	110	48	(	(	PUNCT
dpc-2641	110	49	60.00	60.00	NUM
dpc-2641	110	50	)	)	PUNCT
dpc-2641	110	51	53	53	NUM
dpc-2641	110	52	(	(	PUNCT
dpc-2641	110	53	88.33	88.33	NUM
dpc-2641	110	54	)	)	PUNCT
dpc-2641	110	55	71	71	NUM
dpc-2641	110	56	(	(	PUNCT
dpc-2641	110	57	78.89	78.89	NUM
dpc-2641	110	58	)	)	PUNCT
dpc-2641	110	59	0.002	0.002	NUM
dpc-2641	110	60	positive	positive	ADJ
dpc-2641	110	61	12	12	NUM
dpc-2641	110	62	(	(	PUNCT
dpc-2641	110	63	40.00	40.00	NUM
dpc-2641	110	64	)	)	PUNCT
dpc-2641	110	65	7	7	NUM
dpc-2641	110	66	(	(	PUNCT
dpc-2641	110	67	11.67	11.67	NUM
dpc-2641	110	68	)	)	PUNCT
dpc-2641	110	69	19	19	NUM
dpc-2641	110	70	(	(	PUNCT
dpc-2641	110	71	21.11	21.11	NUM
dpc-2641	110	72	)	)	PUNCT
dpc-2641	110	73	ana	ana	NOUN
dpc-2641	110	74	pattern	pattern	NOUN
dpc-2641	110	75	cytoplasmic	cytoplasmic	ADJ
dpc-2641	110	76	10	10	NUM
dpc-2641	110	77	(	(	PUNCT
dpc-2641	110	78	83.33	83.33	NUM
dpc-2641	110	79	)	)	PUNCT
dpc-2641	110	80	0	0	NUM
dpc-2641	110	81	(	(	PUNCT
dpc-2641	110	82	0.00	0.00	NUM
dpc-2641	110	83	)	)	PUNCT
dpc-2641	110	84	10	10	NUM
dpc-2641	110	85	(	(	PUNCT
dpc-2641	110	86	52.63	52.63	NUM
dpc-2641	110	87	)	)	PUNCT
dpc-2641	110	88	0.001	0.001	NUM
dpc-2641	110	89	granular	granular	NOUN
dpc-2641	110	90	0	0	NUM
dpc-2641	110	91	(	(	PUNCT
dpc-2641	110	92	0.00	0.00	NUM
dpc-2641	110	93	)	)	SYM
dpc-2641	110	94	5	5	NUM
dpc-2641	110	95	(	(	PUNCT
dpc-2641	110	96	71.43	71.43	NUM
dpc-2641	110	97	)	)	PUNCT
dpc-2641	110	98	5	5	NUM
dpc-2641	110	99	(	(	PUNCT
dpc-2641	110	100	26.32	26.32	NUM
dpc-2641	110	101	)	)	PUNCT
dpc-2641	110	102	nucleolar	nucleolar	NOUN
dpc-2641	110	103	1	1	NUM
dpc-2641	110	104	(	(	PUNCT
dpc-2641	110	105	8.33	8.33	NUM
dpc-2641	110	106	)	)	PUNCT
dpc-2641	110	107	0	0	NUM
dpc-2641	110	108	(	(	PUNCT
dpc-2641	110	109	0.00	0.00	NUM
dpc-2641	110	110	)	)	SYM
dpc-2641	110	111	1	1	NUM
dpc-2641	110	112	(	(	PUNCT
dpc-2641	110	113	5.26	5.26	NUM
dpc-2641	110	114	)	)	PUNCT
dpc-2641	110	115	nuclear	nuclear	ADJ
dpc-2641	110	116	/	/	SYM
dpc-2641	110	117	granular	granular	ADJ
dpc-2641	110	118	1	1	NUM
dpc-2641	110	119	(	(	PUNCT
dpc-2641	110	120	8.33	8.33	NUM
dpc-2641	110	121	)	)	PUNCT
dpc-2641	110	122	2	2	NUM
dpc-2641	110	123	(	(	PUNCT
dpc-2641	110	124	28.57	28.57	NUM
dpc-2641	110	125	)	)	PUNCT
dpc-2641	110	126	3	3	NUM
dpc-2641	110	127	(	(	PUNCT
dpc-2641	110	128	15.79	15.79	NUM
dpc-2641	110	129	)	)	PUNCT
dpc-2641	110	130	antitpo	antitpo	NOUN
dpc-2641	110	131	μl	μl	ADP
dpc-2641	110	132	<	<	X
dpc-2641	110	133	9	9	NUM
dpc-2641	110	134	29	29	NUM
dpc-2641	110	135	(	(	PUNCT
dpc-2641	110	136	96.67	96.67	NUM
dpc-2641	110	137	)	)	PUNCT
dpc-2641	110	138	57	57	NUM
dpc-2641	110	139	(	(	PUNCT
dpc-2641	110	140	95.00	95.00	NUM
dpc-2641	110	141	)	)	PUNCT
dpc-2641	110	142	86	86	NUM
dpc-2641	110	143	(	(	PUNCT
dpc-2641	110	144	95.56	95.56	NUM
dpc-2641	110	145	)	)	PUNCT
dpc-2641	110	146	0.718	0.718	NUM
dpc-2641	110	147	>	>	SYM
dpc-2641	110	148	9	9	NUM
dpc-2641	110	149	1	1	NUM
dpc-2641	110	150	(	(	PUNCT
dpc-2641	110	151	3.33	3.33	NUM
dpc-2641	110	152	)	)	PUNCT
dpc-2641	110	153	3	3	NUM
dpc-2641	110	154	(	(	PUNCT
dpc-2641	110	155	5.00	5.00	NUM
dpc-2641	110	156	)	)	PUNCT
dpc-2641	110	157	4	4	NUM
dpc-2641	110	158	(	(	PUNCT
dpc-2641	110	159	4.44	4.44	NUM
dpc-2641	110	160	)	)	PUNCT
dpc-2641	110	161	ana	ana	PROPN
dpc-2641	110	162	=	=	PUNCT
dpc-2641	110	163	antinuclear	antinuclear	ADJ
dpc-2641	110	164	antibody	antibody	NOUN
dpc-2641	110	165	;	;	PUNCT
dpc-2641	110	166	anti	anti	ADJ
dpc-2641	110	167	-	-	ADJ
dpc-2641	110	168	tpo	tpo	NOUN
dpc-2641	110	169	=	=	SYM
dpc-2641	110	170	anti	anti	ADJ
dpc-2641	110	171	-	-	ADJ
dpc-2641	110	172	thyroid	thyroid	ADJ
dpc-2641	110	173	peroxidase	peroxidase	NOUN
dpc-2641	110	174	;	;	PUNCT
dpc-2641	110	175	te	te	PROPN
dpc-2641	110	176	=	=	SYM
dpc-2641	110	177	telogen	telogen	NOUN
dpc-2641	110	178	effluvium	effluvium	NOUN
dpc-2641	110	179	achi	achi	ADJ
dpc-2641	110	180	-	-	PUNCT
dpc-2641	110	181	square	square	ADJ
dpc-2641	110	182	test	test	NOUN
dpc-2641	110	183	table	table	NOUN
dpc-2641	110	184	3	3	NUM
dpc-2641	110	185	.	.	PUNCT
dpc-2641	111	1	the	the	DET
dpc-2641	111	2	relationship	relationship	NOUN
dpc-2641	111	3	between	between	ADP
dpc-2641	111	4	the	the	DET
dpc-2641	111	5	antinuclear	antinuclear	ADJ
dpc-2641	111	6	antibody	antibody	NOUN
dpc-2641	111	7	pattern	pattern	NOUN
dpc-2641	111	8	and	and	CCONJ
dpc-2641	111	9	the	the	DET
dpc-2641	111	10	amount	amount	NOUN
dpc-2641	111	11	of	of	ADP
dpc-2641	111	12	hair	hair	NOUN
dpc-2641	111	13	loss	loss	NOUN
dpc-2641	111	14	in	in	ADP
dpc-2641	111	15	patients	patient	NOUN
dpc-2641	111	16	in	in	ADP
dpc-2641	111	17	the	the	DET
dpc-2641	111	18	covid	covid	NOUN
dpc-2641	111	19	-	-	PUNCT
dpc-2641	111	20	related	relate	VERB
dpc-2641	111	21	hair	hair	NOUN
dpc-2641	111	22	loss	loss	NOUN
dpc-2641	111	23	group	group	NOUN
dpc-2641	111	24	.	.	PUNCT
dpc-2641	112	1	covidrelated	covidrelate	VERB
dpc-2641	112	2	hair	hair	NOUN
dpc-2641	112	3	loss	loss	NOUN
dpc-2641	112	4	group	group	NOUN
dpc-2641	112	5	amount	amount	NOUN
dpc-2641	112	6	of	of	ADP
dpc-2641	112	7	hair	hair	NOUN
dpc-2641	112	8	loss	loss	NOUN
dpc-2641	112	9	p	p	NOUN
dpc-2641	112	10	50	50	NUM
dpc-2641	112	11	hairs	hair	NOUN
dpc-2641	112	12	/	/	SYM
dpc-2641	112	13	day	day	NOUN
dpc-2641	112	14	50	50	NUM
dpc-2641	112	15	-	-	SYM
dpc-2641	112	16	100	100	NUM
dpc-2641	112	17	hairs	hair	NOUN
dpc-2641	112	18	/	/	SYM
dpc-2641	112	19	day	day	NOUN
dpc-2641	112	20	100	100	NUM
dpc-2641	112	21	-	-	SYM
dpc-2641	112	22	150	150	NUM
dpc-2641	112	23	hairs	hair	NOUN
dpc-2641	112	24	/	/	SYM
dpc-2641	112	25	day	day	NOUN
dpc-2641	112	26	>	>	SYM
dpc-2641	112	27	150	150	NUM
dpc-2641	112	28	hairs	hair	NOUN
dpc-2641	112	29	/	/	SYM
dpc-2641	112	30	day	day	NOUN
dpc-2641	112	31	n	n	CCONJ
dpc-2641	112	32	(	(	PUNCT
dpc-2641	112	33	%	%	NOUN
dpc-2641	112	34	)	)	PUNCT
dpc-2641	112	35	n	n	CCONJ
dpc-2641	112	36	(	(	PUNCT
dpc-2641	112	37	%	%	NOUN
dpc-2641	112	38	)	)	PUNCT
dpc-2641	112	39	n	n	CCONJ
dpc-2641	112	40	(	(	PUNCT
dpc-2641	112	41	%	%	NOUN
dpc-2641	112	42	)	)	PUNCT
dpc-2641	112	43	n	n	CCONJ
dpc-2641	112	44	(	(	PUNCT
dpc-2641	112	45	%	%	INTJ
dpc-2641	112	46	)	)	PUNCT
dpc-2641	112	47	ana	ana	PROPN
dpc-2641	112	48	positivity	positivity	PROPN
dpc-2641	112	49	negative	negative	ADJ
dpc-2641	112	50	0(.00	0(.00	NUM
dpc-2641	112	51	)	)	PUNCT
dpc-2641	112	52	3(75.00	3(75.00	NUM
dpc-2641	112	53	)	)	PUNCT
dpc-2641	112	54	14(58.33	14(58.33	NUM
dpc-2641	112	55	)	)	PUNCT
dpc-2641	112	56	1(50.00	1(50.00	NUM
dpc-2641	112	57	)	)	PUNCT
dpc-2641	112	58	0.784	0.784	NUM
dpc-2641	112	59	positive	positive	ADJ
dpc-2641	112	60	0(00	0(00	NOUN
dpc-2641	112	61	)	)	PUNCT
dpc-2641	112	62	1(25.00	1(25.00	NUM
dpc-2641	112	63	)	)	PUNCT
dpc-2641	112	64	10(41.67	10(41.67	NUM
dpc-2641	112	65	)	)	PUNCT
dpc-2641	112	66	1(50.00	1(50.00	NUM
dpc-2641	112	67	)	)	PUNCT
dpc-2641	112	68	ana	ana	NOUN
dpc-2641	112	69	pattern	pattern	NOUN
dpc-2641	112	70	cytoplasmic	cytoplasmic	ADJ
dpc-2641	112	71	0(00	0(00	NOUN
dpc-2641	112	72	)	)	PUNCT
dpc-2641	112	73	1(10.00	1(10.00	NUM
dpc-2641	112	74	)	)	PUNCT
dpc-2641	112	75	9(90.00	9(90.00	NUM
dpc-2641	112	76	)	)	PUNCT
dpc-2641	112	77	0(.00	0(.00	NUM
dpc-2641	112	78	)	)	PUNCT
dpc-2641	112	79	0.016	0.016	NUM
dpc-2641	112	80	granular	granular	ADJ
dpc-2641	112	81	0(00	0(00	NOUN
dpc-2641	112	82	)	)	PUNCT
dpc-2641	112	83	0(.00	0(.00	NUM
dpc-2641	112	84	)	)	PUNCT
dpc-2641	112	85	0(.00	0(.00	NUM
dpc-2641	112	86	)	)	PUNCT
dpc-2641	112	87	0(.00	0(.00	NUM
dpc-2641	112	88	)	)	PUNCT
dpc-2641	112	89	nucleolar	nucleolar	NOUN
dpc-2641	112	90	0(00	0(00	NOUN
dpc-2641	112	91	)	)	PUNCT
dpc-2641	112	92	0(.00	0(.00	NUM
dpc-2641	112	93	)	)	PUNCT
dpc-2641	112	94	1(10.00	1(10.00	NUM
dpc-2641	112	95	)	)	PUNCT
dpc-2641	112	96	0(.00	0(.00	NUM
dpc-2641	112	97	)	)	PUNCT
dpc-2641	112	98	nuclear	nuclear	ADJ
dpc-2641	112	99	/	/	SYM
dpc-2641	112	100	granular	granular	ADJ
dpc-2641	112	101	0(00	0(00	NOUN
dpc-2641	112	102	)	)	PUNCT
dpc-2641	112	103	0(.00	0(.00	NUM
dpc-2641	112	104	)	)	PUNCT
dpc-2641	112	105	0(.00	0(.00	NUM
dpc-2641	112	106	)	)	PUNCT
dpc-2641	112	107	1(100.00	1(100.00	NUM
dpc-2641	112	108	)	)	PUNCT
dpc-2641	112	109	ana	ana	PROPN
dpc-2641	112	110	=	=	PUNCT
dpc-2641	112	111	antinuclear	antinuclear	ADJ
dpc-2641	112	112	antibody	antibody	NOUN
dpc-2641	112	113	original	original	ADJ
dpc-2641	112	114	article	article	NOUN
dpc-2641	112	115	|	|	ADV
dpc-2641	112	116	dermatol	dermatol	ADJ
dpc-2641	112	117	pract	pract	NOUN
dpc-2641	112	118	concept	concept	NOUN
dpc-2641	112	119	.	.	PUNCT
dpc-2641	113	1	2023;13(2):e2023081	2023;13(2):e2023081	NUM
dpc-2641	113	2	5	5	NUM
dpc-2641	113	3	ana	ana	NOUN
dpc-2641	113	4	positivity	positivity	NOUN
dpc-2641	113	5	and	and	CCONJ
dpc-2641	113	6	trichodynia	trichodynia	PROPN
dpc-2641	113	7	or	or	CCONJ
dpc-2641	113	8	between	between	ADP
dpc-2641	113	9	trichodynia	trichodynia	NOUN
dpc-2641	113	10	and	and	CCONJ
dpc-2641	113	11	autoimmunity	autoimmunity	NOUN
dpc-2641	113	12	.	.	PUNCT
dpc-2641	114	1	since	since	SCONJ
dpc-2641	114	2	no	no	DET
dpc-2641	114	3	financial	financial	ADJ
dpc-2641	114	4	support	support	NOUN
dpc-2641	114	5	is	be	AUX
dpc-2641	114	6	received	receive	VERB
dpc-2641	114	7	,	,	PUNCT
dpc-2641	114	8	ena	ena	PROPN
dpc-2641	114	9	(	(	PUNCT
dpc-2641	114	10	extractable	extractable	ADJ
dpc-2641	114	11	nuclear	nuclear	ADJ
dpc-2641	114	12	antigen	antigen	NOUN
dpc-2641	114	13	)	)	PUNCT
dpc-2641	114	14	(	(	PUNCT
dpc-2641	114	15	anti	anti	ADJ
dpc-2641	114	16	-	-	ADJ
dpc-2641	114	17	rnp	rnp	PROPN
dpc-2641	114	18	,	,	PUNCT
dpc-2641	114	19	anti	anti	ADJ
dpc-2641	114	20	-	-	ADJ
dpc-2641	114	21	scl70	scl70	ADJ
dpc-2641	114	22	,	,	PUNCT
dpc-2641	114	23	anti	anti	ADJ
dpc-2641	114	24	-	-	ADJ
dpc-2641	114	25	sm	sm	ADJ
dpc-2641	114	26	,	,	PUNCT
dpc-2641	114	27	anti	anti	ADJ
dpc-2641	114	28	-	-	ADJ
dpc-2641	114	29	ss	ss	NOUN
dpc-2641	114	30	-	-	PUNCT
dpc-2641	114	31	a	a	PRON
dpc-2641	114	32	/	/	SYM
dpc-2641	114	33	ro52	ro52	PROPN
dpc-2641	114	34	,	,	PUNCT
dpc-2641	114	35	anti	anti	ADJ
dpc-2641	114	36	-	-	ADJ
dpc-2641	114	37	ss	ss	NOUN
dpc-2641	114	38	-	-	PUNCT
dpc-2641	114	39	a	a	NOUN
dpc-2641	114	40	/	/	SYM
dpc-2641	114	41	ro60	ro60	PROPN
dpc-2641	114	42	,	,	PUNCT
dpc-2641	114	43	or	or	CCONJ
dpc-2641	114	44	anti	anti	ADJ
dpc-2641	114	45	-	-	ADJ
dpc-2641	114	46	ss	ss	ADJ
dpc-2641	114	47	-	-	PUNCT
dpc-2641	114	48	b	b	NOUN
dpc-2641	114	49	/	/	SYM
dpc-2641	114	50	la	la	NOUN
dpc-2641	114	51	)	)	PUNCT
dpc-2641	114	52	,	,	PUNCT
dpc-2641	114	53	p	p	X
dpc-2641	114	54	-	-	PUNCT
dpc-2641	114	55	anca	anca	NOUN
dpc-2641	114	56	(	(	PUNCT
dpc-2641	114	57	perinuclear	perinuclear	ADJ
dpc-2641	114	58	anti	anti	ADJ
dpc-2641	114	59	-	-	ADJ
dpc-2641	114	60	neutrophil	neutrophil	ADJ
dpc-2641	114	61	cytoplasmic	cytoplasmic	ADJ
dpc-2641	114	62	antibodies	antibody	NOUN
dpc-2641	114	63	)	)	PUNCT
dpc-2641	114	64	,	,	PUNCT
dpc-2641	114	65	anticardiolipin	anticardiolipin	PROPN
dpc-2641	114	66	igm	igm	PROPN
dpc-2641	114	67	,	,	PUNCT
dpc-2641	114	68	and	and	CCONJ
dpc-2641	114	69	igg	igg	PROPN
dpc-2641	114	70	,	,	PUNCT
dpc-2641	114	71	which	which	PRON
dpc-2641	114	72	are	be	AUX
dpc-2641	114	73	frequently	frequently	ADV
dpc-2641	114	74	measured	measure	VERB
dpc-2641	114	75	in	in	ADP
dpc-2641	114	76	covid-19	covid-19	PROPN
dpc-2641	114	77	antibody	antibody	NOUN
dpc-2641	114	78	studies	study	NOUN
dpc-2641	114	79	,	,	PUNCT
dpc-2641	114	80	were	be	AUX
dpc-2641	114	81	not	not	PART
dpc-2641	114	82	measured	measure	VERB
dpc-2641	114	83	and	and	CCONJ
dpc-2641	114	84	were	be	AUX
dpc-2641	114	85	performed	perform	VERB
dpc-2641	114	86	.	.	PUNCT
dpc-2641	115	1	scalp	scalp	NOUN
dpc-2641	115	2	biopsies	biopsy	NOUN
dpc-2641	115	3	.	.	PUNCT
dpc-2641	116	1	moreover	moreover	ADV
dpc-2641	116	2	,	,	PUNCT
dpc-2641	116	3	we	we	PRON
dpc-2641	116	4	did	do	AUX
dpc-2641	116	5	not	not	PART
dpc-2641	116	6	evaluate	evaluate	VERB
dpc-2641	116	7	patients	patient	NOUN
dpc-2641	116	8	stress	stress	NOUN
dpc-2641	116	9	levels	level	NOUN
dpc-2641	116	10	using	use	VERB
dpc-2641	116	11	an	an	DET
dpc-2641	116	12	anxiety	anxiety	NOUN
dpc-2641	116	13	scale	scale	NOUN
dpc-2641	116	14	to	to	PART
dpc-2641	116	15	investigate	investigate	VERB
dpc-2641	116	16	the	the	DET
dpc-2641	116	17	relationship	relationship	NOUN
dpc-2641	116	18	between	between	ADP
dpc-2641	116	19	hair	hair	NOUN
dpc-2641	116	20	loss	loss	NOUN
dpc-2641	116	21	and	and	CCONJ
dpc-2641	116	22	stress	stress	NOUN
dpc-2641	116	23	.	.	PUNCT
dpc-2641	117	1	in	in	ADP
dpc-2641	117	2	conclusion	conclusion	NOUN
dpc-2641	117	3	,	,	PUNCT
dpc-2641	117	4	hair	hair	NOUN
dpc-2641	117	5	loss	loss	NOUN
dpc-2641	117	6	after	after	SCONJ
dpc-2641	117	7	covid-19	covid-19	PROPN
dpc-2641	117	8	infection	infection	NOUN
dpc-2641	117	9	may	may	AUX
dpc-2641	117	10	be	be	AUX
dpc-2641	117	11	triggered	trigger	VERB
dpc-2641	117	12	by	by	ADP
dpc-2641	117	13	the	the	DET
dpc-2641	117	14	release	release	NOUN
dpc-2641	117	15	of	of	ADP
dpc-2641	117	16	autoantibodies	autoantibody	NOUN
dpc-2641	117	17	in	in	ADP
dpc-2641	117	18	response	response	NOUN
dpc-2641	117	19	to	to	ADP
dpc-2641	117	20	the	the	DET
dpc-2641	117	21	infection	infection	NOUN
dpc-2641	117	22	.	.	PUNCT
dpc-2641	118	1	cytoplasmic	cytoplasmic	ADJ
dpc-2641	118	2	ana	ana	PROPN
dpc-2641	118	3	patterns	pattern	NOUN
dpc-2641	118	4	may	may	AUX
dpc-2641	118	5	be	be	AUX
dpc-2641	118	6	essential	essential	ADJ
dpc-2641	118	7	clinical	clinical	ADJ
dpc-2641	118	8	markers	marker	NOUN
dpc-2641	118	9	for	for	ADP
dpc-2641	118	10	elucidating	elucidate	VERB
dpc-2641	118	11	the	the	DET
dpc-2641	118	12	pathogenesis	pathogenesis	NOUN
dpc-2641	118	13	of	of	ADP
dpc-2641	118	14	hair	hair	NOUN
dpc-2641	118	15	loss	loss	NOUN
dpc-2641	118	16	after	after	ADP
dpc-2641	118	17	covid-19	covid-19	PROPN
dpc-2641	118	18	infection	infection	NOUN
dpc-2641	118	19	.	.	PUNCT
dpc-2641	119	1	references	reference	NOUN
dpc-2641	119	2	1	1	NUM
dpc-2641	119	3	.	.	PUNCT
dpc-2641	119	4	harapan	harapan	PROPN
dpc-2641	119	5	h	h	PROPN
dpc-2641	119	6	,	,	PUNCT
dpc-2641	119	7	itoh	itoh	PROPN
dpc-2641	119	8	n	n	CCONJ
dpc-2641	119	9	,	,	PUNCT
dpc-2641	119	10	yufika	yufika	X
dpc-2641	119	11	a	a	NOUN
dpc-2641	119	12	,	,	PUNCT
dpc-2641	119	13	et	et	PROPN
dpc-2641	119	14	al	al	PROPN
dpc-2641	119	15	.	.	PROPN
dpc-2641	119	16	coronavirus	coronavirus	PROPN
dpc-2641	119	17	disease	disease	NOUN
dpc-2641	119	18	2019	2019	NUM
dpc-2641	119	19	(	(	PUNCT
dpc-2641	119	20	covid-19	covid-19	PROPN
dpc-2641	119	21	):	):	PUNCT
dpc-2641	119	22	a	a	DET
dpc-2641	119	23	literature	literature	NOUN
dpc-2641	119	24	review	review	NOUN
dpc-2641	119	25	.	.	PUNCT
dpc-2641	120	1	j	j	PROPN
dpc-2641	120	2	infect	infect	VERB
dpc-2641	120	3	public	public	ADJ
dpc-2641	120	4	health	health	NOUN
dpc-2641	120	5	.	.	PUNCT
dpc-2641	121	1	2020;13(5):667	2020;13(5):667	NUM
dpc-2641	121	2	-	-	PUNCT
dpc-2641	121	3	673	673	NUM
dpc-2641	121	4	.	.	PUNCT
dpc-2641	122	1	doi	doi	NOUN
dpc-2641	122	2	:	:	PUNCT
dpc-2641	122	3	10.1016	10.1016	NUM
dpc-2641	122	4	/	/	SYM
dpc-2641	122	5	j.jiph.2020.03.019	j.jiph.2020.03.019	PROPN
dpc-2641	122	6	.	.	PUNCT
dpc-2641	123	1	pmid	pmid	NOUN
dpc-2641	123	2	:	:	PUNCT
dpc-2641	123	3	32340833	32340833	NUM
dpc-2641	123	4	.	.	PUNCT
dpc-2641	124	1	pmcid	pmcid	NOUN
dpc-2641	124	2	:	:	PUNCT
dpc-2641	124	3	pmc7142680	pmc7142680	NOUN
dpc-2641	124	4	.	.	PUNCT
dpc-2641	125	1	2	2	X
dpc-2641	125	2	.	.	X
dpc-2641	125	3	galeotti	galeotti	PROPN
dpc-2641	125	4	c	c	PROPN
dpc-2641	125	5	,	,	PUNCT
dpc-2641	125	6	bayry	bayry	PROPN
dpc-2641	125	7	j.	j.	PROPN
dpc-2641	125	8	autoimmune	autoimmune	PROPN
dpc-2641	125	9	and	and	CCONJ
dpc-2641	125	10	inflammatory	inflammatory	ADJ
dpc-2641	125	11	diseases	disease	NOUN
dpc-2641	125	12	following	follow	VERB
dpc-2641	125	13	covid-19	covid-19	PROPN
dpc-2641	125	14	.	.	PUNCT
dpc-2641	126	1	nat	nat	PROPN
dpc-2641	126	2	rev	rev	PROPN
dpc-2641	126	3	rheumatol	rheumatol	NOUN
dpc-2641	126	4	.	.	PUNCT
dpc-2641	127	1	2020;16(8):413	2020;16(8):413	PROPN
dpc-2641	127	2	-	-	PUNCT
dpc-2641	127	3	414	414	PROPN
dpc-2641	127	4	.	.	PUNCT
dpc-2641	128	1	doi	doi	NOUN
dpc-2641	128	2	:	:	PUNCT
dpc-2641	128	3	10.1038	10.1038	NUM
dpc-2641	128	4	/	/	SYM
dpc-2641	128	5	s41584	s41584	NOUN
dpc-2641	128	6	-	-	PUNCT
dpc-2641	128	7	020	020	NUM
dpc-2641	128	8	-	-	PUNCT
dpc-2641	128	9	0448	0448	NUM
dpc-2641	128	10	-	-	SYM
dpc-2641	128	11	7	7	NUM
dpc-2641	128	12	.	.	PUNCT
dpc-2641	129	1	pmid	pmid	NOUN
dpc-2641	129	2	:	:	PUNCT
dpc-2641	129	3	32499548	32499548	NUM
dpc-2641	129	4	.	.	PUNCT
dpc-2641	130	1	pmcid	pmcid	NOUN
dpc-2641	130	2	:	:	PUNCT
dpc-2641	130	3	pmc7271827	pmc7271827	NOUN
dpc-2641	130	4	.	.	PUNCT
dpc-2641	131	1	3	3	X
dpc-2641	131	2	.	.	X
dpc-2641	131	3	martora	martora	PROPN
dpc-2641	132	1	f	f	PROPN
dpc-2641	132	2	,	,	PUNCT
dpc-2641	132	3	picone	picone	PROPN
dpc-2641	132	4	v	v	NOUN
dpc-2641	132	5	,	,	PUNCT
dpc-2641	132	6	fornaro	fornaro	NOUN
dpc-2641	132	7	l	l	NOUN
dpc-2641	132	8	,	,	PUNCT
dpc-2641	132	9	fabbrocini	fabbrocini	NOUN
dpc-2641	132	10	g	g	PROPN
dpc-2641	132	11	,	,	PUNCT
dpc-2641	132	12	marasca	marasca	PROPN
dpc-2641	132	13	c.	c.	PROPN
dpc-2641	132	14	can	can	AUX
dpc-2641	132	15	covid-19	covid-19	PROPN
dpc-2641	132	16	cause	cause	VERB
dpc-2641	132	17	atypical	atypical	ADJ
dpc-2641	132	18	forms	form	NOUN
dpc-2641	132	19	of	of	ADP
dpc-2641	132	20	pityriasis	pityriasis	NOUN
dpc-2641	132	21	rosea	rosea	ADJ
dpc-2641	132	22	refractory	refractory	NOUN
dpc-2641	132	23	to	to	ADP
dpc-2641	132	24	conventional	conventional	ADJ
dpc-2641	132	25	therapies	therapy	NOUN
dpc-2641	132	26	?	?	PUNCT
dpc-2641	133	1	j	j	PROPN
dpc-2641	133	2	med	med	ADJ
dpc-2641	133	3	virol	virol	NOUN
dpc-2641	133	4	.	.	PUNCT
dpc-2641	134	1	2022;94(4):1292	2022;94(4):1292	NUM
dpc-2641	134	2	-	-	SYM
dpc-2641	134	3	1293	1293	NUM
dpc-2641	134	4	.	.	PUNCT
dpc-2641	135	1	doi	doi	NOUN
dpc-2641	135	2	:	:	PUNCT
dpc-2641	135	3	10.1002	10.1002	NUM
dpc-2641	135	4	/	/	SYM
dpc-2641	135	5	jmv.27535	jmv.27535	PROPN
dpc-2641	135	6	.	.	PUNCT
dpc-2641	136	1	pmid	pmid	NOUN
dpc-2641	136	2	:	:	PUNCT
dpc-2641	136	3	34931329	34931329	NUM
dpc-2641	136	4	.	.	PUNCT
dpc-2641	137	1	4	4	X
dpc-2641	137	2	.	.	X
dpc-2641	137	3	wollina	wollina	PROPN
dpc-2641	137	4	u	u	PROPN
dpc-2641	137	5	,	,	PUNCT
dpc-2641	137	6	karadağ	karadağ	NOUN
dpc-2641	137	7	as	as	ADP
dpc-2641	137	8	,	,	PUNCT
dpc-2641	137	9	rowland	rowland	PROPN
dpc-2641	137	10	-	-	PUNCT
dpc-2641	137	11	payne	payne	PROPN
dpc-2641	137	12	c	c	PROPN
dpc-2641	137	13	,	,	PUNCT
dpc-2641	137	14	chiriac	chiriac	PROPN
dpc-2641	137	15	a	a	PRON
dpc-2641	137	16	,	,	PUNCT
dpc-2641	137	17	lotti	lotti	NOUN
dpc-2641	137	18	t.	t.	NOUN
dpc-2641	137	19	cutaneous	cutaneous	ADJ
dpc-2641	137	20	signs	sign	NOUN
dpc-2641	137	21	in	in	ADP
dpc-2641	137	22	covid-19	covid-19	PROPN
dpc-2641	137	23	patients	patient	NOUN
dpc-2641	137	24	:	:	PUNCT
dpc-2641	137	25	a	a	DET
dpc-2641	137	26	review	review	NOUN
dpc-2641	137	27	.	.	PUNCT
dpc-2641	138	1	dermatol	dermatol	NOUN
dpc-2641	138	2	cytoplasmic	cytoplasmic	ADJ
dpc-2641	138	3	patterns	pattern	NOUN
dpc-2641	138	4	even	even	ADV
dpc-2641	138	5	at	at	ADP
dpc-2641	138	6	a	a	DET
dpc-2641	138	7	titer	titer	NOUN
dpc-2641	138	8	of	of	ADP
dpc-2641	138	9	1:100	1:100	NUM
dpc-2641	138	10	.	.	PUNCT
dpc-2641	139	1	furthermore	furthermore	ADV
dpc-2641	139	2	,	,	PUNCT
dpc-2641	139	3	nucleolar	nucleolar	ADJ
dpc-2641	139	4	patterns	pattern	NOUN
dpc-2641	139	5	have	have	AUX
dpc-2641	139	6	been	be	AUX
dpc-2641	139	7	shown	show	VERB
dpc-2641	139	8	to	to	PART
dpc-2641	139	9	be	be	AUX
dpc-2641	139	10	dominant	dominant	ADJ
dpc-2641	139	11	in	in	ADP
dpc-2641	139	12	covid-19	covid-19	PROPN
dpc-2641	140	1	[	[	X
dpc-2641	140	2	15,17,18,23	15,17,18,23	NUM
dpc-2641	140	3	]	]	PUNCT
dpc-2641	140	4	.	.	PUNCT
dpc-2641	141	1	thus	thus	ADV
dpc-2641	141	2	,	,	PUNCT
dpc-2641	141	3	our	our	PRON
dpc-2641	141	4	results	result	NOUN
dpc-2641	141	5	differ	differ	VERB
dpc-2641	141	6	from	from	ADP
dpc-2641	141	7	those	those	PRON
dpc-2641	141	8	of	of	ADP
dpc-2641	141	9	previous	previous	ADJ
dpc-2641	141	10	studies	study	NOUN
dpc-2641	141	11	in	in	ADP
dpc-2641	141	12	this	this	DET
dpc-2641	141	13	respect	respect	NOUN
dpc-2641	141	14	.	.	PUNCT
dpc-2641	142	1	massabki	massabki	PROPN
dpc-2641	142	2	et	et	PROPN
dpc-2641	142	3	al	al	PROPN
dpc-2641	143	1	[	[	X
dpc-2641	143	2	24	24	NUM
dpc-2641	143	3	]	]	PUNCT
dpc-2641	143	4	and	and	CCONJ
dpc-2641	143	5	eystathioy	eystathioy	NOUN
dpc-2641	143	6	et	et	NOUN
dpc-2641	143	7	al	al	PROPN
dpc-2641	144	1	[	[	X
dpc-2641	144	2	25	25	NUM
dpc-2641	144	3	]	]	PUNCT
dpc-2641	144	4	suggested	suggest	VERB
dpc-2641	144	5	that	that	SCONJ
dpc-2641	144	6	cytoplasmic	cytoplasmic	ADJ
dpc-2641	144	7	patterns	pattern	NOUN
dpc-2641	144	8	at	at	ADP
dpc-2641	144	9	low	low	ADJ
dpc-2641	144	10	and	and	CCONJ
dpc-2641	144	11	moderate	moderate	ADJ
dpc-2641	144	12	titers	titer	NOUN
dpc-2641	144	13	had	have	VERB
dpc-2641	144	14	low	low	ADJ
dpc-2641	144	15	clinical	clinical	ADJ
dpc-2641	144	16	relevance	relevance	NOUN
dpc-2641	144	17	.	.	PUNCT
dpc-2641	145	1	conversely	conversely	ADV
dpc-2641	145	2	,	,	PUNCT
dpc-2641	145	3	pazini	pazini	PROPN
dpc-2641	145	4	et	et	PROPN
dpc-2641	145	5	al	al	PROPN
dpc-2641	145	6	reported	report	VERB
dpc-2641	145	7	that	that	SCONJ
dpc-2641	145	8	they	they	PRON
dpc-2641	145	9	were	be	AUX
dpc-2641	145	10	associated	associate	VERB
dpc-2641	145	11	with	with	ADP
dpc-2641	145	12	autoimmune	autoimmune	ADJ
dpc-2641	145	13	diseases	disease	NOUN
dpc-2641	145	14	even	even	ADV
dpc-2641	145	15	at	at	ADP
dpc-2641	145	16	low	low	ADJ
dpc-2641	145	17	titers	titer	NOUN
dpc-2641	145	18	[	[	X
dpc-2641	145	19	26	26	NUM
dpc-2641	145	20	]	]	PUNCT
dpc-2641	145	21	.	.	PUNCT
dpc-2641	146	1	in	in	ADP
dpc-2641	146	2	our	our	PRON
dpc-2641	146	3	study	study	NOUN
dpc-2641	146	4	,	,	PUNCT
dpc-2641	146	5	the	the	DET
dpc-2641	146	6	cytoplasmic	cytoplasmic	ADJ
dpc-2641	146	7	pattern	pattern	NOUN
dpc-2641	146	8	of	of	ADP
dpc-2641	146	9	ana	ana	PROPN
dpc-2641	146	10	was	be	AUX
dpc-2641	146	11	positive	positive	ADJ
dpc-2641	146	12	even	even	ADV
dpc-2641	146	13	at	at	ADP
dpc-2641	146	14	low	low	ADJ
dpc-2641	146	15	titer	titer	NOUN
dpc-2641	146	16	,	,	PUNCT
dpc-2641	146	17	but	but	CCONJ
dpc-2641	146	18	it	it	PRON
dpc-2641	146	19	was	be	AUX
dpc-2641	146	20	also	also	ADV
dpc-2641	146	21	clinically	clinically	ADV
dpc-2641	146	22	significant	significant	ADJ
dpc-2641	146	23	.	.	PUNCT
dpc-2641	147	1	trichodynia	trichodynia	PROPN
dpc-2641	147	2	is	be	AUX
dpc-2641	147	3	a	a	DET
dpc-2641	147	4	symptom	symptom	NOUN
dpc-2641	147	5	of	of	ADP
dpc-2641	147	6	local	local	ADJ
dpc-2641	147	7	paresthesia	paresthesia	NOUN
dpc-2641	147	8	often	often	ADV
dpc-2641	147	9	associated	associate	VERB
dpc-2641	147	10	with	with	ADP
dpc-2641	147	11	telogen	telogen	NOUN
dpc-2641	147	12	effluvium	effluvium	NOUN
dpc-2641	147	13	,	,	PUNCT
dpc-2641	147	14	androgenetic	androgenetic	ADJ
dpc-2641	147	15	alopecia	alopecia	NOUN
dpc-2641	147	16	,	,	PUNCT
dpc-2641	147	17	and	and	CCONJ
dpc-2641	147	18	alopecia	alopecia	NOUN
dpc-2641	147	19	areata	areata	VERB
dpc-2641	148	1	[	[	X
dpc-2641	148	2	27,28	27,28	NUM
dpc-2641	148	3	]	]	X
dpc-2641	148	4	.	.	PUNCT
dpc-2641	149	1	it	it	PRON
dpc-2641	149	2	is	be	AUX
dpc-2641	149	3	a	a	DET
dpc-2641	149	4	crucial	crucial	ADJ
dpc-2641	149	5	dermatological	dermatological	ADJ
dpc-2641	149	6	marker	marker	NOUN
dpc-2641	149	7	of	of	ADP
dpc-2641	149	8	the	the	DET
dpc-2641	149	9	severity	severity	NOUN
dpc-2641	149	10	of	of	ADP
dpc-2641	149	11	hair	hair	NOUN
dpc-2641	149	12	disease	disease	NOUN
dpc-2641	149	13	and	and	CCONJ
dpc-2641	149	14	the	the	DET
dpc-2641	149	15	response	response	NOUN
dpc-2641	149	16	to	to	ADP
dpc-2641	149	17	treatment	treatment	NOUN
dpc-2641	149	18	[	[	X
dpc-2641	149	19	29	29	NUM
dpc-2641	149	20	]	]	PUNCT
dpc-2641	149	21	.	.	PUNCT
dpc-2641	150	1	the	the	DET
dpc-2641	150	2	pathophysiology	pathophysiology	NOUN
dpc-2641	150	3	of	of	ADP
dpc-2641	150	4	trichodynia	trichodynia	PROPN
dpc-2641	150	5	is	be	AUX
dpc-2641	150	6	unclear	unclear	ADJ
dpc-2641	150	7	,	,	PUNCT
dpc-2641	150	8	although	although	SCONJ
dpc-2641	150	9	substance	substance	NOUN
dpc-2641	150	10	p	p	X
dpc-2641	150	11	,	,	PUNCT
dpc-2641	150	12	a	a	DET
dpc-2641	150	13	stress	stress	NOUN
dpc-2641	150	14	-	-	PUNCT
dpc-2641	150	15	related	relate	VERB
dpc-2641	150	16	neuronal	neuronal	ADJ
dpc-2641	150	17	peptide	peptide	NOUN
dpc-2641	150	18	,	,	PUNCT
dpc-2641	150	19	has	have	AUX
dpc-2641	150	20	been	be	AUX
dpc-2641	150	21	suggested	suggest	VERB
dpc-2641	150	22	to	to	PART
dpc-2641	150	23	elicit	elicit	VERB
dpc-2641	150	24	the	the	DET
dpc-2641	150	25	sensation	sensation	NOUN
dpc-2641	150	26	[	[	X
dpc-2641	150	27	28	28	NUM
dpc-2641	150	28	]	]	PUNCT
dpc-2641	150	29	.	.	PUNCT
dpc-2641	151	1	according	accord	VERB
dpc-2641	151	2	to	to	ADP
dpc-2641	151	3	previous	previous	ADJ
dpc-2641	151	4	studies	study	NOUN
dpc-2641	151	5	,	,	PUNCT
dpc-2641	151	6	the	the	DET
dpc-2641	151	7	rates	rate	NOUN
dpc-2641	151	8	of	of	ADP
dpc-2641	151	9	coexistence	coexistence	NOUN
dpc-2641	151	10	between	between	ADP
dpc-2641	151	11	telogen	telogen	NOUN
dpc-2641	151	12	effluvium	effluvium	NOUN
dpc-2641	151	13	and	and	CCONJ
dpc-2641	151	14	trichodynia	trichodynia	PROPN
dpc-2641	151	15	range	range	VERB
dpc-2641	151	16	from	from	ADP
dpc-2641	151	17	34	34	NUM
dpc-2641	151	18	%	%	NOUN
dpc-2641	151	19	to	to	ADP
dpc-2641	151	20	73.6	73.6	NUM
dpc-2641	151	21	%	%	NOUN
dpc-2641	151	22	,	,	PUNCT
dpc-2641	151	23	while	while	SCONJ
dpc-2641	151	24	the	the	DET
dpc-2641	151	25	rates	rate	NOUN
dpc-2641	151	26	of	of	ADP
dpc-2641	151	27	coexistence	coexistence	NOUN
dpc-2641	151	28	between	between	ADP
dpc-2641	151	29	aga	aga	PROPN
dpc-2641	151	30	(	(	PUNCT
dpc-2641	151	31	androgenetic	androgenetic	ADJ
dpc-2641	151	32	alopecia	alopecia	NOUN
dpc-2641	151	33	)	)	PUNCT
dpc-2641	151	34	and	and	CCONJ
dpc-2641	151	35	trichodynia	trichodynia	PROPN
dpc-2641	151	36	range	range	VERB
dpc-2641	151	37	from	from	ADP
dpc-2641	151	38	26.4	26.4	NUM
dpc-2641	151	39	%	%	NOUN
dpc-2641	151	40	to	to	PART
dpc-2641	151	41	36	36	NUM
dpc-2641	151	42	%	%	NOUN
dpc-2641	151	43	[	[	X
dpc-2641	151	44	30	30	NUM
dpc-2641	151	45	-	-	SYM
dpc-2641	151	46	32	32	NUM
dpc-2641	151	47	]	]	PUNCT
dpc-2641	151	48	.	.	PUNCT
dpc-2641	152	1	starace	starace	PROPN
dpc-2641	152	2	et	et	PROPN
dpc-2641	152	3	al	al	PROPN
dpc-2641	152	4	reported	report	VERB
dpc-2641	152	5	that	that	SCONJ
dpc-2641	152	6	telogen	telogen	NOUN
dpc-2641	152	7	effluvium	effluvium	NOUN
dpc-2641	152	8	coexisted	coexist	VERB
dpc-2641	152	9	with	with	ADP
dpc-2641	152	10	trichodynia	trichodynia	NOUN
dpc-2641	152	11	in	in	ADP
dpc-2641	152	12	58.4	58.4	NUM
dpc-2641	152	13	%	%	NOUN
dpc-2641	152	14	of	of	ADP
dpc-2641	152	15	covid-19	covid-19	PROPN
dpc-2641	152	16	patients	patient	NOUN
dpc-2641	152	17	[	[	X
dpc-2641	152	18	33	33	NUM
dpc-2641	152	19	]	]	PUNCT
dpc-2641	152	20	,	,	PUNCT
dpc-2641	152	21	which	which	PRON
dpc-2641	152	22	is	be	AUX
dpc-2641	152	23	comparable	comparable	ADJ
dpc-2641	152	24	to	to	ADP
dpc-2641	152	25	our	our	PRON
dpc-2641	152	26	findings	finding	NOUN
dpc-2641	152	27	.	.	PUNCT
dpc-2641	153	1	di	di	PROPN
dpc-2641	153	2	landro	landro	PROPN
dpc-2641	153	3	et	et	PROPN
dpc-2641	153	4	al	al	PROPN
dpc-2641	153	5	.	.	PROPN
dpc-2641	153	6	suggested	suggest	VERB
dpc-2641	153	7	that	that	SCONJ
dpc-2641	153	8	severity	severity	NOUN
dpc-2641	153	9	of	of	ADP
dpc-2641	153	10	trichodynia	trichodynia	PROPN
dpc-2641	153	11	might	might	AUX
dpc-2641	153	12	be	be	AUX
dpc-2641	153	13	directly	directly	ADV
dpc-2641	153	14	related	relate	VERB
dpc-2641	153	15	to	to	ADP
dpc-2641	153	16	the	the	DET
dpc-2641	153	17	severity	severity	NOUN
dpc-2641	153	18	and	and	CCONJ
dpc-2641	153	19	intensity	intensity	NOUN
dpc-2641	153	20	of	of	ADP
dpc-2641	153	21	hair	hair	NOUN
dpc-2641	153	22	loss	loss	NOUN
dpc-2641	154	1	[	[	X
dpc-2641	154	2	34	34	NUM
dpc-2641	154	3	]	]	PUNCT
dpc-2641	154	4	.	.	PUNCT
dpc-2641	155	1	in	in	ADP
dpc-2641	155	2	this	this	DET
dpc-2641	155	3	study	study	NOUN
dpc-2641	155	4	,	,	PUNCT
dpc-2641	155	5	diffuse	diffuse	VERB
dpc-2641	155	6	hair	hair	NOUN
dpc-2641	155	7	loss	loss	NOUN
dpc-2641	155	8	after	after	SCONJ
dpc-2641	155	9	covid	covid	PROPN
dpc-2641	155	10	infection	infection	NOUN
dpc-2641	155	11	was	be	AUX
dpc-2641	155	12	observed	observe	VERB
dpc-2641	155	13	in	in	ADP
dpc-2641	155	14	53.3	53.3	NUM
dpc-2641	155	15	%	%	NOUN
dpc-2641	155	16	of	of	ADP
dpc-2641	155	17	the	the	DET
dpc-2641	155	18	patients	patient	NOUN
dpc-2641	155	19	.	.	PUNCT
dpc-2641	156	1	the	the	DET
dpc-2641	156	2	significant	significant	ADJ
dpc-2641	156	3	relationship	relationship	NOUN
dpc-2641	156	4	between	between	ADP
dpc-2641	156	5	trichodynia	trichodynia	PROPN
dpc-2641	156	6	and	and	CCONJ
dpc-2641	156	7	diffuse	diffuse	VERB
dpc-2641	156	8	hair	hair	NOUN
dpc-2641	156	9	loss	loss	NOUN
dpc-2641	156	10	supports	support	VERB
dpc-2641	156	11	di	di	NOUN
dpc-2641	156	12	landro	landro	NOUN
dpc-2641	156	13	et	et	PROPN
dpc-2641	156	14	al	al	PROPN
dpc-2641	156	15	.	.	PROPN
dpc-2641	156	16	’s	’s	PART
dpc-2641	156	17	hypothesis	hypothesis	NOUN
dpc-2641	156	18	.	.	PUNCT
dpc-2641	157	1	however	however	ADV
dpc-2641	157	2	,	,	PUNCT
dpc-2641	157	3	our	our	PRON
dpc-2641	157	4	results	result	NOUN
dpc-2641	157	5	did	do	AUX
dpc-2641	157	6	not	not	PART
dpc-2641	157	7	show	show	VERB
dpc-2641	157	8	a	a	DET
dpc-2641	157	9	significant	significant	ADJ
dpc-2641	157	10	relationship	relationship	NOUN
dpc-2641	157	11	between	between	ADP
dpc-2641	157	12	table	table	NOUN
dpc-2641	157	13	4	4	NUM
dpc-2641	157	14	.	.	PUNCT
dpc-2641	158	1	the	the	DET
dpc-2641	158	2	relationship	relationship	NOUN
dpc-2641	158	3	between	between	ADP
dpc-2641	158	4	antinuclear	antinuclear	ADJ
dpc-2641	158	5	antibody	antibody	NOUN
dpc-2641	158	6	positivity	positivity	NOUN
dpc-2641	158	7	and	and	CCONJ
dpc-2641	158	8	clinical	clinical	ADJ
dpc-2641	158	9	findings	finding	NOUN
dpc-2641	158	10	in	in	ADP
dpc-2641	158	11	patients	patient	NOUN
dpc-2641	158	12	in	in	ADP
dpc-2641	158	13	the	the	DET
dpc-2641	158	14	covid	covid	NOUN
dpc-2641	158	15	-	-	PUNCT
dpc-2641	158	16	related	relate	VERB
dpc-2641	158	17	hair	hair	NOUN
dpc-2641	158	18	loss	loss	NOUN
dpc-2641	158	19	group	group	NOUN
dpc-2641	158	20	.	.	PUNCT
dpc-2641	159	1	ana	ana	PROPN
dpc-2641	159	2	pa	pa	PROPN
dpc-2641	159	3	negative	negative	ADJ
dpc-2641	159	4	positive	positive	ADJ
dpc-2641	159	5	n	n	CCONJ
dpc-2641	159	6	(	(	PUNCT
dpc-2641	159	7	%	%	NOUN
dpc-2641	159	8	)	)	PUNCT
dpc-2641	159	9	n	n	CCONJ
dpc-2641	159	10	(	(	PUNCT
dpc-2641	159	11	%	%	INTJ
dpc-2641	159	12	)	)	PUNCT
dpc-2641	159	13	trichodynia	trichodynia	NOUN
dpc-2641	160	1	no	no	DET
dpc-2641	160	2	8	8	NUM
dpc-2641	160	3	(	(	PUNCT
dpc-2641	160	4	44.44	44.44	NUM
dpc-2641	160	5	)	)	PUNCT
dpc-2641	160	6	3	3	NUM
dpc-2641	160	7	(	(	PUNCT
dpc-2641	160	8	25.00	25.00	NUM
dpc-2641	160	9	)	)	PUNCT
dpc-2641	160	10	0.279	0.279	NUM
dpc-2641	160	11	yes	yes	NOUN
dpc-2641	160	12	10	10	NUM
dpc-2641	160	13	(	(	PUNCT
dpc-2641	160	14	55.56	55.56	NUM
dpc-2641	160	15	)	)	PUNCT
dpc-2641	160	16	9	9	NUM
dpc-2641	160	17	(	(	PUNCT
dpc-2641	160	18	75.00	75.00	NUM
dpc-2641	160	19	)	)	PUNCT
dpc-2641	160	20	duration	duration	NOUN
dpc-2641	160	21	of	of	ADP
dpc-2641	160	22	hair	hair	NOUN
dpc-2641	160	23	loss	loss	NOUN
dpc-2641	160	24	(	(	PUNCT
dpc-2641	160	25	weeks	week	NOUN
dpc-2641	160	26	)	)	PUNCT
dpc-2641	160	27	,	,	PUNCT
dpc-2641	160	28	mean	mean	VERB
dpc-2641	160	29	±	±	NUM
dpc-2641	160	30	sd	sd	ADP
dpc-2641	160	31	12.89±6.48	12.89±6.48	NUM
dpc-2641	160	32	15.33±9.00	15.33±9.00	NUM
dpc-2641	160	33	0.520b	0.520b	NUM
dpc-2641	160	34	oilyscalp	oilyscalp	NOUN
dpc-2641	161	1	no	no	DET
dpc-2641	161	2	9	9	NUM
dpc-2641	161	3	(	(	PUNCT
dpc-2641	161	4	50.00	50.00	NUM
dpc-2641	161	5	)	)	PUNCT
dpc-2641	161	6	6	6	NUM
dpc-2641	161	7	(	(	PUNCT
dpc-2641	161	8	50.00	50.00	NUM
dpc-2641	161	9	)	)	PUNCT
dpc-2641	161	10	1.000	1.000	NUM
dpc-2641	161	11	yes	yes	NOUN
dpc-2641	161	12	9	9	NUM
dpc-2641	161	13	(	(	PUNCT
dpc-2641	161	14	50.00	50.00	NUM
dpc-2641	161	15	)	)	PUNCT
dpc-2641	161	16	6	6	NUM
dpc-2641	161	17	(	(	PUNCT
dpc-2641	161	18	50.00	50.00	NUM
dpc-2641	161	19	)	)	PUNCT
dpc-2641	161	20	dandruff	dandruff	NOUN
dpc-2641	161	21	no	no	DET
dpc-2641	161	22	5	5	NUM
dpc-2641	161	23	(	(	PUNCT
dpc-2641	161	24	27.78	27.78	NUM
dpc-2641	161	25	)	)	PUNCT
dpc-2641	161	26	6	6	NUM
dpc-2641	161	27	(	(	PUNCT
dpc-2641	161	28	50.00	50.00	NUM
dpc-2641	161	29	)	)	PUNCT
dpc-2641	161	30	0.216	0.216	NUM
dpc-2641	161	31	yes	yes	NOUN
dpc-2641	161	32	13	13	NUM
dpc-2641	161	33	(	(	PUNCT
dpc-2641	161	34	72.22	72.22	NUM
dpc-2641	161	35	)	)	PUNCT
dpc-2641	161	36	6	6	NUM
dpc-2641	161	37	(	(	PUNCT
dpc-2641	161	38	50.00	50.00	NUM
dpc-2641	161	39	)	)	PUNCT
dpc-2641	161	40	diffuse	diffuse	VERB
dpc-2641	161	41	loss	loss	NOUN
dpc-2641	161	42	of	of	ADP
dpc-2641	161	43	hair	hair	NOUN
dpc-2641	161	44	volume	volume	NOUN
dpc-2641	161	45	no	no	DET
dpc-2641	161	46	14	14	NUM
dpc-2641	161	47	(	(	PUNCT
dpc-2641	161	48	77.78	77.78	NUM
dpc-2641	161	49	)	)	PUNCT
dpc-2641	161	50	0	0	NUM
dpc-2641	162	1	(	(	PUNCT
dpc-2641	162	2	0.00	0.00	NUM
dpc-2641	162	3	)	)	PUNCT
dpc-2641	163	1	<	<	X
dpc-2641	163	2	0.001	0.001	NUM
dpc-2641	163	3	yes	yes	NOUN
dpc-2641	163	4	4	4	NUM
dpc-2641	163	5	(	(	PUNCT
dpc-2641	163	6	22.22	22.22	NUM
dpc-2641	163	7	)	)	PUNCT
dpc-2641	163	8	12	12	NUM
dpc-2641	163	9	(	(	PUNCT
dpc-2641	163	10	100.00	100.00	NUM
dpc-2641	163	11	)	)	PUNCT
dpc-2641	163	12	pull	pull	VERB
dpc-2641	163	13	test	test	NOUN
dpc-2641	163	14	negative	negative	ADJ
dpc-2641	163	15	8	8	NUM
dpc-2641	163	16	(	(	PUNCT
dpc-2641	163	17	44.44	44.44	NUM
dpc-2641	163	18	)	)	PUNCT
dpc-2641	163	19	1	1	NUM
dpc-2641	163	20	(	(	PUNCT
dpc-2641	163	21	8.33	8.33	NUM
dpc-2641	163	22	)	)	PUNCT
dpc-2641	163	23	0.034	0.034	NUM
dpc-2641	163	24	positive	positive	ADJ
dpc-2641	163	25	10	10	NUM
dpc-2641	163	26	(	(	PUNCT
dpc-2641	163	27	55.56	55.56	NUM
dpc-2641	163	28	)	)	PUNCT
dpc-2641	163	29	11	11	NUM
dpc-2641	163	30	(	(	PUNCT
dpc-2641	163	31	91.67	91.67	NUM
dpc-2641	163	32	)	)	PUNCT
dpc-2641	163	33	a	a	DET
dpc-2641	163	34	chi	chi	ADJ
dpc-2641	163	35	-	-	PUNCT
dpc-2641	163	36	square	square	ADJ
dpc-2641	163	37	test	test	NOUN
dpc-2641	163	38	;	;	PUNCT
dpc-2641	163	39	bmann	bmann	PROPN
dpc-2641	163	40	whitney	whitney	PROPN
dpc-2641	163	41	u	u	PROPN
dpc-2641	163	42	test	test	NOUN
dpc-2641	163	43	ana	ana	PROPN
dpc-2641	163	44	=	=	PUNCT
dpc-2641	163	45	antinuclear	antinuclear	ADJ
dpc-2641	163	46	antibody	antibody	NOUN
dpc-2641	163	47	.	.	PUNCT
dpc-2641	164	1	6	6	NUM
dpc-2641	164	2	original	original	ADJ
dpc-2641	164	3	article	article	NOUN
dpc-2641	164	4	|	|	ADV
dpc-2641	164	5	dermatol	dermatol	ADJ
dpc-2641	164	6	pract	pract	NOUN
dpc-2641	164	7	concept	concept	NOUN
dpc-2641	164	8	.	.	PUNCT
dpc-2641	165	1	2023;13(2):e2023081	2023;13(2):e2023081	NUM
dpc-2641	165	2	2020;3:100073	2020;3:100073	NOUN
dpc-2641	165	3	.	.	PUNCT
dpc-2641	166	1	doi	doi	NOUN
dpc-2641	166	2	:	:	PUNCT
dpc-2641	166	3	10.1016	10.1016	NUM
dpc-2641	166	4	/	/	SYM
dpc-2641	166	5	j.jtauto.2020.100073	j.jtauto.2020.100073	NOUN
dpc-2641	166	6	.	.	PUNCT
dpc-2641	167	1	pmid	pmid	NOUN
dpc-2641	167	2	:	:	PUNCT
dpc-2641	167	3	33263103	33263103	NUM
dpc-2641	167	4	.	.	PUNCT
dpc-2641	168	1	pmcid	pmcid	NOUN
dpc-2641	168	2	:	:	PUNCT
dpc-2641	168	3	pmc7691817	pmc7691817	NOUN
dpc-2641	168	4	.	.	PUNCT
dpc-2641	169	1	18	18	NUM
dpc-2641	169	2	.	.	X
dpc-2641	170	1	pascolini	pascolini	PROPN
dpc-2641	170	2	s	s	PROPN
dpc-2641	170	3	,	,	PUNCT
dpc-2641	170	4	vannini	vannini	VERB
dpc-2641	170	5	a	a	PRON
dpc-2641	170	6	,	,	PUNCT
dpc-2641	170	7	deleonardi	deleonardi	PROPN
dpc-2641	170	8	g	g	PROPN
dpc-2641	170	9	,	,	PUNCT
dpc-2641	170	10	et	et	PROPN
dpc-2641	170	11	al	al	PROPN
dpc-2641	170	12	.	.	PUNCT
dpc-2641	171	1	covid-19	covid-19	PROPN
dpc-2641	171	2	and	and	CCONJ
dpc-2641	171	3	immunological	immunological	ADJ
dpc-2641	171	4	dysregulation	dysregulation	NOUN
dpc-2641	171	5	:	:	PUNCT
dpc-2641	171	6	can	can	AUX
dpc-2641	171	7	autoantibodies	autoantibody	NOUN
dpc-2641	171	8	be	be	AUX
dpc-2641	171	9	useful	useful	ADJ
dpc-2641	171	10	?	?	PUNCT
dpc-2641	172	1	clin	clin	PROPN
dpc-2641	172	2	transl	transl	PROPN
dpc-2641	172	3	sci	sci	PROPN
dpc-2641	172	4	.	.	PUNCT
dpc-2641	173	1	2021;14(2):502	2021;14(2):502	PROPN
dpc-2641	173	2	-	-	PUNCT
dpc-2641	173	3	508	508	NUM
dpc-2641	173	4	.	.	PUNCT
dpc-2641	174	1	doi	doi	NOUN
dpc-2641	174	2	:	:	PUNCT
dpc-2641	174	3	10.1111	10.1111	NUM
dpc-2641	174	4	/	/	SYM
dpc-2641	174	5	cts.12908	cts.12908	NUM
dpc-2641	174	6	.	.	PUNCT
dpc-2641	175	1	pmid	pmid	NOUN
dpc-2641	175	2	:	:	PUNCT
dpc-2641	175	3	32989903	32989903	NUM
dpc-2641	175	4	.	.	PUNCT
dpc-2641	176	1	pmcid	pmcid	NOUN
dpc-2641	176	2	:	:	PUNCT
dpc-2641	176	3	pmc7536986	pmc7536986	ADJ
dpc-2641	176	4	.	.	PUNCT
dpc-2641	177	1	19	19	NUM
dpc-2641	177	2	.	.	PUNCT
dpc-2641	177	3	sacchi	sacchi	PROPN
dpc-2641	177	4	mc	mc	PROPN
dpc-2641	177	5	,	,	PUNCT
dpc-2641	177	6	tamiazzo	tamiazzo	PROPN
dpc-2641	177	7	s	s	PROPN
dpc-2641	177	8	,	,	PUNCT
dpc-2641	177	9	stobbione	stobbione	VERB
dpc-2641	177	10	p	p	NOUN
dpc-2641	177	11	,	,	PUNCT
dpc-2641	177	12	et	et	PROPN
dpc-2641	177	13	al	al	PROPN
dpc-2641	177	14	.	.	PUNCT
dpc-2641	178	1	sars	sars	PROPN
dpc-2641	178	2	-	-	PUNCT
dpc-2641	178	3	cov-2	cov-2	PART
dpc-2641	178	4	infection	infection	NOUN
dpc-2641	178	5	as	as	ADP
dpc-2641	178	6	a	a	DET
dpc-2641	178	7	trigger	trigger	NOUN
dpc-2641	178	8	of	of	ADP
dpc-2641	178	9	autoimmune	autoimmune	ADJ
dpc-2641	178	10	response	response	NOUN
dpc-2641	178	11	.	.	PUNCT
dpc-2641	179	1	clin	clin	PROPN
dpc-2641	179	2	transl	transl	PROPN
dpc-2641	179	3	sci	sci	PROPN
dpc-2641	179	4	.	.	PUNCT
dpc-2641	179	5	2021;14(3):898	2021;14(3):898	PROPN
dpc-2641	179	6	-	-	PUNCT
dpc-2641	179	7	907	907	NUM
dpc-2641	179	8	.	.	PUNCT
dpc-2641	179	9	doi	doi	NOUN
dpc-2641	179	10	:	:	PUNCT
dpc-2641	179	11	10.1111	10.1111	NUM
dpc-2641	179	12	/	/	SYM
dpc-2641	179	13	cts.12953	cts.12953	NOUN
dpc-2641	179	14	.	.	PUNCT
dpc-2641	180	1	pmid	pmid	NOUN
dpc-2641	180	2	:	:	PUNCT
dpc-2641	180	3	33306235	33306235	NUM
dpc-2641	180	4	.	.	PUNCT
dpc-2641	181	1	pmcid	pmcid	NOUN
dpc-2641	181	2	:	:	PUNCT
dpc-2641	181	3	pmc8212749	pmc8212749	NOUN
dpc-2641	181	4	.	.	PUNCT
dpc-2641	182	1	20	20	NUM
dpc-2641	182	2	.	.	X
dpc-2641	182	3	trahtemberg	trahtemberg	PROPN
dpc-2641	182	4	u	u	PROPN
dpc-2641	182	5	,	,	PUNCT
dpc-2641	182	6	fritzler	fritzler	PROPN
dpc-2641	182	7	mj	mj	PROPN
dpc-2641	182	8	;	;	PUNCT
dpc-2641	182	9	on	on	ADP
dpc-2641	182	10	behalf	behalf	NOUN
dpc-2641	182	11	of	of	ADP
dpc-2641	182	12	the	the	DET
dpc-2641	182	13	covid-19	covid-19	PROPN
dpc-2641	182	14	chapter	chapter	NOUN
dpc-2641	182	15	of	of	ADP
dpc-2641	182	16	the	the	DET
dpc-2641	182	17	“	"	PUNCT
dpc-2641	182	18	longitudinal	longitudinal	ADJ
dpc-2641	182	19	biomarkers	biomarker	NOUN
dpc-2641	182	20	in	in	ADP
dpc-2641	182	21	lung	lung	NOUN
dpc-2641	182	22	injury	injury	NOUN
dpc-2641	182	23	”	"	PUNCT
dpc-2641	182	24	study	study	NOUN
dpc-2641	182	25	group	group	NOUN
dpc-2641	182	26	.	.	PUNCT
dpc-2641	183	1	covid-19	covid-19	PROPN
dpc-2641	183	2	-	-	PUNCT
dpc-2641	183	3	associated	associate	VERB
dpc-2641	183	4	autoimmunity	autoimmunity	NOUN
dpc-2641	183	5	as	as	ADP
dpc-2641	183	6	a	a	DET
dpc-2641	183	7	feature	feature	NOUN
dpc-2641	183	8	of	of	ADP
dpc-2641	183	9	acute	acute	ADJ
dpc-2641	183	10	respiratory	respiratory	ADJ
dpc-2641	183	11	failure	failure	NOUN
dpc-2641	183	12	.	.	PUNCT
dpc-2641	184	1	intensive	intensive	ADJ
dpc-2641	184	2	care	care	NOUN
dpc-2641	184	3	med	me	VERB
dpc-2641	184	4	.	.	PUNCT
dpc-2641	185	1	2021;47(7):801	2021;47(7):801	NUM
dpc-2641	185	2	-	-	NUM
dpc-2641	185	3	804	804	NUM
dpc-2641	185	4	.	.	PUNCT
dpc-2641	186	1	doi	doi	NOUN
dpc-2641	186	2	:	:	PUNCT
dpc-2641	186	3	10.1007	10.1007	NUM
dpc-2641	186	4	/	/	SYM
dpc-2641	186	5	s00134	s00134	PROPN
dpc-2641	186	6	-	-	PUNCT
dpc-2641	186	7	021	021	NUM
dpc-2641	186	8	-	-	PUNCT
dpc-2641	186	9	06408	06408	NUM
dpc-2641	186	10	-	-	PUNCT
dpc-2641	186	11	z.	z.	PROPN
dpc-2641	186	12	pmid	pmid	PROPN
dpc-2641	186	13	:	:	PUNCT
dpc-2641	186	14	33928414	33928414	NUM
dpc-2641	186	15	.	.	PUNCT
dpc-2641	187	1	pmcid	pmcid	NOUN
dpc-2641	187	2	:	:	PUNCT
dpc-2641	187	3	pmc8084710	pmc8084710	ADJ
dpc-2641	187	4	.	.	PUNCT
dpc-2641	188	1	21	21	NUM
dpc-2641	188	2	.	.	PUNCT
dpc-2641	189	1	yorulmaz	yorulmaz	INTJ
dpc-2641	189	2	a	a	PRON
dpc-2641	189	3	,	,	PUNCT
dpc-2641	189	4	hayran	hayran	PROPN
dpc-2641	189	5	y	y	PROPN
dpc-2641	189	6	,	,	PUNCT
dpc-2641	189	7	ozdemir	ozdemir	PROPN
dpc-2641	189	8	ak	ak	PROPN
dpc-2641	189	9	,	,	PUNCT
dpc-2641	189	10	et	et	PROPN
dpc-2641	189	11	al	al	PROPN
dpc-2641	189	12	.	.	PROPN
dpc-2641	189	13	telogen	telogen	PROPN
dpc-2641	189	14	effluvium	effluvium	NOUN
dpc-2641	189	15	in	in	ADP
dpc-2641	189	16	daily	daily	ADJ
dpc-2641	189	17	practice	practice	NOUN
dpc-2641	189	18	:	:	PUNCT
dpc-2641	189	19	patient	patient	ADJ
dpc-2641	189	20	characteristics	characteristic	NOUN
dpc-2641	189	21	,	,	PUNCT
dpc-2641	189	22	laboratory	laboratory	NOUN
dpc-2641	189	23	parameters	parameter	NOUN
dpc-2641	189	24	,	,	PUNCT
dpc-2641	189	25	and	and	CCONJ
dpc-2641	189	26	treatment	treatment	NOUN
dpc-2641	189	27	modalities	modality	NOUN
dpc-2641	189	28	of	of	ADP
dpc-2641	189	29	3028	3028	NUM
dpc-2641	189	30	patients	patient	NOUN
dpc-2641	189	31	with	with	ADP
dpc-2641	189	32	telogen	telogen	NOUN
dpc-2641	189	33	effluvium	effluvium	NOUN
dpc-2641	189	34	.	.	PUNCT
dpc-2641	190	1	j	j	PROPN
dpc-2641	190	2	cosmet	cosmet	PROPN
dpc-2641	190	3	dermatol	dermatol	NOUN
dpc-2641	190	4	.	.	PUNCT
dpc-2641	191	1	2022;21(6):2610	2022;21(6):2610	NUM
dpc-2641	191	2	-	-	SYM
dpc-2641	191	3	2617	2617	NUM
dpc-2641	191	4	.	.	PUNCT
dpc-2641	192	1	doi	doi	NOUN
dpc-2641	192	2	:	:	PUNCT
dpc-2641	192	3	10.1111	10.1111	NUM
dpc-2641	192	4	/jocd.14413	/jocd.14413	PUNCT
dpc-2641	192	5	.	.	PUNCT
dpc-2641	193	1	pmid	pmid	NOUN
dpc-2641	193	2	:	:	PUNCT
dpc-2641	193	3	34449961	34449961	NUM
dpc-2641	193	4	.	.	PUNCT
dpc-2641	194	1	22	22	NUM
dpc-2641	194	2	.	.	PUNCT
dpc-2641	195	1	kłosowicz	kłosowicz	PROPN
dpc-2641	195	2	a	a	X
dpc-2641	195	3	,	,	PUNCT
dpc-2641	195	4	englert	englert	PROPN
dpc-2641	195	5	k	k	PROPN
dpc-2641	195	6	,	,	PUNCT
dpc-2641	195	7	pełka	pełka	PROPN
dpc-2641	195	8	k	k	PROPN
dpc-2641	195	9	,	,	PUNCT
dpc-2641	195	10	pastuszczak	pastuszczak	PROPN
dpc-2641	195	11	m	m	PROPN
dpc-2641	195	12	,	,	PUNCT
dpc-2641	195	13	pastuszczak	pastuszczak	PROPN
dpc-2641	195	14	a.	a.	NOUN
dpc-2641	195	15	autoimmunity	autoimmunity	NOUN
dpc-2641	195	16	in	in	ADP
dpc-2641	195	17	lichen	lichen	NOUN
dpc-2641	195	18	planopilaris	planopilaris	NOUN
dpc-2641	195	19	patients	patient	NOUN
dpc-2641	195	20	.	.	PUNCT
dpc-2641	196	1	pol	pol	PROPN
dpc-2641	196	2	merkur	merkur	PROPN
dpc-2641	196	3	lekarski	lekarski	PROPN
dpc-2641	196	4	.	.	PUNCT
dpc-2641	197	1	2019;46(271):32	2019;46(271):32	NOUN
dpc-2641	197	2	-	-	PUNCT
dpc-2641	197	3	35	35	NUM
dpc-2641	197	4	.	.	PUNCT
dpc-2641	198	1	pmid	pmid	NOUN
dpc-2641	198	2	:	:	PUNCT
dpc-2641	198	3	30810113	30810113	NUM
dpc-2641	198	4	.	.	PUNCT
dpc-2641	199	1	23	23	NUM
dpc-2641	199	2	.	.	PUNCT
dpc-2641	200	1	chang	chang	PROPN
dpc-2641	200	2	se	se	PROPN
dpc-2641	200	3	,	,	PUNCT
dpc-2641	200	4	feng	feng	PROPN
dpc-2641	200	5	a	a	X
dpc-2641	200	6	,	,	PUNCT
dpc-2641	200	7	meng	meng	PROPN
dpc-2641	200	8	w	w	PROPN
dpc-2641	200	9	,	,	PUNCT
dpc-2641	200	10	et	et	PROPN
dpc-2641	200	11	al	al	PROPN
dpc-2641	200	12	.	.	PUNCT
dpc-2641	201	1	new	new	ADJ
dpc-2641	201	2	-	-	PUNCT
dpc-2641	201	3	onset	onset	NOUN
dpc-2641	201	4	igg	igg	NOUN
dpc-2641	201	5	autoantibodies	autoantibody	NOUN
dpc-2641	201	6	in	in	ADP
dpc-2641	201	7	hospitalized	hospitalize	VERB
dpc-2641	201	8	patients	patient	NOUN
dpc-2641	201	9	with	with	ADP
dpc-2641	201	10	covid-19	covid-19	PROPN
dpc-2641	201	11	.	.	PUNCT
dpc-2641	202	1	nat	nat	PROPN
dpc-2641	202	2	commun	commun	PROPN
dpc-2641	202	3	.	.	PUNCT
dpc-2641	203	1	2021;12(1):5417	2021;12(1):5417	NUM
dpc-2641	203	2	.	.	PUNCT
dpc-2641	204	1	doi	doi	NOUN
dpc-2641	204	2	:	:	PUNCT
dpc-2641	204	3	10.1038	10.1038	NUM
dpc-2641	204	4	/	/	SYM
dpc-2641	204	5	s41467	s41467	NOUN
dpc-2641	204	6	-	-	PUNCT
dpc-2641	204	7	021	021	NUM
dpc-2641	204	8	-	-	PUNCT
dpc-2641	204	9	25509	25509	NUM
dpc-2641	204	10	-	-	SYM
dpc-2641	204	11	3	3	NUM
dpc-2641	204	12	.	.	PUNCT
dpc-2641	205	1	pmid	pmid	NOUN
dpc-2641	205	2	:	:	PUNCT
dpc-2641	205	3	34521836	34521836	NUM
dpc-2641	205	4	.	.	PUNCT
dpc-2641	206	1	pmcid	pmcid	NOUN
dpc-2641	206	2	:	:	PUNCT
dpc-2641	206	3	pmc8440763	pmc8440763	NOUN
dpc-2641	206	4	.	.	PUNCT
dpc-2641	207	1	24	24	NUM
dpc-2641	207	2	.	.	PUNCT
dpc-2641	208	1	massabki	massabki	PROPN
dpc-2641	208	2	ps	ps	PROPN
dpc-2641	208	3	,	,	PUNCT
dpc-2641	208	4	accetturi	accetturi	PROPN
dpc-2641	208	5	c	c	PROPN
dpc-2641	208	6	,	,	PUNCT
dpc-2641	208	7	nishie	nishie	PROPN
dpc-2641	208	8	ia	ia	PROPN
dpc-2641	208	9	,	,	PUNCT
dpc-2641	208	10	da	da	PROPN
dpc-2641	208	11	silva	silva	PROPN
dpc-2641	208	12	np	np	PROPN
dpc-2641	208	13	,	,	PUNCT
dpc-2641	208	14	sato	sato	PROPN
dpc-2641	208	15	ei	ei	PROPN
dpc-2641	208	16	,	,	PUNCT
dpc-2641	208	17	andrade	andrade	PROPN
dpc-2641	208	18	le	le	X
dpc-2641	208	19	.	.	PUNCT
dpc-2641	209	1	clinical	clinical	ADJ
dpc-2641	209	2	implications	implication	NOUN
dpc-2641	209	3	of	of	ADP
dpc-2641	209	4	autoantibodies	autoantibody	NOUN
dpc-2641	209	5	in	in	ADP
dpc-2641	209	6	hiv	hiv	PROPN
dpc-2641	209	7	infection	infection	NOUN
dpc-2641	209	8	.	.	PUNCT
dpc-2641	210	1	aids	aids	PROPN
dpc-2641	210	2	.	.	PUNCT
dpc-2641	211	1	1997;11(15):1845	1997;11(15):1845	NUM
dpc-2641	211	2	-	-	SYM
dpc-2641	211	3	1850	1850	NUM
dpc-2641	211	4	.	.	PUNCT
dpc-2641	212	1	doi	doi	NOUN
dpc-2641	212	2	:	:	PUNCT
dpc-2641	212	3	10.1097/00002030	10.1097/00002030	NUM
dpc-2641	212	4	-	-	SYM
dpc-2641	212	5	199715000	199715000	NUM
dpc-2641	212	6	-00009	-00009	NOUN
dpc-2641	212	7	.	.	PUNCT
dpc-2641	213	1	pmid	pmid	NOUN
dpc-2641	213	2	:	:	PUNCT
dpc-2641	213	3	9412703	9412703	NUM
dpc-2641	213	4	.	.	PUNCT
dpc-2641	214	1	25	25	NUM
dpc-2641	214	2	.	.	PUNCT
dpc-2641	214	3	eystathioy	eystathioy	PROPN
dpc-2641	214	4	t	t	PROPN
dpc-2641	214	5	,	,	PUNCT
dpc-2641	214	6	chan	chan	PROPN
dpc-2641	214	7	ek	ek	PROPN
dpc-2641	214	8	,	,	PUNCT
dpc-2641	214	9	tenenbaum	tenenbaum	PROPN
dpc-2641	214	10	sa	sa	PROPN
dpc-2641	214	11	,	,	PUNCT
dpc-2641	214	12	keene	keene	PROPN
dpc-2641	214	13	jd	jd	PROPN
dpc-2641	214	14	,	,	PUNCT
dpc-2641	214	15	griffith	griffith	PROPN
dpc-2641	214	16	k	k	PROPN
dpc-2641	214	17	,	,	PUNCT
dpc-2641	214	18	fritzler	fritzler	PROPN
dpc-2641	214	19	mj	mj	PROPN
dpc-2641	214	20	.	.	PUNCT
dpc-2641	215	1	a	a	DET
dpc-2641	215	2	phosphorylated	phosphorylate	VERB
dpc-2641	215	3	cytoplasmic	cytoplasmic	ADJ
dpc-2641	215	4	autoantigen	autoantigen	PROPN
dpc-2641	215	5	,	,	PUNCT
dpc-2641	215	6	gw182	gw182	PROPN
dpc-2641	215	7	,	,	PUNCT
dpc-2641	215	8	associates	associate	NOUN
dpc-2641	215	9	with	with	ADP
dpc-2641	215	10	a	a	DET
dpc-2641	215	11	unique	unique	ADJ
dpc-2641	215	12	population	population	NOUN
dpc-2641	215	13	of	of	ADP
dpc-2641	215	14	human	human	ADJ
dpc-2641	215	15	mrnas	mrna	NOUN
dpc-2641	215	16	within	within	ADP
dpc-2641	215	17	novel	novel	ADJ
dpc-2641	215	18	cytoplasmic	cytoplasmic	ADJ
dpc-2641	215	19	speckles	speckle	NOUN
dpc-2641	215	20	.	.	PUNCT
dpc-2641	216	1	mol	mol	ADP
dpc-2641	216	2	biol	biol	ADJ
dpc-2641	216	3	cell	cell	NOUN
dpc-2641	216	4	.	.	PUNCT
dpc-2641	217	1	2002;13(4	2002;13(4	NUM
dpc-2641	217	2	):	):	PUNCT
dpc-2641	217	3	1338	1338	NUM
dpc-2641	217	4	-	-	SYM
dpc-2641	217	5	1351	1351	NUM
dpc-2641	217	6	.	.	PUNCT
dpc-2641	218	1	doi	doi	NOUN
dpc-2641	218	2	:	:	PUNCT
dpc-2641	218	3	10.1091	10.1091	NUM
dpc-2641	218	4	/	/	SYM
dpc-2641	218	5	mbc.01	mbc.01	NOUN
dpc-2641	218	6	-	-	PUNCT
dpc-2641	218	7	11	11	NUM
dpc-2641	218	8	-	-	PUNCT
dpc-2641	218	9	0544	0544	NUM
dpc-2641	218	10	.	.	PUNCT
dpc-2641	219	1	pmid	pmid	NOUN
dpc-2641	219	2	:	:	PUNCT
dpc-2641	219	3	11950943	11950943	NUM
dpc-2641	219	4	.	.	PUNCT
dpc-2641	220	1	pmcid	pmcid	NOUN
dpc-2641	220	2	:	:	PUNCT
dpc-2641	220	3	pmc102273	pmc102273	ADJ
dpc-2641	220	4	.	.	PUNCT
dpc-2641	221	1	26	26	NUM
dpc-2641	221	2	.	.	X
dpc-2641	221	3	pazini	pazini	PROPN
dpc-2641	221	4	am	am	PROPN
dpc-2641	221	5	,	,	PUNCT
dpc-2641	221	6	fleck	fleck	PROPN
dpc-2641	221	7	j	j	PROPN
dpc-2641	221	8	,	,	PUNCT
dpc-2641	221	9	dos	do	VERB
dpc-2641	221	10	santos	santos	PROPN
dpc-2641	221	11	rs	rs	PROPN
dpc-2641	221	12	,	,	PUNCT
dpc-2641	221	13	beck	beck	PROPN
dpc-2641	221	14	st	st	PROPN
dpc-2641	221	15	.	.	PROPN
dpc-2641	221	16	clinical	clinical	ADJ
dpc-2641	221	17	relevance	relevance	NOUN
dpc-2641	221	18	and	and	CCONJ
dpc-2641	221	19	frequency	frequency	NOUN
dpc-2641	221	20	of	of	ADP
dpc-2641	221	21	cytoplasmic	cytoplasmic	ADJ
dpc-2641	221	22	and	and	CCONJ
dpc-2641	221	23	nuclear	nuclear	ADJ
dpc-2641	221	24	dense	dense	ADJ
dpc-2641	221	25	fine	fine	ADJ
dpc-2641	221	26	speckled	speckled	ADJ
dpc-2641	221	27	patterns	pattern	NOUN
dpc-2641	221	28	observed	observe	VERB
dpc-2641	221	29	in	in	ADP
dpc-2641	221	30	ana	ana	PROPN
dpc-2641	221	31	-	-	PUNCT
dpc-2641	221	32	hep-2	hep-2	PROPN
dpc-2641	221	33	.	.	PUNCT
dpc-2641	222	1	rev	rev	PROPN
dpc-2641	222	2	bras	bras	PROPN
dpc-2641	222	3	reumatol	reumatol	ADJ
dpc-2641	222	4	.	.	PUNCT
dpc-2641	223	1	2010;50(6):655	2010;50(6):655	NUM
dpc-2641	223	2	-	-	PUNCT
dpc-2641	223	3	660	660	NUM
dpc-2641	223	4	.	.	PUNCT
dpc-2641	224	1	pmid	pmid	NOUN
dpc-2641	224	2	:	:	PUNCT
dpc-2641	224	3	21243306	21243306	NUM
dpc-2641	224	4	.	.	PUNCT
dpc-2641	225	1	27	27	NUM
dpc-2641	225	2	.	.	PUNCT
dpc-2641	226	1	xerfan	xerfan	PROPN
dpc-2641	226	2	ems	ems	PROPN
dpc-2641	226	3	,	,	PUNCT
dpc-2641	226	4	andersen	andersen	PROPN
dpc-2641	226	5	ml	ml	PROPN
dpc-2641	226	6	,	,	PUNCT
dpc-2641	226	7	facina	facina	PROPN
dpc-2641	226	8	as	as	ADP
dpc-2641	226	9	,	,	PUNCT
dpc-2641	226	10	tufik	tufik	NOUN
dpc-2641	226	11	s	s	PROPN
dpc-2641	226	12	,	,	PUNCT
dpc-2641	226	13	tomimori	tomimori	X
dpc-2641	226	14	j.	j.	PROPN
dpc-2641	226	15	the	the	DET
dpc-2641	226	16	role	role	NOUN
dpc-2641	226	17	of	of	ADP
dpc-2641	226	18	sleep	sleep	NOUN
dpc-2641	226	19	in	in	ADP
dpc-2641	226	20	telogen	telogen	NOUN
dpc-2641	226	21	effluvium	effluvium	NOUN
dpc-2641	226	22	and	and	CCONJ
dpc-2641	226	23	trichodynia	trichodynia	NOUN
dpc-2641	226	24	:	:	PUNCT
dpc-2641	226	25	a	a	DET
dpc-2641	226	26	commentary	commentary	NOUN
dpc-2641	226	27	in	in	ADP
dpc-2641	226	28	the	the	DET
dpc-2641	226	29	context	context	NOUN
dpc-2641	226	30	of	of	ADP
dpc-2641	226	31	the	the	DET
dpc-2641	226	32	current	current	ADJ
dpc-2641	226	33	pandemic	pandemic	NOUN
dpc-2641	226	34	.	.	PUNCT
dpc-2641	227	1	j	j	PROPN
dpc-2641	227	2	cosmet	cosmet	PROPN
dpc-2641	227	3	dermatol	dermatol	NOUN
dpc-2641	227	4	.	.	PUNCT
dpc-2641	228	1	2021;20(4):1088	2021;20(4):1088	NUM
dpc-2641	228	2	-	-	PUNCT
dpc-2641	228	3	1090	1090	NUM
dpc-2641	228	4	.	.	PUNCT
dpc-2641	229	1	doi	doi	NOUN
dpc-2641	229	2	:	:	PUNCT
dpc-2641	229	3	10.1111	10.1111	NUM
dpc-2641	229	4	/	/	SYM
dpc-2641	229	5	jocd.13929	jocd.13929	PROPN
dpc-2641	229	6	.	.	PUNCT
dpc-2641	230	1	pmid	pmid	NOUN
dpc-2641	230	2	:	:	PUNCT
dpc-2641	230	3	33387387	33387387	NUM
dpc-2641	230	4	.	.	PUNCT
dpc-2641	231	1	28	28	NUM
dpc-2641	231	2	.	.	PUNCT
dpc-2641	231	3	rebora	rebora	PROPN
dpc-2641	231	4	a.	a.	PROPN
dpc-2641	231	5	trichodynia	trichodynia	PROPN
dpc-2641	231	6	:	:	PUNCT
dpc-2641	231	7	a	a	DET
dpc-2641	231	8	review	review	NOUN
dpc-2641	231	9	of	of	ADP
dpc-2641	231	10	the	the	DET
dpc-2641	231	11	literature	literature	NOUN
dpc-2641	231	12	.	.	PUNCT
dpc-2641	232	1	int	int	PROPN
dpc-2641	232	2	j	j	PROPN
dpc-2641	232	3	dermatol	dermatol	NOUN
dpc-2641	232	4	.	.	PUNCT
dpc-2641	233	1	2016;55(4):382	2016;55(4):382	NUM
dpc-2641	233	2	-	-	SYM
dpc-2641	233	3	384	384	NUM
dpc-2641	233	4	.	.	PUNCT
dpc-2641	234	1	doi	doi	NOUN
dpc-2641	234	2	:	:	PUNCT
dpc-2641	234	3	10.1111	10.1111	NUM
dpc-2641	234	4	/	/	SYM
dpc-2641	234	5	ijd.13204	ijd.13204	NOUN
dpc-2641	234	6	.	.	PUNCT
dpc-2641	235	1	pmid	pmid	NOUN
dpc-2641	235	2	:	:	PUNCT
dpc-2641	235	3	26696219	26696219	NUM
dpc-2641	235	4	.	.	PUNCT
dpc-2641	236	1	29	29	NUM
dpc-2641	236	2	.	.	PUNCT
dpc-2641	236	3	mubki	mubki	PROPN
dpc-2641	236	4	t	t	PROPN
dpc-2641	236	5	,	,	PUNCT
dpc-2641	236	6	rudnicka	rudnicka	NOUN
dpc-2641	236	7	l	l	PROPN
dpc-2641	236	8	,	,	PUNCT
dpc-2641	236	9	olszewska	olszewska	PROPN
dpc-2641	236	10	m	m	PROPN
dpc-2641	236	11	,	,	PUNCT
dpc-2641	236	12	shapiro	shapiro	PROPN
dpc-2641	236	13	j.	j.	PROPN
dpc-2641	236	14	evaluation	evaluation	PROPN
dpc-2641	236	15	and	and	CCONJ
dpc-2641	236	16	diagnosis	diagnosis	NOUN
dpc-2641	236	17	of	of	ADP
dpc-2641	236	18	the	the	DET
dpc-2641	236	19	hair	hair	NOUN
dpc-2641	236	20	loss	loss	NOUN
dpc-2641	236	21	patient	patient	NOUN
dpc-2641	236	22	:	:	PUNCT
dpc-2641	236	23	part	part	NOUN
dpc-2641	236	24	i.	i.	PROPN
dpc-2641	236	25	history	history	PROPN
dpc-2641	236	26	and	and	CCONJ
dpc-2641	236	27	clinical	clinical	ADJ
dpc-2641	236	28	examination	examination	NOUN
dpc-2641	236	29	.	.	PUNCT
dpc-2641	237	1	j	j	PROPN
dpc-2641	237	2	am	be	AUX
dpc-2641	237	3	acad	acad	ADJ
dpc-2641	237	4	dermatol	dermatol	NOUN
dpc-2641	237	5	.	.	PUNCT
dpc-2641	238	1	2014;71(3):415.e1	2014;71(3):415.e1	PROPN
dpc-2641	238	2	-	-	PUNCT
dpc-2641	238	3	415.e15	415.e15	PROPN
dpc-2641	238	4	.	.	PUNCT
dpc-2641	239	1	doi	doi	NOUN
dpc-2641	239	2	:	:	PUNCT
dpc-2641	239	3	10.1016	10.1016	NUM
dpc-2641	239	4	/	/	SYM
dpc-2641	239	5	j.jaad.2014.04.070	j.jaad.2014.04.070	PROPN
dpc-2641	239	6	.	.	PUNCT
dpc-2641	240	1	pmid	pmid	NOUN
dpc-2641	240	2	:	:	PUNCT
dpc-2641	240	3	25128118	25128118	NUM
dpc-2641	240	4	.	.	PUNCT
dpc-2641	241	1	30	30	NUM
dpc-2641	241	2	.	.	PUNCT
dpc-2641	242	1	baldari	baldari	PROPN
dpc-2641	242	2	m	m	PROPN
dpc-2641	242	3	,	,	PUNCT
dpc-2641	242	4	montinari	montinari	PROPN
dpc-2641	242	5	m	m	PROPN
dpc-2641	242	6	,	,	PUNCT
dpc-2641	242	7	guarrera	guarrera	PROPN
dpc-2641	242	8	m	m	PROPN
dpc-2641	242	9	,	,	PUNCT
dpc-2641	242	10	rebora	rebora	PROPN
dpc-2641	242	11	a.	a.	PROPN
dpc-2641	242	12	trichodynia	trichodynia	PROPN
dpc-2641	242	13	is	be	AUX
dpc-2641	242	14	a	a	DET
dpc-2641	242	15	distinguishing	distinguish	VERB
dpc-2641	242	16	symptom	symptom	NOUN
dpc-2641	242	17	of	of	ADP
dpc-2641	242	18	telogen	telogen	NOUN
dpc-2641	242	19	effluvium	effluvium	NOUN
dpc-2641	242	20	.	.	PUNCT
dpc-2641	243	1	j	j	PROPN
dpc-2641	243	2	eur	eur	PROPN
dpc-2641	243	3	acad	acad	PROPN
dpc-2641	243	4	dermatol	dermatol	NOUN
dpc-2641	243	5	venereol	venereol	NOUN
dpc-2641	243	6	.	.	PUNCT
dpc-2641	244	1	2009;23(6):733	2009;23(6):733	NUM
dpc-2641	244	2	-	-	PUNCT
dpc-2641	244	3	734	734	NUM
dpc-2641	244	4	.	.	PUNCT
dpc-2641	245	1	doi	doi	NOUN
dpc-2641	245	2	:	:	PUNCT
dpc-2641	245	3	10.1111	10.1111	NUM
dpc-2641	245	4	/	/	SYM
dpc-2641	245	5	j.	j.	PROPN
dpc-2641	245	6	1468	1468	NUM
dpc-2641	245	7	-	-	PUNCT
dpc-2641	245	8	3083.2009.03201.x	3083.2009.03201.x	NOUN
dpc-2641	245	9	.	.	PUNCT
dpc-2641	246	1	pmid	pmid	NOUN
dpc-2641	246	2	:	:	PUNCT
dpc-2641	246	3	19281607	19281607	NUM
dpc-2641	246	4	.	.	PUNCT
dpc-2641	247	1	ther	ther	INTJ
dpc-2641	247	2	.	.	PUNCT
dpc-2641	248	1	2020;33(5):e13549	2020;33(5):e13549	X
dpc-2641	248	2	.	.	PUNCT
dpc-2641	248	3	doi	doi	NOUN
dpc-2641	248	4	:	:	PUNCT
dpc-2641	248	5	10.1111	10.1111	NUM
dpc-2641	248	6	/	/	SYM
dpc-2641	248	7	dth.13549	dth.13549	PROPN
dpc-2641	248	8	.	.	PUNCT
dpc-2641	249	1	pmid	pmid	NOUN
dpc-2641	249	2	:	:	PUNCT
dpc-2641	249	3	32390279	32390279	NUM
dpc-2641	249	4	.	.	PUNCT
dpc-2641	250	1	pmcid	pmcid	NOUN
dpc-2641	250	2	:	:	PUNCT
dpc-2641	250	3	pmc7273098	pmc7273098	NOUN
dpc-2641	250	4	.	.	PUNCT
dpc-2641	251	1	5	5	X
dpc-2641	251	2	.	.	X
dpc-2641	251	3	wollina	wollina	PROPN
dpc-2641	251	4	u	u	PROPN
dpc-2641	251	5	,	,	PUNCT
dpc-2641	251	6	karadağ	karadağ	NOUN
dpc-2641	251	7	as	as	ADP
dpc-2641	251	8	,	,	PUNCT
dpc-2641	251	9	rowland	rowland	PROPN
dpc-2641	251	10	-	-	PUNCT
dpc-2641	251	11	payne	payne	PROPN
dpc-2641	251	12	c	c	PROPN
dpc-2641	251	13	,	,	PUNCT
dpc-2641	251	14	chiriac	chiriac	PROPN
dpc-2641	251	15	a	a	PRON
dpc-2641	251	16	,	,	PUNCT
dpc-2641	251	17	lotti	lotti	NOUN
dpc-2641	251	18	t.	t.	NOUN
dpc-2641	251	19	cutaneous	cutaneous	ADJ
dpc-2641	251	20	signs	sign	NOUN
dpc-2641	251	21	in	in	ADP
dpc-2641	251	22	covid-19	covid-19	PROPN
dpc-2641	251	23	patients	patient	NOUN
dpc-2641	251	24	:	:	PUNCT
dpc-2641	251	25	a	a	DET
dpc-2641	251	26	review	review	NOUN
dpc-2641	251	27	.	.	PUNCT
dpc-2641	252	1	dermatol	dermatol	NOUN
dpc-2641	252	2	ther	ther	ADV
dpc-2641	252	3	.	.	PUNCT
dpc-2641	253	1	2020;33(5):e13549	2020;33(5):e13549	X
dpc-2641	253	2	.	.	PUNCT
dpc-2641	253	3	doi	doi	NOUN
dpc-2641	253	4	:	:	PUNCT
dpc-2641	253	5	10.1111	10.1111	NUM
dpc-2641	253	6	/	/	SYM
dpc-2641	253	7	dth.13549	dth.13549	PROPN
dpc-2641	253	8	.	.	PUNCT
dpc-2641	254	1	pmid	pmid	NOUN
dpc-2641	254	2	:	:	PUNCT
dpc-2641	254	3	32390279	32390279	NUM
dpc-2641	254	4	.	.	PUNCT
dpc-2641	255	1	pmcid	pmcid	NOUN
dpc-2641	255	2	:	:	PUNCT
dpc-2641	255	3	pmc7273098	pmc7273098	NOUN
dpc-2641	255	4	.	.	PUNCT
dpc-2641	256	1	6	6	X
dpc-2641	256	2	.	.	X
dpc-2641	256	3	hong	hong	PROPN
dpc-2641	256	4	jk	jk	PROPN
dpc-2641	256	5	,	,	PUNCT
dpc-2641	256	6	chopra	chopra	PROPN
dpc-2641	256	7	s	s	PROPN
dpc-2641	256	8	,	,	PUNCT
dpc-2641	256	9	kahn	kahn	PROPN
dpc-2641	256	10	ja	ja	PROPN
dpc-2641	256	11	,	,	PUNCT
dpc-2641	256	12	kim	kim	PROPN
dpc-2641	256	13	b	b	PROPN
dpc-2641	256	14	,	,	PUNCT
dpc-2641	256	15	khemichian	khemichian	PROPN
dpc-2641	256	16	s.	s.	PROPN
dpc-2641	256	17	autoimmune	autoimmune	PROPN
dpc-2641	256	18	hepatitis	hepatitis	PROPN
dpc-2641	256	19	triggered	trigger	VERB
dpc-2641	256	20	by	by	ADP
dpc-2641	256	21	covid-19	covid-19	PROPN
dpc-2641	256	22	.	.	PUNCT
dpc-2641	256	23	intern	intern	PROPN
dpc-2641	256	24	med	med	PROPN
dpc-2641	256	25	j.	j.	PROPN
dpc-2641	256	26	2021;51(7	2021;51(7	NUM
dpc-2641	256	27	):	):	PUNCT
dpc-2641	256	28	1182	1182	NUM
dpc-2641	256	29	-	-	SYM
dpc-2641	256	30	1183	1183	NUM
dpc-2641	256	31	.	.	PUNCT
dpc-2641	257	1	doi	doi	NOUN
dpc-2641	257	2	:	:	PUNCT
dpc-2641	257	3	10.1111	10.1111	NUM
dpc-2641	257	4	/	/	SYM
dpc-2641	257	5	imj.15420	imj.15420	NOUN
dpc-2641	257	6	.	.	PUNCT
dpc-2641	258	1	pmid	pmid	NOUN
dpc-2641	258	2	:	:	PUNCT
dpc-2641	258	3	34278694	34278694	NUM
dpc-2641	258	4	.	.	PUNCT
dpc-2641	259	1	pmcid	pmcid	NOUN
dpc-2641	259	2	:	:	PUNCT
dpc-2641	259	3	pmc8447478	pmc8447478	VERB
dpc-2641	259	4	.	.	PUNCT
dpc-2641	260	1	7	7	X
dpc-2641	260	2	.	.	X
dpc-2641	260	3	nikiphorou	nikiphorou	PROPN
dpc-2641	260	4	e	e	PROPN
dpc-2641	260	5	,	,	PUNCT
dpc-2641	260	6	alpizar	alpizar	NOUN
dpc-2641	260	7	-	-	PUNCT
dpc-2641	260	8	rodriguez	rodriguez	NOUN
dpc-2641	260	9	d	d	PROPN
dpc-2641	260	10	,	,	PUNCT
dpc-2641	260	11	gastelum	gastelum	NOUN
dpc-2641	260	12	-	-	PUNCT
dpc-2641	260	13	strozzi	strozzi	ADV
dpc-2641	260	14	a	a	NOUN
dpc-2641	260	15	,	,	PUNCT
dpc-2641	260	16	buch	buch	PROPN
dpc-2641	260	17	m	m	PROPN
dpc-2641	260	18	,	,	PUNCT
dpc-2641	260	19	peláez	peláez	ADJ
dpc-2641	260	20	-	-	PUNCT
dpc-2641	260	21	ballestas	ballestas	NOUN
dpc-2641	260	22	i.	i.	PROPN
dpc-2641	260	23	syndemics	syndemics	PROPN
dpc-2641	260	24	&	&	CCONJ
dpc-2641	260	25	syndemogenesis	syndemogenesis	NOUN
dpc-2641	260	26	in	in	ADP
dpc-2641	260	27	covid-19	covid-19	PROPN
dpc-2641	260	28	and	and	CCONJ
dpc-2641	260	29	rheumatic	rheumatic	ADJ
dpc-2641	260	30	and	and	CCONJ
dpc-2641	260	31	musculoskeletal	musculoskeletal	ADJ
dpc-2641	260	32	diseases	disease	NOUN
dpc-2641	260	33	:	:	PUNCT
dpc-2641	260	34	old	old	ADJ
dpc-2641	260	35	challenges	challenge	NOUN
dpc-2641	260	36	,	,	PUNCT
dpc-2641	260	37	new	new	ADJ
dpc-2641	260	38	era	era	NOUN
dpc-2641	260	39	.	.	PUNCT
dpc-2641	261	1	rheumatology	rheumatology	NOUN
dpc-2641	261	2	(	(	PUNCT
dpc-2641	261	3	oxford	oxford	PROPN
dpc-2641	261	4	)	)	PUNCT
dpc-2641	261	5	.	.	PUNCT
dpc-2641	262	1	2021;60(5	2021;60(5	NUM
dpc-2641	262	2	):	):	PUNCT
dpc-2641	262	3	20402045	20402045	NUM
dpc-2641	262	4	.	.	PUNCT
dpc-2641	263	1	doi	doi	NOUN
dpc-2641	263	2	:	:	PUNCT
dpc-2641	263	3	10.1093	10.1093	NUM
dpc-2641	263	4	/	/	SYM
dpc-2641	263	5	rheumatology	rheumatology	NOUN
dpc-2641	263	6	/	/	SYM
dpc-2641	263	7	keaa840	keaa840	PROPN
dpc-2641	263	8	.	.	PUNCT
dpc-2641	264	1	pmid	pmid	NOUN
dpc-2641	264	2	:	:	PUNCT
dpc-2641	264	3	33496334	33496334	NUM
dpc-2641	264	4	.	.	PUNCT
dpc-2641	265	1	pmcid	pmcid	NOUN
dpc-2641	265	2	:	:	PUNCT
dpc-2641	265	3	pmc7928641	pmc7928641	PROPN
dpc-2641	265	4	.	.	PUNCT
dpc-2641	266	1	8	8	X
dpc-2641	266	2	.	.	PUNCT
dpc-2641	267	1	walters	walters	PROPN
dpc-2641	267	2	hm	hm	PROPN
dpc-2641	267	3	,	,	PUNCT
dpc-2641	267	4	mian	mian	PROPN
dpc-2641	267	5	z	z	PROPN
dpc-2641	267	6	,	,	PUNCT
dpc-2641	267	7	thomas	thomas	PROPN
dpc-2641	267	8	l	l	PROPN
dpc-2641	267	9	,	,	PUNCT
dpc-2641	267	10	et	et	PROPN
dpc-2641	267	11	al	al	PROPN
dpc-2641	267	12	.	.	PROPN
dpc-2641	267	13	seroprevalence	seroprevalence	NOUN
dpc-2641	267	14	and	and	CCONJ
dpc-2641	267	15	clinical	clinical	ADJ
dpc-2641	267	16	outcomes	outcome	NOUN
dpc-2641	267	17	of	of	ADP
dpc-2641	267	18	sars	sar	NOUN
dpc-2641	267	19	-	-	PUNCT
dpc-2641	267	20	cov-2	cov-2	NOUN
dpc-2641	267	21	in	in	ADP
dpc-2641	267	22	paediatric	paediatric	ADJ
dpc-2641	267	23	patients	patient	NOUN
dpc-2641	267	24	with	with	ADP
dpc-2641	267	25	rheumatic	rheumatic	ADJ
dpc-2641	267	26	disease	disease	NOUN
dpc-2641	267	27	.	.	PUNCT
dpc-2641	268	1	rheumatology	rheumatology	NOUN
dpc-2641	268	2	(	(	PUNCT
dpc-2641	268	3	oxford	oxford	PROPN
dpc-2641	268	4	)	)	PUNCT
dpc-2641	268	5	.	.	PUNCT
dpc-2641	269	1	2022;61(si2):si112	2022;61(si2):si112	NUM
dpc-2641	269	2	-	-	PUNCT
dpc-2641	269	3	si119	si119	PROPN
dpc-2641	269	4	.	.	PUNCT
dpc-2641	269	5	doi	doi	PROPN
dpc-2641	269	6	:	:	PUNCT
dpc-2641	269	7	10.1093	10.1093	NUM
dpc-2641	269	8	/	/	SYM
dpc-2641	269	9	rheumatology	rheumatology	NOUN
dpc-2641	269	10	/	/	SYM
dpc-2641	269	11	keab730	keab730	PROPN
dpc-2641	269	12	.	.	PUNCT
dpc-2641	270	1	pmid	pmid	NOUN
dpc-2641	270	2	:	:	PUNCT
dpc-2641	270	3	34599820	34599820	NUM
dpc-2641	270	4	.	.	PUNCT
dpc-2641	271	1	9	9	X
dpc-2641	271	2	.	.	NUM
dpc-2641	271	3	vlad	vlad	PROPN
dpc-2641	271	4	a	a	PRON
dpc-2641	271	5	,	,	PUNCT
dpc-2641	271	6	serban	serban	PROPN
dpc-2641	271	7	v	v	PROPN
dpc-2641	271	8	,	,	PUNCT
dpc-2641	271	9	timar	timar	PROPN
dpc-2641	271	10	r	r	PROPN
dpc-2641	271	11	,	,	PUNCT
dpc-2641	271	12	et	et	PROPN
dpc-2641	271	13	al	al	PROPN
dpc-2641	271	14	.	.	PROPN
dpc-2641	271	15	increased	increase	VERB
dpc-2641	271	16	incidence	incidence	NOUN
dpc-2641	271	17	of	of	ADP
dpc-2641	271	18	type	type	NOUN
dpc-2641	271	19	1	1	NUM
dpc-2641	271	20	diabetes	diabetes	NOUN
dpc-2641	271	21	during	during	ADP
dpc-2641	271	22	the	the	DET
dpc-2641	271	23	covid-19	covid-19	PROPN
dpc-2641	271	24	pandemic	pandemic	NOUN
dpc-2641	271	25	in	in	ADP
dpc-2641	271	26	romanian	romanian	ADJ
dpc-2641	271	27	children	child	NOUN
dpc-2641	271	28	.	.	PUNCT
dpc-2641	272	1	medicina	medicina	PROPN
dpc-2641	272	2	(	(	PUNCT
dpc-2641	272	3	kaunas	kaunas	PROPN
dpc-2641	272	4	)	)	PUNCT
dpc-2641	272	5	.	.	PUNCT
dpc-2641	273	1	2021;57(9):973	2021;57(9):973	NUM
dpc-2641	273	2	.	.	PUNCT
dpc-2641	274	1	doi	doi	NOUN
dpc-2641	274	2	:	:	PUNCT
dpc-2641	274	3	10.3390/	10.3390/	NUM
dpc-2641	274	4	medicina57090973	medicina57090973	PROPN
dpc-2641	274	5	.	.	PUNCT
dpc-2641	275	1	pmid	pmid	NOUN
dpc-2641	275	2	:	:	PUNCT
dpc-2641	275	3	34577896	34577896	NUM
dpc-2641	275	4	.	.	PUNCT
dpc-2641	276	1	pmcid	pmcid	NOUN
dpc-2641	276	2	:	:	PUNCT
dpc-2641	276	3	pmc8470921	pmc8470921	ADJ
dpc-2641	276	4	.	.	PUNCT
dpc-2641	277	1	10	10	NUM
dpc-2641	277	2	.	.	X
dpc-2641	278	1	aringer	aringer	PROPN
dpc-2641	278	2	m	m	PROPN
dpc-2641	278	3	,	,	PUNCT
dpc-2641	278	4	johnson	johnson	PROPN
dpc-2641	278	5	sr	sr	PROPN
dpc-2641	278	6	.	.	PUNCT
dpc-2641	279	1	systemic	systemic	ADJ
dpc-2641	279	2	lupus	lupus	PROPN
dpc-2641	279	3	erythematosus	erythematosus	PROPN
dpc-2641	279	4	classification	classification	NOUN
dpc-2641	279	5	and	and	CCONJ
dpc-2641	279	6	diagnosis	diagnosis	NOUN
dpc-2641	279	7	.	.	PUNCT
dpc-2641	280	1	rheum	rheum	NOUN
dpc-2641	280	2	dis	dis	PROPN
dpc-2641	280	3	clin	clin	PROPN
dpc-2641	280	4	north	north	PROPN
dpc-2641	280	5	am	be	AUX
dpc-2641	280	6	.	.	PUNCT
dpc-2641	281	1	2021;47(3	2021;47(3	NUM
dpc-2641	281	2	):	):	PUNCT
dpc-2641	281	3	501	501	NUM
dpc-2641	281	4	-	-	SYM
dpc-2641	281	5	511	511	NUM
dpc-2641	281	6	.	.	PUNCT
dpc-2641	282	1	doi	doi	NOUN
dpc-2641	282	2	:	:	PUNCT
dpc-2641	282	3	10.1016	10.1016	NUM
dpc-2641	282	4	/	/	SYM
dpc-2641	282	5	j.rdc.2021.04.011	j.rdc.2021.04.011	PROPN
dpc-2641	282	6	.	.	PUNCT
dpc-2641	283	1	pmid	pmid	NOUN
dpc-2641	283	2	:	:	PUNCT
dpc-2641	283	3	34215376	34215376	NUM
dpc-2641	283	4	.	.	PUNCT
dpc-2641	284	1	11	11	NUM
dpc-2641	284	2	.	.	PUNCT
dpc-2641	285	1	choi	choi	PROPN
dpc-2641	285	2	wj	wj	PROPN
dpc-2641	285	3	,	,	PUNCT
dpc-2641	285	4	kim	kim	PROPN
dpc-2641	285	5	je	je	PROPN
dpc-2641	285	6	,	,	PUNCT
dpc-2641	285	7	kang	kang	PROPN
dpc-2641	285	8	h.	h.	PROPN
dpc-2641	285	9	frequency	frequency	PROPN
dpc-2641	285	10	of	of	ADP
dpc-2641	285	11	antinuclear	antinuclear	ADJ
dpc-2641	285	12	antibody	antibody	NOUN
dpc-2641	285	13	positivity	positivity	NOUN
dpc-2641	285	14	in	in	ADP
dpc-2641	285	15	patients	patient	NOUN
dpc-2641	285	16	with	with	ADP
dpc-2641	285	17	pattern	pattern	NOUN
dpc-2641	285	18	hair	hair	NOUN
dpc-2641	285	19	loss	loss	NOUN
dpc-2641	285	20	.	.	PUNCT
dpc-2641	286	1	ann	ann	PROPN
dpc-2641	286	2	dermatol	dermatol	NOUN
dpc-2641	286	3	.	.	PUNCT
dpc-2641	287	1	2015;27(2):210	2015;27(2):210	NOUN
dpc-2641	287	2	-	-	PUNCT
dpc-2641	287	3	212	212	NUM
dpc-2641	287	4	.	.	PUNCT
dpc-2641	288	1	doi	doi	NOUN
dpc-2641	288	2	:	:	PUNCT
dpc-2641	288	3	10.5021	10.5021	NUM
dpc-2641	288	4	/	/	SYM
dpc-2641	288	5	ad.2015.27.2.210	ad.2015.27.2.210	NOUN
dpc-2641	288	6	.	.	PUNCT
dpc-2641	289	1	pmid	pmid	NOUN
dpc-2641	289	2	:	:	PUNCT
dpc-2641	289	3	25834364	25834364	NUM
dpc-2641	289	4	.	.	PUNCT
dpc-2641	290	1	pmcid	pmcid	NOUN
dpc-2641	290	2	:	:	PUNCT
dpc-2641	290	3	pmc4377414	pmc4377414	NOUN
dpc-2641	290	4	.	.	PUNCT
dpc-2641	291	1	12	12	NUM
dpc-2641	291	2	.	.	PUNCT
dpc-2641	291	3	martínez	martínez	PROPN
dpc-2641	291	4	-	-	PUNCT
dpc-2641	291	5	velasco	velasco	PROPN
dpc-2641	291	6	ma	ma	PROPN
dpc-2641	291	7	,	,	PUNCT
dpc-2641	291	8	vázquez	vázquez	PROPN
dpc-2641	291	9	-	-	PUNCT
dpc-2641	291	10	herrera	herrera	PROPN
dpc-2641	291	11	ne	ne	PROPN
dpc-2641	291	12	,	,	PUNCT
dpc-2641	291	13	maddy	maddy	PROPN
dpc-2641	291	14	aj	aj	PROPN
dpc-2641	291	15	,	,	PUNCT
dpc-2641	291	16	asz	asz	PROPN
dpc-2641	291	17	-	-	PUNCT
dpc-2641	291	18	sigall	sigall	NOUN
dpc-2641	292	1	d	d	PROPN
dpc-2641	292	2	,	,	PUNCT
dpc-2641	292	3	tosti	tosti	PROPN
dpc-2641	292	4	a.	a.	NOUN
dpc-2641	292	5	the	the	DET
dpc-2641	292	6	hair	hair	NOUN
dpc-2641	292	7	shedding	shed	VERB
dpc-2641	292	8	visual	visual	ADJ
dpc-2641	292	9	scale	scale	NOUN
dpc-2641	292	10	:	:	PUNCT
dpc-2641	292	11	a	a	DET
dpc-2641	292	12	quick	quick	ADJ
dpc-2641	292	13	tool	tool	NOUN
dpc-2641	292	14	to	to	PART
dpc-2641	292	15	assess	assess	VERB
dpc-2641	292	16	hair	hair	NOUN
dpc-2641	292	17	loss	loss	NOUN
dpc-2641	292	18	in	in	ADP
dpc-2641	292	19	women	woman	NOUN
dpc-2641	292	20	.	.	PUNCT
dpc-2641	293	1	dermatol	dermatol	NOUN
dpc-2641	293	2	ther	ther	ADV
dpc-2641	293	3	(	(	PUNCT
dpc-2641	293	4	heidelb	heidelb	NOUN
dpc-2641	293	5	)	)	PUNCT
dpc-2641	293	6	.	.	PUNCT
dpc-2641	294	1	2017;7(1):155	2017;7(1):155	NUM
dpc-2641	294	2	-	-	SYM
dpc-2641	294	3	165	165	NUM
dpc-2641	294	4	.	.	PUNCT
dpc-2641	295	1	doi	doi	NOUN
dpc-2641	295	2	:	:	PUNCT
dpc-2641	295	3	10.1007	10.1007	NUM
dpc-2641	295	4	/	/	SYM
dpc-2641	295	5	s13555	s13555	PROPN
dpc-2641	295	6	-	-	PUNCT
dpc-2641	295	7	017	017	NUM
dpc-2641	295	8	-	-	PUNCT
dpc-2641	295	9	0171	0171	NUM
dpc-2641	295	10	-	-	SYM
dpc-2641	295	11	8	8	NUM
dpc-2641	295	12	.	.	PUNCT
dpc-2641	296	1	pmid	pmid	NOUN
dpc-2641	296	2	:	:	PUNCT
dpc-2641	296	3	28220468	28220468	NUM
dpc-2641	296	4	.	.	PUNCT
dpc-2641	297	1	pmcid	pmcid	ADJ
dpc-2641	297	2	:	:	PUNCT
dpc-2641	297	3	pmc5336434	pmc5336434	NOUN
dpc-2641	297	4	.	.	PUNCT
dpc-2641	298	1	13	13	NUM
dpc-2641	298	2	.	.	PUNCT
dpc-2641	298	3	peker	peker	PROPN
dpc-2641	298	4	bo	bo	PROPN
dpc-2641	298	5	,	,	PUNCT
dpc-2641	298	6	şener	şener	PROPN
dpc-2641	298	7	ag	ag	PROPN
dpc-2641	298	8	,	,	PUNCT
dpc-2641	298	9	kaptan	kaptan	PROPN
dpc-2641	298	10	aydoğmuş	aydoğmuş	PROPN
dpc-2641	298	11	f.	f.	PROPN
dpc-2641	298	12	antinuclear	antinuclear	PROPN
dpc-2641	298	13	antibodies	antibodies	PROPN
dpc-2641	298	14	(	(	PUNCT
dpc-2641	298	15	anas	anas	PROPN
dpc-2641	298	16	)	)	PUNCT
dpc-2641	298	17	detected	detect	VERB
dpc-2641	298	18	by	by	ADP
dpc-2641	298	19	indirect	indirect	ADJ
dpc-2641	298	20	immunofluorescence	immunofluorescence	NOUN
dpc-2641	298	21	(	(	PUNCT
dpc-2641	298	22	iif	iif	PROPN
dpc-2641	298	23	)	)	PUNCT
dpc-2641	298	24	method	method	NOUN
dpc-2641	298	25	in	in	ADP
dpc-2641	298	26	acute	acute	ADJ
dpc-2641	298	27	covid-19	covid-19	PROPN
dpc-2641	298	28	infection	infection	NOUN
dpc-2641	298	29	;	;	PUNCT
dpc-2641	298	30	future	future	ADJ
dpc-2641	298	31	roadmap	roadmap	NOUN
dpc-2641	298	32	for	for	ADP
dpc-2641	298	33	laboratory	laboratory	NOUN
dpc-2641	298	34	diagnosis	diagnosis	NOUN
dpc-2641	298	35	.	.	PUNCT
dpc-2641	299	1	j	j	PROPN
dpc-2641	299	2	immunol	immunol	NOUN
dpc-2641	299	3	methods	method	NOUN
dpc-2641	299	4	.	.	PUNCT
dpc-2641	300	1	2021;499:113174	2021;499:113174	NUM
dpc-2641	300	2	.	.	PUNCT
dpc-2641	301	1	doi	doi	NOUN
dpc-2641	301	2	:	:	PUNCT
dpc-2641	301	3	10.1016	10.1016	NUM
dpc-2641	301	4	/	/	SYM
dpc-2641	301	5	j	j	PROPN
dpc-2641	301	6	.jim.2021.113174	.jim.2021.113174	PROPN
dpc-2641	301	7	.	.	PUNCT
dpc-2641	302	1	pmid	pmid	NOUN
dpc-2641	302	2	:	:	PUNCT
dpc-2641	302	3	34737165	34737165	NUM
dpc-2641	302	4	.	.	PUNCT
dpc-2641	303	1	pmcid	pmcid	NOUN
dpc-2641	303	2	:	:	PUNCT
dpc-2641	303	3	pmc8556075	pmc8556075	ADJ
dpc-2641	303	4	.	.	PUNCT
dpc-2641	304	1	14	14	NUM
dpc-2641	304	2	.	.	X
dpc-2641	305	1	ruggiero	ruggiero	PROPN
dpc-2641	306	1	a	a	PRON
dpc-2641	306	2	,	,	PUNCT
dpc-2641	306	3	martora	martora	PROPN
dpc-2641	306	4	f	f	X
dpc-2641	306	5	,	,	PUNCT
dpc-2641	306	6	picone	picone	PROPN
dpc-2641	306	7	v	v	PROPN
dpc-2641	306	8	,	,	PUNCT
dpc-2641	306	9	et	et	PROPN
dpc-2641	306	10	al	al	PROPN
dpc-2641	306	11	.	.	PUNCT
dpc-2641	307	1	the	the	DET
dpc-2641	307	2	impact	impact	NOUN
dpc-2641	307	3	of	of	ADP
dpc-2641	307	4	covid-19	covid-19	PROPN
dpc-2641	307	5	infection	infection	NOUN
dpc-2641	307	6	on	on	ADP
dpc-2641	307	7	patients	patient	NOUN
dpc-2641	307	8	with	with	ADP
dpc-2641	307	9	psoriasis	psoriasis	NOUN
dpc-2641	307	10	treated	treat	VERB
dpc-2641	307	11	with	with	ADP
dpc-2641	307	12	biologics	biologic	NOUN
dpc-2641	307	13	:	:	PUNCT
dpc-2641	307	14	an	an	DET
dpc-2641	307	15	italian	italian	ADJ
dpc-2641	307	16	experience	experience	NOUN
dpc-2641	307	17	.	.	PUNCT
dpc-2641	308	1	clin	clin	PROPN
dpc-2641	308	2	exp	exp	NOUN
dpc-2641	308	3	dermatol	dermatol	NOUN
dpc-2641	308	4	.	.	PUNCT
dpc-2641	309	1	2022;47(12	2022;47(12	NUM
dpc-2641	309	2	):	):	PUNCT
dpc-2641	309	3	2280	2280	NUM
dpc-2641	309	4	-	-	SYM
dpc-2641	309	5	2282	2282	NUM
dpc-2641	309	6	.	.	PUNCT
dpc-2641	310	1	doi	doi	NOUN
dpc-2641	310	2	:	:	PUNCT
dpc-2641	310	3	10.1111	10.1111	NUM
dpc-2641	310	4	/	/	SYM
dpc-2641	310	5	ced.15336	ced.15336	PROPN
dpc-2641	310	6	.	.	PUNCT
dpc-2641	311	1	pmid	pmid	NOUN
dpc-2641	311	2	:	:	PUNCT
dpc-2641	311	3	35867020	35867020	NUM
dpc-2641	311	4	.	.	PUNCT
dpc-2641	312	1	pmcid	pmcid	NOUN
dpc-2641	312	2	:	:	PUNCT
dpc-2641	312	3	pmc9349949	pmc9349949	NOUN
dpc-2641	312	4	.	.	PUNCT
dpc-2641	313	1	15	15	NUM
dpc-2641	313	2	.	.	X
dpc-2641	314	1	chang	chang	PROPN
dpc-2641	314	2	sh	sh	PROPN
dpc-2641	314	3	,	,	PUNCT
dpc-2641	314	4	minn	minn	PROPN
dpc-2641	314	5	d	d	PROPN
dpc-2641	314	6	,	,	PUNCT
dpc-2641	314	7	kim	kim	PROPN
dpc-2641	314	8	yk	yk	PROPN
dpc-2641	314	9	.	.	PUNCT
dpc-2641	314	10	autoantibodies	autoantibody	NOUN
dpc-2641	314	11	in	in	ADP
dpc-2641	314	12	moderate	moderate	ADJ
dpc-2641	314	13	and	and	CCONJ
dpc-2641	314	14	critical	critical	ADJ
dpc-2641	314	15	cases	case	NOUN
dpc-2641	314	16	of	of	ADP
dpc-2641	314	17	covid-19	covid-19	PROPN
dpc-2641	314	18	.	.	PUNCT
dpc-2641	314	19	clin	clin	PROPN
dpc-2641	314	20	transl	transl	PROPN
dpc-2641	314	21	sci	sci	PROPN
dpc-2641	314	22	.	.	PUNCT
dpc-2641	315	1	2021;14(5	2021;14(5	NUM
dpc-2641	315	2	):	):	PUNCT
dpc-2641	315	3	1625	1625	NUM
dpc-2641	315	4	-	-	SYM
dpc-2641	315	5	1626	1626	NUM
dpc-2641	315	6	.	.	PUNCT
dpc-2641	316	1	doi	doi	NOUN
dpc-2641	316	2	:	:	PUNCT
dpc-2641	316	3	10.1111	10.1111	NUM
dpc-2641	316	4	/	/	SYM
dpc-2641	316	5	cts.13036	cts.13036	X
dpc-2641	316	6	.	.	PUNCT
dpc-2641	317	1	pmid	pmid	NOUN
dpc-2641	317	2	:	:	PUNCT
dpc-2641	317	3	33934534	33934534	NUM
dpc-2641	317	4	.	.	PUNCT
dpc-2641	318	1	pmcid	pmcid	NOUN
dpc-2641	318	2	:	:	PUNCT
dpc-2641	318	3	pmc8239866	pmc8239866	PROPN
dpc-2641	318	4	.	.	PUNCT
dpc-2641	319	1	16	16	NUM
dpc-2641	319	2	.	.	PUNCT
dpc-2641	320	1	gazzaruso	gazzaruso	PROPN
dpc-2641	320	2	c	c	PROPN
dpc-2641	320	3	,	,	PUNCT
dpc-2641	320	4	carlo	carlo	PROPN
dpc-2641	320	5	stella	stella	PROPN
dpc-2641	320	6	n	n	CCONJ
dpc-2641	320	7	,	,	PUNCT
dpc-2641	320	8	mariani	mariani	PROPN
dpc-2641	320	9	g	g	PROPN
dpc-2641	320	10	,	,	PUNCT
dpc-2641	320	11	et	et	PROPN
dpc-2641	320	12	al	al	PROPN
dpc-2641	320	13	.	.	PROPN
dpc-2641	321	1	high	high	ADJ
dpc-2641	321	2	prevalence	prevalence	NOUN
dpc-2641	321	3	of	of	ADP
dpc-2641	321	4	antinuclear	antinuclear	ADJ
dpc-2641	321	5	antibodies	antibody	NOUN
dpc-2641	321	6	and	and	CCONJ
dpc-2641	321	7	lupus	lupus	NOUN
dpc-2641	321	8	anticoagulant	anticoagulant	NOUN
dpc-2641	321	9	in	in	ADP
dpc-2641	321	10	patients	patient	NOUN
dpc-2641	321	11	hospitalized	hospitalize	VERB
dpc-2641	321	12	for	for	ADP
dpc-2641	321	13	sars	sar	NOUN
dpc-2641	321	14	-	-	PUNCT
dpc-2641	321	15	cov2	cov2	PROPN
dpc-2641	321	16	pneumonia	pneumonia	NOUN
dpc-2641	321	17	.	.	PUNCT
dpc-2641	322	1	clin	clin	PROPN
dpc-2641	322	2	rheumatol	rheumatol	NOUN
dpc-2641	322	3	.	.	PUNCT
dpc-2641	323	1	2020;39(7):2095	2020;39(7):2095	NUM
dpc-2641	323	2	-	-	SYM
dpc-2641	323	3	2097	2097	NUM
dpc-2641	323	4	.	.	PUNCT
dpc-2641	324	1	doi	doi	NOUN
dpc-2641	324	2	:	:	PUNCT
dpc-2641	324	3	10.1007	10.1007	NUM
dpc-2641	324	4	/	/	SYM
dpc-2641	324	5	s10067	s10067	NOUN
dpc-2641	324	6	-	-	PUNCT
dpc-2641	324	7	020	020	NUM
dpc-2641	324	8	-	-	PUNCT
dpc-2641	324	9	05180	05180	NUM
dpc-2641	324	10	-	-	SYM
dpc-2641	324	11	7	7	NUM
dpc-2641	324	12	.	.	PUNCT
dpc-2641	325	1	pmid	pmid	NOUN
dpc-2641	325	2	:	:	PUNCT
dpc-2641	325	3	32462425	32462425	NUM
dpc-2641	325	4	.	.	PUNCT
dpc-2641	326	1	pmcid	pmcid	NOUN
dpc-2641	326	2	:	:	PUNCT
dpc-2641	326	3	pmc7251560	pmc7251560	NOUN
dpc-2641	326	4	.	.	PUNCT
dpc-2641	327	1	17	17	NUM
dpc-2641	327	2	.	.	PUNCT
dpc-2641	327	3	lerma	lerma	PROPN
dpc-2641	327	4	la	la	PROPN
dpc-2641	327	5	,	,	PUNCT
dpc-2641	327	6	chaudhary	chaudhary	PROPN
dpc-2641	327	7	a	a	X
dpc-2641	327	8	,	,	PUNCT
dpc-2641	327	9	bryan	bryan	PROPN
dpc-2641	327	10	a	a	PROPN
dpc-2641	327	11	,	,	PUNCT
dpc-2641	327	12	morishima	morishima	PROPN
dpc-2641	327	13	c	c	PROPN
dpc-2641	327	14	,	,	PUNCT
dpc-2641	327	15	wener	wener	PROPN
dpc-2641	327	16	mh	mh	PROPN
dpc-2641	327	17	,	,	PUNCT
dpc-2641	327	18	fink	fink	PROPN
dpc-2641	327	19	sl	sl	PROPN
dpc-2641	327	20	.	.	PUNCT
dpc-2641	327	21	prevalence	prevalence	NOUN
dpc-2641	327	22	of	of	ADP
dpc-2641	327	23	autoantibody	autoantibody	ADJ
dpc-2641	327	24	responses	response	NOUN
dpc-2641	327	25	in	in	ADP
dpc-2641	327	26	acute	acute	ADJ
dpc-2641	327	27	coronavirus	coronavirus	NOUN
dpc-2641	327	28	disease	disease	NOUN
dpc-2641	327	29	2019	2019	NUM
dpc-2641	327	30	(	(	PUNCT
dpc-2641	327	31	covid-19	covid-19	PROPN
dpc-2641	327	32	)	)	PUNCT
dpc-2641	327	33	.	.	PUNCT
dpc-2641	328	1	j	j	PROPN
dpc-2641	328	2	transl	transl	PROPN
dpc-2641	328	3	autoimmun	autoimmun	PROPN
dpc-2641	328	4	.	.	PUNCT
dpc-2641	329	1	original	original	ADJ
dpc-2641	329	2	article	article	NOUN
dpc-2641	329	3	|	|	ADV
dpc-2641	329	4	dermatol	dermatol	ADJ
dpc-2641	329	5	pract	pract	NOUN
dpc-2641	329	6	concept	concept	NOUN
dpc-2641	329	7	.	.	PUNCT
dpc-2641	330	1	2023;13(2):e2023081	2023;13(2):e2023081	NUM
dpc-2641	330	2	7	7	NUM
dpc-2641	330	3	33	33	NUM
dpc-2641	330	4	.	.	PUNCT
dpc-2641	331	1	starace	starace	PROPN
dpc-2641	331	2	m	m	PROPN
dpc-2641	331	3	,	,	PUNCT
dpc-2641	331	4	iorizzo	iorizzo	VERB
dpc-2641	331	5	m	m	PROPN
dpc-2641	331	6	,	,	PUNCT
dpc-2641	331	7	sechi	sechi	PROPN
dpc-2641	331	8	a	a	PROPN
dpc-2641	331	9	,	,	PUNCT
dpc-2641	331	10	et	et	PROPN
dpc-2641	331	11	al	al	PROPN
dpc-2641	331	12	.	.	PUNCT
dpc-2641	332	1	trichodynia	trichodynia	PROPN
dpc-2641	332	2	and	and	CCONJ
dpc-2641	332	3	telogen	telogen	NOUN
dpc-2641	332	4	effluvium	effluvium	NOUN
dpc-2641	332	5	in	in	ADP
dpc-2641	332	6	covid-19	covid-19	PROPN
dpc-2641	332	7	patients	patient	NOUN
dpc-2641	332	8	:	:	PUNCT
dpc-2641	332	9	results	result	NOUN
dpc-2641	332	10	of	of	ADP
dpc-2641	332	11	an	an	DET
dpc-2641	332	12	international	international	ADJ
dpc-2641	332	13	expert	expert	NOUN
dpc-2641	332	14	opinion	opinion	NOUN
dpc-2641	332	15	survey	survey	NOUN
dpc-2641	332	16	on	on	ADP
dpc-2641	332	17	diagnosis	diagnosis	NOUN
dpc-2641	332	18	and	and	CCONJ
dpc-2641	332	19	management	management	NOUN
dpc-2641	332	20	.	.	PUNCT
dpc-2641	333	1	jaad	jaad	PROPN
dpc-2641	333	2	int	int	PROPN
dpc-2641	333	3	.	.	PUNCT
dpc-2641	334	1	2021;5:11	2021;5:11	PROPN
dpc-2641	334	2	-	-	PUNCT
dpc-2641	334	3	18	18	NUM
dpc-2641	334	4	.	.	PUNCT
dpc-2641	335	1	doi	doi	NOUN
dpc-2641	335	2	:	:	PUNCT
dpc-2641	335	3	10.1016	10.1016	NUM
dpc-2641	335	4	/	/	SYM
dpc-2641	335	5	j.jdin.2021.07.006	j.jdin.2021.07.006	PROPN
dpc-2641	335	6	.	.	PUNCT
dpc-2641	336	1	pmid	pmid	NOUN
dpc-2641	336	2	:	:	PUNCT
dpc-2641	336	3	34368790	34368790	NUM
dpc-2641	336	4	.	.	PUNCT
dpc-2641	337	1	pmcid	pmcid	NOUN
dpc-2641	337	2	:	:	PUNCT
dpc-2641	337	3	pmc8328568	pmc8328568	NOUN
dpc-2641	337	4	.	.	PUNCT
dpc-2641	338	1	34	34	NUM
dpc-2641	338	2	.	.	X
dpc-2641	338	3	di	di	PROPN
dpc-2641	338	4	landro	landro	PROPN
dpc-2641	338	5	a	a	DET
dpc-2641	338	6	,	,	PUNCT
dpc-2641	338	7	naldi	naldi	PROPN
dpc-2641	338	8	l	l	PROPN
dpc-2641	338	9	,	,	PUNCT
dpc-2641	338	10	glaser	glaser	PROPN
dpc-2641	338	11	e	e	PROPN
dpc-2641	338	12	,	,	PUNCT
dpc-2641	338	13	paus	paus	PROPN
dpc-2641	338	14	r	r	PROPN
dpc-2641	338	15	,	,	PUNCT
dpc-2641	338	16	tosti	tosti	PROPN
dpc-2641	338	17	a.	a.	NOUN
dpc-2641	338	18	pathobiology	pathobiology	NOUN
dpc-2641	338	19	questions	question	NOUN
dpc-2641	338	20	raised	raise	VERB
dpc-2641	338	21	by	by	ADP
dpc-2641	338	22	telogen	telogen	NOUN
dpc-2641	338	23	effluvium	effluvium	NOUN
dpc-2641	338	24	and	and	CCONJ
dpc-2641	338	25	trichodynia	trichodynia	NOUN
dpc-2641	338	26	in	in	ADP
dpc-2641	338	27	covid-19	covid-19	PROPN
dpc-2641	338	28	patients	patient	NOUN
dpc-2641	338	29	.	.	PUNCT
dpc-2641	339	1	exp	exp	NOUN
dpc-2641	339	2	dermatol	dermatol	NOUN
dpc-2641	339	3	.	.	PUNCT
dpc-2641	340	1	2021;30(7):999	2021;30(7):999	NOUN
dpc-2641	340	2	-	-	SYM
dpc-2641	340	3	1000	1000	NUM
dpc-2641	340	4	.	.	PUNCT
dpc-2641	341	1	doi	doi	NOUN
dpc-2641	341	2	:	:	PUNCT
dpc-2641	341	3	10.1111	10.1111	NUM
dpc-2641	341	4	/	/	SYM
dpc-2641	341	5	exd.14352	exd.14352	NOUN
dpc-2641	341	6	.	.	PUNCT
dpc-2641	342	1	pmid	pmid	NOUN
dpc-2641	342	2	:	:	PUNCT
dpc-2641	342	3	33838048	33838048	NUM
dpc-2641	342	4	.	.	PUNCT
dpc-2641	343	1	pmcid	pmcid	NOUN
dpc-2641	343	2	:	:	PUNCT
dpc-2641	343	3	pmc8250761	pmc8250761	NOUN
dpc-2641	343	4	.	.	PUNCT
dpc-2641	344	1	31	31	NUM
dpc-2641	344	2	.	.	PUNCT
dpc-2641	345	1	kivanç	kivanç	NOUN
dpc-2641	345	2	-	-	PUNCT
dpc-2641	345	3	altunay	altunay	PROPN
dpc-2641	345	4	i	i	NOUN
dpc-2641	345	5	,	,	PUNCT
dpc-2641	345	6	savaş	savaş	PROPN
dpc-2641	345	7	c	c	PROPN
dpc-2641	345	8	,	,	PUNCT
dpc-2641	345	9	gökdemir	gökdemir	PROPN
dpc-2641	345	10	g	g	PROPN
dpc-2641	345	11	,	,	PUNCT
dpc-2641	345	12	köşlü	köşlü	X
dpc-2641	345	13	a	a	X
dpc-2641	345	14	,	,	PUNCT
dpc-2641	345	15	ayaydin	ayaydin	VERB
dpc-2641	345	16	eb	eb	PROPN
dpc-2641	345	17	.	.	PUNCT
dpc-2641	346	1	the	the	DET
dpc-2641	346	2	presence	presence	NOUN
dpc-2641	346	3	of	of	ADP
dpc-2641	346	4	trichodynia	trichodynia	PROPN
dpc-2641	346	5	in	in	ADP
dpc-2641	346	6	patients	patient	NOUN
dpc-2641	346	7	with	with	ADP
dpc-2641	346	8	telogen	telogen	NOUN
dpc-2641	346	9	effluvium	effluvium	NOUN
dpc-2641	346	10	and	and	CCONJ
dpc-2641	346	11	androgenetic	androgenetic	ADJ
dpc-2641	346	12	alopecia	alopecia	NOUN
dpc-2641	346	13	.	.	PUNCT
dpc-2641	347	1	int	int	PROPN
dpc-2641	347	2	j	j	PROPN
dpc-2641	347	3	dermatol	dermatol	NOUN
dpc-2641	347	4	.	.	PUNCT
dpc-2641	348	1	2003;42(9):691	2003;42(9):691	NUM
dpc-2641	348	2	-	-	PUNCT
dpc-2641	348	3	693	693	NUM
dpc-2641	348	4	.	.	PUNCT
dpc-2641	349	1	doi	doi	NOUN
dpc-2641	349	2	:	:	PUNCT
dpc-2641	349	3	10.1046	10.1046	NUM
dpc-2641	349	4	/	/	SYM
dpc-2641	349	5	j.1365	j.1365	NOUN
dpc-2641	349	6	-	-	PUNCT
dpc-2641	349	7	4362.2003.01847.x	4362.2003.01847.x	NOUN
dpc-2641	349	8	.	.	PUNCT
dpc-2641	350	1	pmid	pmid	NOUN
dpc-2641	350	2	:	:	PUNCT
dpc-2641	350	3	12956679	12956679	NUM
dpc-2641	350	4	.	.	PUNCT
dpc-2641	351	1	32	32	NUM
dpc-2641	351	2	.	.	PUNCT
dpc-2641	352	1	durusoy	durusoy	PROPN
dpc-2641	352	2	c	c	NOUN
dpc-2641	352	3	,	,	PUNCT
dpc-2641	352	4	ozenli	ozenli	ADJ
dpc-2641	352	5	y	y	PROPN
dpc-2641	352	6	,	,	PUNCT
dpc-2641	352	7	adiguzel	adiguzel	VERB
dpc-2641	352	8	a	a	PRON
dpc-2641	352	9	,	,	PUNCT
dpc-2641	352	10	et	et	PROPN
dpc-2641	352	11	al	al	PROPN
dpc-2641	352	12	.	.	PUNCT
dpc-2641	353	1	the	the	DET
dpc-2641	353	2	role	role	NOUN
dpc-2641	353	3	of	of	ADP
dpc-2641	353	4	psychological	psychological	ADJ
dpc-2641	353	5	factors	factor	NOUN
dpc-2641	353	6	and	and	CCONJ
dpc-2641	353	7	serum	serum	NOUN
dpc-2641	353	8	zinc	zinc	NOUN
dpc-2641	353	9	,	,	PUNCT
dpc-2641	353	10	folate	folate	NOUN
dpc-2641	353	11	and	and	CCONJ
dpc-2641	353	12	vitamin	vitamin	NOUN
dpc-2641	353	13	b12	b12	NOUN
dpc-2641	353	14	levels	level	NOUN
dpc-2641	353	15	in	in	ADP
dpc-2641	353	16	the	the	DET
dpc-2641	353	17	aetiology	aetiology	NOUN
dpc-2641	353	18	of	of	ADP
dpc-2641	353	19	trichodynia	trichodynia	NOUN
dpc-2641	353	20	:	:	PUNCT
dpc-2641	353	21	a	a	DET
dpc-2641	353	22	case	case	NOUN
dpc-2641	353	23	-	-	PUNCT
dpc-2641	353	24	control	control	NOUN
dpc-2641	353	25	study	study	NOUN
dpc-2641	353	26	.	.	PUNCT
dpc-2641	354	1	clin	clin	PROPN
dpc-2641	354	2	exp	exp	NOUN
dpc-2641	354	3	dermatol	dermatol	NOUN
dpc-2641	354	4	.	.	PUNCT
dpc-2641	355	1	2009;34(7):789	2009;34(7):789	ADV
dpc-2641	355	2	-	-	PUNCT
dpc-2641	355	3	792	792	NUM
dpc-2641	355	4	.	.	PUNCT
dpc-2641	356	1	doi	doi	NOUN
dpc-2641	356	2	:	:	PUNCT
dpc-2641	356	3	10.1111	10.1111	NUM
dpc-2641	356	4	/	/	SYM
dpc-2641	356	5	j.1365	j.1365	NOUN
dpc-2641	356	6	-	-	PUNCT
dpc-2641	356	7	2230.2008.03165.x	2230.2008.03165.x	NUM
dpc-2641	356	8	.	.	PUNCT
dpc-2641	357	1	pmid	pmid	NOUN
dpc-2641	357	2	:	:	PUNCT
dpc-2641	357	3	19508569	19508569	NUM
dpc-2641	357	4	.	.	PUNCT